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Abstract 
Cyathostomins are ubiquitous in horses and high strongyle burdens are associated with colic. 
Parasite control, often using anthelmintic drugs, is an important element of equine healthcare. 
Anthelmintic dosing is also a risk factor for colic, which may be due to disruption of the 
mutualistic microbiota within the hindgut. This thesis describes studies to evaluate the current 
efficacy of equine anthelmintics and interactions with intestinal bacterial populations which 
may underlie the reported association with colic. 
Faecal egg count data from horses throughout Great Britain was used to calculate strongyle 
egg reappearance periods (ERP) for ivermectin and moxidectin. For both drugs reduced ERP 
was detected compared to earlier studies. The ovicidal efficacy of fenbendazole was evaluated 
in resistant cyathostomins. Using an in vitro egg hatch viability assay, an 80% reduction of egg 
hatch rate was detected but this only persisted for three days following treatment. These studies 
further characterise the growing problem of anthelmintic resistance in equine parasites. 
Microbiota-anthelmintic interaction was evaluated over three studies: i)  In vitro feed 
fermentation was used to detect a decrease in fermentation rate and gas production following 
moxidectin administration; ii) 16S rRNA sequencing of faecal microbiota before and after 
moxidectin treatment revealed no change in bacterial community profile; and iii) 1H NMR 
metabolomics identified no significant differences in urinary and faecal metabolite profiles pre- 
and post-moxidectin treatment but in-vitro fermentations did show differences in alanine, 
ethanol, 5-HT, formate and maltose following moxidectin treatment.  
These studies further characterise reduced efficacy of anthelmintics against equine 
cyathostomins and suggest that although moxidectin treatment has no measurable effect on 
bacterial community profile, it may be associated with functional changes in the gut 
microbiome.  
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Chapter 1 
1.0 Introduction 
1.1. The equine gastrointestinal tract 
The horse is a mono-gastric hindgut fermenter (McDonald et al., 2011), its large intestine 
comprising an enlarged anaerobic fermentation chamber that contains a highly complex 
community of microbiota, Figure 1.1. (Daly et al., 2001). The hindgut microbiota consists of 
bacteria, fungi, archaea and protozoa, all organisms that ferment digesta, predominantly 
structural carbohydrates, producing short chain fatty acids (SCFAs, also known as volatile fatty 
acids, VFAs). The predominant SCFAs in the horse are acetate, propionate and butyrate (Frape, 
2010) which can provide 60-70% of the horses’ daily energy requirements (Bergman, 1990).  
 
Figure 1.1. The anatomy of the equine gastro-intestinal tract. Image supplied by Hartpury 
College (Pers com).  
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The hindgut ecosystem is complex and until recently was relatively uncharacterised (Shepherd 
et al., 2012). In humans the gut microbiome has received greater attention and there is a 
growing body of evidence that the human microbiome plays a major role in many aspects of 
human health (Jones et al., 2014). Extrapolating to the horse, it is likely that the gut microbiome 
plays a much more important role than just fermenting digesta.  
It is now known that the metabolic impact of human gut microbiota on the host involves the 
gut, liver, muscle and brain (Nicholson et al., 2012). Furthermore in humans a number of drugs 
that are metabolised or co-metabolised by the gut microbiota have recently been identified (Li 
and Jai, 2013). In horses the gut microbiota have been characterised in conditions such as 
laminitis, colic and equine grass sickness (Steelman et al., 2012; Biddle et al., 2013; Leng et 
al., 2015). Unsurprisingly systemic antimicrobial use has also been shown to alter the 
composition of faecal microbiota (Costa et al., 2015; Arnold et al., 2017).  Recent work has 
also started to look at the effect of drugs other than antimicrobials on equine hindgut microbiota 
(Tyma et al., 2017).  
Parasitic nematodes (macrobiota) have evolved to co-reside within the hindgut microbiome 
(Bancroft et al., 2012; Nielsen 2012; Peachey et al., 2017a). Commensal and symbiotic 
microbiota aim to condition their environment with minimal effect on the host, whereas 
parasites, living off their host, frequently negatively impact upon their host’s health (Reynolds 
et al., 2015).  
1.2. Intestinal disease in horses  
Acute intestinal disease, commonly referred to as colic, is the single biggest cause of equine 
mortality (Tinker et al., 1997; Goncalves et al., 2002; Hillyer et al., 2002; Archer and 
Proudman, 2006). “Colic” is an umbrella term for a number of different conditions, the 
aetiology of which is often multi-factorial in nature (Archer and Proudman, 2006). This 
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condition is recognised by both veterinarians and horse owners as potentially life threatening 
(Gonclaves et al., 2002; Al Jassim and Andrews, 2009). Previous colic research has focussed 
on risk factors, prevention and medical and surgical management. The focus of this thesis is on 
factors associated with impaired parasite control which may affect the risk of colic.  
1.2.1. Risk factors for colic 
One of the biggest risk factors for colic within routine daily horse management is change to the 
diet (Tinker et al., 1997; Cohen et al., 1999; Hudson et al., 2001; Hillyer et al., 2002). Feeding 
practices have long been associated with colic, Gamgee (1857) stated “too much hay and an 
excessive quantity of corn may induce violent indigestion and gripes… new hay and new oats 
combined are proverbially known to be injurious”. When the diet is changed rapidly, especially 
when altering starch rich concentrate feeds, this alters the hindgut microbiota. High levels of 
hydrolysable carbohydrates (CHOs) and fermentable CHOs found predominantly in cereals 
can reach the hindgut and be rapidly fermented (Potter et al., 1992; Longland et al., 1999; 
Hoffman et al., 2001; Julliand et al., 2001; de Fombelle et al., 2003).  Rapid fermentation of 
these CHOs leads to an excess of lactic acid as a fermentation product which leads to hindgut 
acidification (Julliand et al., 2001; de Fombelle et al., 2003).  
The environment in the normal equine hindgut is usually around pH 7.0 (Julliand et al., 2001: 
Medina et al., 2002) and anaerobic. Fibrobacter spp., which are cellulolytic bacteria, and 
members of the Ruminococcaceae are acid-intolerant and as pH decreases, these bacteria are 
suppressed and completely inhibited at pH <5.9 (Shirazi-Beechey, 2008; Daly et al., 2012). 
Similarly as rapidly fermentable CHO increases, the saccharolytic Bacillus-Lactobacillus-
Streptococcus (LBS) group proliferates (Shirazi-Beechey 2008). These saccharolytic species 
are responsible for the production of lactate and favour hydrolysable CHOs as substrates. They 
do not ferment structural carbohydrates, instead they use oligosaccharides released by 
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fibrolytic organisms (Daly et al., 2012). Members of the LBS group, including Streptococcus 
bovis are associated with acidosis of the hindgut (Daly et al., 2012: Biddle et al., 2013). An 
overview of the fermentation pathways of dietary carbohydrates in the horses’ hindgut can be 
seen in Figure 1.2. below.  
 
Figure 1.2. Fermentation pathways of dietary carbohydrates in the horses’ hindgut (Shirazi-
Beechey, 2008).  
Figure 1. 2 demonstrates the conversion by Veillonella of lactate to the SCFA propionate, a 
source of useful energy to horses. In humans and ruminants as lactic acid in the hindgut 
increases the abundance of Veillonellaceae spp. also increases, forming up to 10% of the 
hindgut microbiota (Duncan et al., 2007; Daly et al., 2012). However in the horse the 
population of Veillonellaceae spp. appears to remain around 1% of the hindgut microbiota 
even when the lactate content increases (Daly et al., 2012; Proudman et al., 2015).  
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Clinical observations and the studies cited above suggest that the equine hindgut microbiota 
may not adapt well to abrupt dietary change.  
1.3. Parasitism and colic 
Parasitism is a well-documented cause of colic in the horse (Archer and Proudman, 2006), 
having been associated with significant burdens of strongyles, Anoplocephala perfoliata and 
Parascaris equorum (Reinemeyer and Nielsen, 2009).  Historically the large strongyle, 
Strongylus vulgaris, was believed to be responsible for up to 90% of all colic episodes in 
domesticated horses (White, 1997). In the 1960s Strongylus vulgaris was deemed the most 
prevalent and the most pathogenic parasite of the horse. The larvae of this parasite migrate 
from the large intestine through the mesenteric arteries causing thrombosis and arteritis which 
can lead to thrombo-embolism resulting in severe colic and death due to infarction and necrosis 
of the intestinal wall (Proudman and Matthews, 2000; Nielsen et al., 2008). Prophylactic 
anthelmintic use was employed to target Strongylus vulgaris. This approach had the desired 
effect as by the early 1980s the small strongyles, cyathostomins, frequently made up almost 
100% of a horses strongyle egg output (Nielsen et al., 2008; Kaplan and Nielsen, 2010). 
However the reduction in prevalence of Strongylus vulgaris did not lead to a reduction in the 
number of colic cases presented to veterinary surgeons. Nevertheless epidemiological studies 
have identified that well-structured parasite control programmes do reduce the risk of colic 
occurrences (Uhlinger 1990; Cohen et al., 1999; Hillyer et al., 2002).  
Cyathostomins have also been implicated in the onset of colic (Murphy et al., 1997). The first 
report of cyathostomins associated colic was in France in 1913 (Herd, 1990).  In a multiyear 
study Uhlinger (1990) reported that the use of effective anthelmintic schedules to suppress 
faecal egg counts in horses resulted in a reduced incidence of colic. Furthermore as the 
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anthelmintic schedule improved and the faecal egg counts reduced, the incidence of colic 
decreased proportionally (Uhlinger, 1990).  
Cyathostomins have previously been associated with caecocaecal intussusceptions and non-
strangulating infarctions (Lyons et al., 1994; Mair and Pearson, 1995). While it has been 
suggested that colic associated with cyathostomins is rare (Reinemeyer and Nielsen, 2009), 
further epidemiological studies have identified a reduced risk of colic when targeting 
cyathostomins with prophylactic anthelmintic treatment (Reeves et al., 1996). Murphy and 
Love (1997) identified a pathological role of L3 larvae invading the hindgut, supporting earlier 
studies linking cyathostomins to changes in intestinal motility (Bueno et al., 1979).  
1.3.1. Cyathostomins 
Cyathostomins are ubiquitous in grazing horses, and currently the most prevalent  and 
pathogenic parasites of the horse (Love et al., 1999; Kaplan and Nielsen, 2010; Matthews, 
2011; Relf et al., 2011). With over 50 different species identified, it is only recently that 
research has started to provide a greater understanding of the contribution that each 
cyathostomin species plays in the parasites epidemiology, clinical disease and in anthelmintic 
resistance (Matthews, 2008; 2011). The most pathogenic stage of the cyathostomes non-
migratory lifestyle is the larval emergence from the intestinal mucosa, Figure 1.3. Infective L3 
larvae are ingested by the horse from pasture. The L3 larvae travel to the large intestine where 
they penetrate the submucosa and mucosa into the intestinal wall. Once encysted in the mucosa 
the L3 develop into Early L3 (EL3) stages, known as hypobiosis, and can remain in this state 
for two years or greater (Love and Mckeand, 1997). However EL3 can move straight to late 
L3 phase (LL3), then on to Early L4 (EL4) where they then re-emerge into the lumen and 
undergo one final moult before becoming sexually reproducing adult cyathostomins, Figure 
1.3. (Matthews, 2008; 2011). The adult parasites have a much lower pathogenicity than the 
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larval stages but are easier to target with anthelmintics which prevent further egg shedding and 
re-infection (Kaplan and Nielsen, 2010). 
While horses are susceptible to cyathostomin infections throughout their lives, young animals 
have higher burdens compared to mature animals. This suggests that some immunity is gained 
from previous exposure (Lyons et al., 1999; Klei and Chapman, 1999). An immunological 
mechanism to prevent infection has been proposed; upregulation of cytokines by Th-2-type T-
cells. Cytokines IL-4, IL-5, IL-6, IL- 9, IL-10 and IL-13 have been identified in both murine 
models and in horses when looking at strongyle infections (Klei and Chapman, 1999). However 
this immunity mechanism is still not well understood.  
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Figure 1.3. (A) The non-migratory cyathostomin lifecycle, the red boxes depict the most 
pathogenic aspect of the life cycle. (B) The gut lumen showing ingested L3 larvae becoming 
encysted and either continuing to develop or going into hypobiosis before re-emerging as L4 
larvae into the gut lumen. A mass emergence of L4 can lead to clinical disease 
cyathostominosis. Figure adapted from Fort Dodge (2008).  
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While cyathostomins are classed as the most pathogenic parasite of equids, clinical disease is 
uncommon (Reinemeyer and Nielsen, 2009). Larval cyathostominosis is the clinical disease 
that occurs when encysted cyathostomin larvae synchronously re-emerge from the mucosa into 
the gut lumen (Love et al., 1999). Horses present with diarrhoea and weight loss (Murphy et 
al., 1997; Proudman, 1999) and this condition is most commonly seen in younger animals in 
the early spring (Murphy et al., 1997; Matthews, 2011). In some animals this syndrome will 
present as colic (Matthews, 2011).  The mechanisms behind larval cyathostominosis are not 
fully understood. Changes in ingested L3 cyathostomins linked to the external environment 
e.g. cold conditioning, the numbers of adult nematodes in the gut lumen providing negative 
feedback to encysted larvae, and recent anthelmintic treatment have all been implicated in the 
onset of disease (Murphy et al., 1997; Love et al., 1999; Matthews, 2008; 2011). Up to 90% of 
a horse’s cyathostomin burden can be encysted (Duncan et al., 1998; Dowdall et al., 2002; 
Matthews, 2008). Horses that appear clinically healthy can harbour cyathostomin burdens 
numbering hundreds of thousands of larvae or worms without showing signs of clinical disease 
(Fog et al., 2011; Stratford et al., 2011). However it is well-established that the higher the 
cyathostomin burden the greater the risk of clinical disease (Matthews, 2008; 2011). 
The pathogenesis of cyathostomin infections is as an inflammatory enteropathy due to larval 
penetration or larval emergence from the large intestinal mucosa (Love and Murphy, 1997; 
Love et al., 1999). Differences in the levels of inflammatory cytokines, specifically IL-4, IL-
10 and TNFα have been identified in horses harbouring cyathostomins compared to untreated 
controls (Matthews et al., 2004). Mast cells have also been identified as playing a role in 
cyathostomin infected horses (du Toit et al., 2007).  
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1.3.2. Parasite control mechanisms  
Since the 1960s anthelmintic dosing has been the predominant form of equine endoparasite 
control. In an attempt to reduce the prevalence of Strongylus vulgaris and reduce incidence of 
colic, the interval dose programme was proposed. Drudge and Lyons (1966) suggested 
anthelmintic treatment every 8 weeks to prevent Strongylus vulgaris egg shedding and prevent 
the parasite reaching L5 maturity. This regimen shaped anthelmintic use and is still in use by 
many horse owners today.   
However there are other forms of parasite control to consider alongside anthelmintics. 
Strongyle infections are picked up on the pasture, only one study has reported that L3 larvae 
could survive in deep littered stables (McGirr et al., 2015). Pasture management consisting of 
dung removal has previously been identified as the most effective form of parasite control 
(Herd, 1986; Coles, 2002; Lloyd et al., 2000; Nielsen et al., 2010a). Removal of faeces is 
preferred to chain harrowing which spreads infective larvae and increases pasture fouling (Herd 
1990). Cross grazing with ruminants is also an effective method of parasite control (Coles, 
2002).  
There has been some work on the use of the nematophagous fungus Duddingtonia flagrans 
which was identified by Braga et al. (2009) to have efficacy against L3 larvae in vitro. Further 
reports by Cazapal-Monteiro et al. (2012) and Arias et al. (2012) indicated that spreading D. 
flagrans on pasture increased the egg reappearance time of horses treated with moxidectin. 
Maderia de Carvalho et al. (2012) supplemented horses daily with D. flagrans and also showed 
increased anthelmintic egg reappearance times. A daily dose of D. flagrans of a sufficient 
quantity, <3 x 105 per kg of body weight, has been reported to significantly reduce 
cyathostomin L3 larvae (Buzatti et al., 2015).  However Nielsen (2012) reported that while this 
biological technique was patented in the early 2000s no commercial product has yet reached 
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the market. The reason behind this is unknown, however survival through the gastro intestinal 
tract would require investigation and calculation of a sufficient dose that survives digestion 
also requires consideration.  
There has been some focus on the use of tannin rich forages in reducing strongyle egg viability 
(Collas et al., 2015).  There has also been some work into the use of plant extracts, in vitro, on 
cyathostomins with significant effects on egg hatch viability and larval inhibition (Peachey et 
al., 2015:2016).  
While many different methods of parasite control have been explored over the past 50 years, 
there is still a heavy reliance on anthelmintics as the primary strategy for intestinal nematode 
control.  
1.3.3. Anthelmintics 
The first broad spectrum group of anthelmintics, the benzimidazoles (BZs), were introduced to 
the market in the 1960s (Herd, 1990). Benzimidazoles act on β-tubulin proteins and interfere 
with glucose metabolism starving the parasite to death (Martin, 1997; Brady and Nichols, 
2009).  Fenbendazole is licensed for treatment against large and small strongyles in horses. It 
is also licensed to treat the larval stages of cyathostomins whilst encysted in the gut mucosa. 
For this larvacidal efficacy the anthelmintic is administered orally over five consecutive days.  
Early studies into the efficacy of BZs identified 97-100% efficacy on adult cyathostomins and 
46-78% efficacy on L4 larvae using both faecal egg counts and worm counts at necropsy 
(Colgazier et al., 1977). The lower efficacy on the L4 larvae was proposed to be down to L4 
emergence from the mucosa between treatment and necropsy (Colgazier et al., 1977).  
Larvacidal efficacy of fenbendazole has been reported as >91.5% on early 3rd stage larvae and 
>99.4% on late 3rd stage and developmental 4th stage encysted larvae (Duncan et al., 1998). 
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BZs also claim ovicidal efficacy unlike other anthelmintic classes licensed for horses (Lacey 
et al., 1987). 
The tetrahydropyrimidines (THPs) were the second group of broad spectrum anthelmintics 
licensed for equine nematode treatment in the 1970s. When introduced to the market the active 
drug pyrantel was shown to eliminate 89-96% of adult cyathostomins in a single dose (Lyons 
et al., 1974). Pyrantel is only efficacious against adult nematodes, it acts as an agonist on 
acetylcholine receptors of nematode muscle cells leading to paralysis (Martin, 1997).  
In the 1980s the macrocyclic lactone (ML) group of broad spectrum anthelmintics were 
introduced.  Ivermectin was licensed for equine nematode treatment in the early 1980s and 
moxidectin was licensed in the UK in the late 1990s (Kaplan, 2004). The two compounds are 
chemically related and share similar structural features. Ivermectin is a modified avermectin 
that possesses a disaccharide linked to the carbon ring structure. Moxidectin lacks this sugar 
and is classified as a milbemycin (Cobb and Boeckh, 2009). Avermectins and milbemycins 
collectively make up the ML group (Sangster, 1999). 
Both of these anthelmintics also share a common mode of action targeting the nematodes 
pharynx and binding with glutamate-gated Cl‾ channels  increasing Cl‾ currents leading to 
paralysis (Sangster, 1999; Schumacher and Taintor, 2008; Cobb and Boeckh, 2009). 
Ivermectin also causes paralysis to the somatic musculature but this site is suggested to be less 
sensitive to the compound than the pharynx. In both in vitro and in vivo studies of ruminant 
species, resistance to ivermectin also is associated with side-resistance to moxidectin, thus 
suggesting the common mode of action. This side-resistance has not yet been reported in horse 
cyathostomins (Sangster, 1999).  
Early studies indicated that both ivermectin and moxidectin had 99% efficacy against adult 
cyathostomins and 98% efficacy against luminal L4 cyathostomins. For the encysted stages 
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neither ivermectin nor moxidectin were effective against EL3 larvae and only moxidectin was 
efficacious against encysted LL3 (62.6-79.1%) (Xiao et al., 1994). Further work by Bairden et 
al. (2006) identified 99% moxidectin efficacy on adults and L4 in the lumen and 92.2% for 
encysted EL3 larvae. This work identified that moxidectin was useful as a larvicidal treatment 
for cyathostomins. Its lipophilic nature means that efficacy against cyathostomin larvae may 
persist for 2-3 weeks post administration (Schumacher and Taintor, 2008).  Different studies  
have evaluated larvicidal efficacy on necropsied horses at different time periods post dosing 
which has shown differences in the efficacy of the EL3 and LL3, DL4 stages of encysted 
development (Matthews, 2008). 
The egg reappearance period of ivermectin was 8-10 weeks when it was first marketed 
(Borgsteede et al., 1993). The datasheets for Ivermectin products in the UK no longer contain 
ERP times (NOAH compendium, 2017a). Moxidectin egg reappearance was reported in excess 
of 13 weeks, and up to 24 weeks, post treatment when it was first introduced (Jacobs et al., 
1995; DiPietro et al., 1997; Demeulenaere et al., 1997; Boersema et al., 1998). The current 
marketing authorisation for moxidectin states 90 days egg suppression for cyathostomins 
(NOAH Compendium, 2017b). 
The larvacidal efficacy of both a five consecutive day dose of fenbendazole and a single dose 
of moxidectin has previously been compared (Steinbach et al, 2006). This study highlighted 
that both of these treatments were efficacious against mucosal stages of cyathostomin 
development, fenbendazole for 4-6 days post treatment and moxidectin for 6-14 days post 
treatment.  
1.3.4. Anthelmintic control strategies 
Between the 1960s and the 1990s the continual addition of new anthelmintics being licensed 
for equine nematode treatment meant that prophylactic use of anthelmintics was the main focus 
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for parasite control.  Over time horse owners and veterinarians have developed an irrational 
fear of parasites (Kaplan and Nielsen, 2010), leading to regular anthelmintic treatment to 
prevent colic. Veterinarians would often answer questions on parasite control with ‘there is a 
drug for that’ (Sangster, 2003).  This compulsion to treat horses for parasites, without the 
knowledge of the horse’s parasite status, aiming treatment at a parasite that is no longer 
prevalent, is a practice that is 40 years out of date (Kaplan and Nielsen, 2010).   
In 1999 Biggin et al. surveyed pony club members to identify parasite control practices and 
knowledge. Ivermectin was the predominant anthelmintic used within this group, moxidectin 
was not available when this data was collected. Respondents reported they changed the brand 
of anthelmintic with each treatment, however brand does not necessarily identify with 
anthelmintic class. The majority of respondents were confused as to the efficacy of the different 
anthelmintics for specific parasites.  There was some understanding of pasture management 
but faecal removal from pasture was less frequent than recommended to reduce pasture 
contamination (Biggin et al., 1999). Similarly Lloyd et al. (2000) surveyed horse owners on 
parasite control practices and found that ivermectin was the predominant anthelmintic used. 
Again, at the time of data collection moxidectin was not yet available. This study reported a 
greater focus on twice weekly dung removal from pasture compared to the findings of Biggin 
et al. (1999). Most of the respondents of Lloyd’s study dosed horses with anthelmintic at a 
frequency of eight weeks or less. In a similar study by Allison et al. (2011)  owners 
predominantly selected moxidectin followed by ivermectin for anthelmintic dosing. Of 574 
respondents less than 60% were comfortable with their current anthelmintic schedule but 39% 
never used faecal egg counts and 20% only used FECs sporadically. These findings suggest 
that while some horse owners have started to realise that reliance on anthelmintics is 
unsustainable for nematode control, many horse managers are still using outdated control 
strategies. 
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1.3.5. Sustainable parasite control strategies 
With anthelmintic resistance becoming a greater concern there has been a shift in focus away 
from prophylactic anthelmintic treatment. Faecal egg counts were reported as a useful 
economical tool to identify horses that shed high numbers of nematode eggs and therefore 
selective chemotherapy with anthelmintics could be targeted at these animals (Gomez and 
Georgi, 1991). Further work by Duncan and Love (1991) identified that this selective treatment 
approach may also be more economically viable than an interval dose regimen. Part of the 
rationale for a targeted anthelmintic approach is that the parasite distribution within horses 
tends to be over-dispersed, thus concentrated to few animals, Figure 1.4. (Duncan and Love, 
1991; Matthews, 2008; Stratford et al., 2011). Typically on a horse premises 80% of the 
parasite population resides within 20% of the horses present on that premises (Stratford et al., 
2011). Young animals in particular are more susceptible to infection, (Klei and Chapman, 
1999). These points collectively suggest that diagnostic testing should be employed to identify 
horses within a population that are the high egg shedders, in order to target treatments at these 
animals.  
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Figure 1.4. Schematic diagram of the over dispersion of cyathostomins within a horse 
population, shaded horses harbouring cyathostomin burdens of concern, unshaded harbouring 
very low cyathostomins burdens. Treating high shedders and leaving low shedders untreated 
creates a refugium (Matthews, 2008).   
 
Faecal egg counts are considered by many to be the cornerstone of equine parasitological 
diagnostic techniques. There are numerous different egg counting techniques including 
McMaster, Stoll and Wisconsin (Nielsen et al., 2010a; Nielsen 2014). Modifications of these 
techniques, commercial kits (Presland et al., 2005) and refined methods with increased 
sensitivity have all been employed. Fundamentally all of these techniques are designed to float 
nematode eggs to allow quantification via microscopy (Nielsen et al., 2010a; Stratford et al., 
2011; Nielsen 2014).  
Faecal egg counting is a low cost diagnostic option that is quick and simple to perform. Sample 
collection is straight forward and non-invasive making it possible for horse managers to collect 
samples and submit these for analysis. For greatest accuracy samples should be tested within 
12 hours of faecal excretion, however samples have been successfully refrigerated in air tight 
containers for up to 120 hours without significant alteration in egg numbers (Nielsen et al., 
2010b).  This diagnostic technique holds limitations but forms part of a holistic approach to 
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parasite control. When using faecal egg counts and interpreting the data several limitations 
need to be considered: the lower limit for egg detection, repeatability of results, consideration 
of the horse’s age, previous anthelmintic dosing history and the time of year the sample was 
taken.  
Lloyd (2009) reported that some horses continually shed low levels of faecal eggs, but their 
egg shedding predictability could not be defined without 12 months of monitoring. Similarly 
their previous anthelmintic history also influenced high or low egg shedding when moving to 
a monitoring-based programme (Lloyd, 2009). Concerns over fluctuations in daily nematode 
egg output have previously been reported (Uhlinger, 1993). Recent studies have evaluated 
variability in faecal egg output over time; Carstensen et al. (2013) found that from a group of 
six horses FECs undertaken on five consecutive days were not significantly different. Using a 
longitudinal approach over a two year period Lester et al. (2017) screened the faeces of a group 
of 573 horses four times over two years. They reported that 73% of horses remained in the 
same egg shedding category throughout the study and 94% remained in the same treatment 
category. For those horses that received no anthelmintic treatment over the study, 90.4% 
remained within the same egg shedding category. Horses that changed egg-shedding category 
were predominantly young animals. The overall results of this study suggest that horses with 
low strongyle burdens are likely to consistently remain low over time.  
Historically concerns over using a FEC monitoring approach have centred on the limitation of 
high proportions of cyathostomins being encysted within the mucosa and therefore 
undetectable. Recent work has identified the potential to detect encysted cyathostomin larvae 
using an ELISA assay, however this test is not yet commercially available (Mitchell et al., 
2016). Until such a time that this test is commercially available faecal egg counts remain the 
gold standard for estimating strongyle burdens.  
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 Earlier studies reported that there was no correlation between FEC and total cyathostomin 
burden, luminal and mucosal stages, (Uhlinger, 1993). However Nielsen et al. (2010c) found 
that FECs of 500 epg and below were correlated with lower total worm burdens.  
There is debate in the literature concerning the threshold FEC reading which should trigger 
anthelmintic intervention. The first point to consider here is each horse is an individual, 
therefore age, previous anthelmintic dosing history, pasture management, stocking densities 
time of year and faecal egg count history will all play a role in clinical decision-making. Early 
studies suggested treating horses with a FEC >100 epg (Gomez and Gerogi, 1991). This has 
subsequently been modified to >200 epg, now the most commonly cited cut-off in the literature 
(Matthews, 2008; Kaplan and Nielsen, 2010; Nielsen, 2014). However both Uhlinger (1993) 
and Nielsen (2012) recommend treatment cut-offs could be >500 epg in mature horses. It is 
important to note here that these cut-off points are arbitrary, “best guess” figures based upon 
the limited information available (Uhlinger, 2007). Taken together our limited understanding 
of cyathostomin biology and infection pathogenicity mean that ideal cut offs for anthelmintic 
treatment are currently unknown. 
1.3.6. Refugia 
A fundamental concept of sustainable parasite control is having a proportion of parasites within 
a population not exposed to anthelmintics, thus remaining “in refugium” (Sangster, 1999; 
Matthews, 2008; Nielsen et al., 2010a; Nielsen et al., 2014). These parasites that remain 
unexposed to anthelmintic reduce the selection pressure for anthelmintic resistance by keeping 
drug susceptible parasites within the population (Figure 1.4.). By only treating high egg 
shedding horses the nematodes in the rest of the horse population remain in refugia (Nielsen et 
al., 2010a).   As refugia refers to any nematodes not exposed to anthelmintic, mucosal stage 
cyathostomins remain in refugia when the horse is dosed with ivermectin, pyrantel, or a single 
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dose of fenbendazole as these drugs are not efficacious against the encysted mucosal stages 
(Kaplan and Nielsen, 2010).  
1.3.7. Application of sustainable parasite control 
One of the greatest challenges in implementing sustainable parasite control measures is owner 
uptake. Over the past 20 years there have been studies published identifying the need to move 
to sustainable parasite control programmes. The findings of Biggin et al. (1999) identified that 
horse owners were frequently using anthelmintics but worm burdens were not a great concern. 
Allison et al. (2011) reported that horse owners were concerned about anthelmintic use and the 
risk of resistance development but were constrained by livery yard rules, or misinformed on 
how to use faecal egg counts which meant they remained reliant on anthelmintics (Allison et 
al., 2011). Although Duncan and Love (1991) identified the potential for financial savings 
taking this approach, horse owners still express hesitation and concerns over the costs 
implicated in moving to a monitoring-based approach (Nielsen et al., 2010a). It has been 
reported that owners who bought anthelmintics from their veterinarian were more likely to use 
faecal egg counts (Easton et al., 2016). The same study identified owners who bought 
anthelmintics via all of the possible routes e.g. veterinarian, suitably qualified person or 
pharmacist were all using faecal egg count monitoring to some extent, but there was limited 
uptake of efficacy testing (Easton et al., 2016).  
A recent study by Vineer et al. (2017) concluded that focussing on emphasising the risk of 
anthelmintic resistance was not enough to change horse owner behaviour. More effort needs to 
be focussed on appropriate knowledge transfer and training mechanisms and more research 
focus on owner opinions and attitudes towards equine parasite control are needed to support 
behavioural change.  
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1.3.8. Shortened egg reappearance periods 
Anthelmintic resistance is a process that occurs over time, it is a manifestation of adaptive 
evolution. The stage between drug-sensitive parasites and drug-resistant parasites is referred to 
as reduced efficacy (Lyons et al., 2011). Reduced efficacy of anthelmintics is seen as shortened 
egg reappearance periods and viewed as an early sign of anthelmintic resistance (Sangster 
1999; Kaplan and Nielsen 2010; Lyons et al., 2011).   
When anthelmintics are first licensed they all have an evidence-based efficacy period (egg 
reappearance period, ERP) stated on the marketing authorisation which is reproduced as a 
product data sheet. The ERP is the period post treatment during which egg shedding is below 
a given threshold. The ERP period varies with each anthelmintic, guide e.g. for BZs it is 6-8 
weeks, for THPs 6 weeks, IVM 8-10 weeks and MOX >13 weeks (Stratford et al., 2011).   
One problem with using ERP is the lack of definition of ERP. In a range of studies that have 
set out to investigate efficacy, ERP has been interpreted differently.  Some view ERP as the 
first point where any eggs are seen post treatment, e.g. Little et al. (2003). Other studies use 
the point the group arithmetic mean FEC >10% of the Day 0 value (Borgsteede et al., 1993; 
Jacobs et al., 1995; Boersema et al., 1998; Mercier et al., 2001; von Samson-Himmelstjerna et 
al., 2007; Larsen et al., 2011). A third approach is to look for a percentage faecal egg count 
reduction (FECR) within the stated egg reappearance period for the product (Larson et al., 
2011; Molento et al., 2012; Nielsen et al., 2013a; Relf et al., 2014). This lack of definition 
makes it difficult to compare studies.  
Several studies have been conducted in the USA to determine the current ERP of ML 
anthelmintics. In 2011 Lyons et al. conducted a field study on 369 horses at 14 farms in 
Kentucky. Overall the ERP for ivermectin was similar on most farms returning positive counts 
at 4 weeks post treatment and moxidectin returning positive FECs at 5 weeks post treatment. 
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The farms had all used ML anthelmintics extensively in prophylactic programmes in the past. 
Lyons et al. (2011) reported that most farms had used ivermectin but some had not used 
moxidectin before yet still showed reduced moxidectin efficacy. Little et al. (2003), over a 3 
year period, detected positive faecal egg counts before 8 weeks following ivermectin at a North 
Carolina stud farm. More recently Lyons et al. (2017) reported ERP for moxidectin at 4-6 
weeks. 
In Australia Edward and Hoffmann (2008) looked at FEC patterns in 50 horses at 10 farms post 
treatment over 3 years. The study highlighted that overall there was shortened egg reappearance 
following ivermectin treatment, with eggs reappearing from 26 days post treatment in horses 
that were regularly dosed at 6-8 week intervals (Edward and Hoffmann, 2008). In the UK 
Dudeney et al. (2008) were the first to highlight reduced efficacy to ivermectin. More recent 
studies have identified egg reappearance from 6 weeks post moxidectin treatment (Tzelos et 
al., 2017). 
1.3.9. Anthelmintic resistance 
The first reports of anthelmintic resistance in equine cyathostomins was to phenothiazine in 
1958 by Poynter and Hughes in the UK and in 1961 by Drudge and Elam in the USA (Kaplan, 
2004), therefore the concept of anthelmintic resistance is not new. Anthelmintic resistance is 
inherited from one generation to the next via the genome. Because cyathostomins have high 
levels of genetic diversity and are generally present in populations of hundreds of thousands in 
most healthy animals, resistant genes can develop and spread quickly within  populations 
(Matthews 2008; 2011). 
Benzimidazole resistance in cyathostomins  was first reported in 1965 in Kentucky (Herd, 
1990; Kaplan, 2004). Resistance to one member of the benzimidazole family confers resistance 
to other members of that class, with the exception of oxibendazole which appears to remain 
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efficacious against resistant cyathostomins for a limited time (Prichard, 1990; Tarigo-Martinie 
et al., 2001). Resistance to this group of anthelmintics  has continued to spread and has now 
been documented as widespread and worldwide (Matthews, 2008). In some areas prevalence 
of benzimidazole resistant strains of cyathostomins has been found on 100% of premises 
investigated (Kaplan et al., 2004; Kaplan and Nielsen, 2010).  
Cyathostomin resistance to pyrantel is documented in the USA (Kaplan, 2002; Kaplan et al., 
2004; Relf, et al., 2011). However in the USA low dosages of pyrantel were historically given 
daily as a feed additive which increased selection pressure for resistance (Kaplan et al., 2004; 
Kaplan and Nielsen, 2010). It has been postulated that resistance to pyrantel  and ivermectin 
has been slow to develop in cyathostomins due to the lack of larvacidal efficacy creating a 
larger refugium (Kaplan and Nielsen 2010; Stratford et al., 2011). There is growing concern 
about the development of multi drug resistance (MDR) in cyathostomins following the reports 
of widespread MDR in sheep (Matthews, 2008). This is especially critical due to the limited 
drug classes licensed for equine nematode treatment.  
A significant concern for equine clinicians is efficacy of the larvicidal properties of 
fenbendazole, given at a five consecutive day dose at 7.5mg/kg, and moxidectin. The most 
pathogenic stage of the cyathostomin lifecycle is larval re-emergence from encysted 
development. With limited anthelmintic treatment options available to target these encysted 
larval stages, resistance to these larvacidal drugs is a serious concern. There have been no 
controlled efficacy or critical trials conducted on the larvacidal efficacy of fenbendazole in 
resistant populations. Studies have documented continuous egg shedding following five 
continuous days of treatment in known resistant populations (Matthews, 2008). A study by 
Hodgkinson et al. (2005) used stabled horses that were known to harbour BZ resistant 
cyathostomins. These horses were treated with pyrantel to remove any adult parasite 
population. Efficacy of pyrantel was tested using a faecal egg count reduction test which 
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resulted in an average 98% reduction. Seven days post pyrantel treatment these horses were 
given a five day larvacidal dose of fenbendazole. At 28 days post FBZ treatment, strongyle 
eggs were reappearing in faecal egg counts. As these horses were stabled, and therefore 
unlikely to become infected within their environment, this egg appearance was suggested to be 
due to a failure of the FBZ on the mucosal stages (Matthews, 2008). This contrasts to the 
findings of Duncan et al. (1998) where in BZ susceptible cyathostomins, larvicidal efficacy on 
encysted larvae was >91.5% on early 3rd stage larvae and >99.4% on late 3rd stage and 
developmental 4th stages. 
A study in Kentucky compared both five day fenbendazole and moxidectin larvicidal 
treatments in a group of yearlings at the University of Kentucky. All of the yearlings had faecal 
samples taken on day 0 and a proportion of the yearlings were given a larvacidal dose of 
fenbendazole as part of a faecal egg count reduction test. There was no significant difference 
in faecal egg count results between day 0 and day 14 in the FBZ treated horses (Rossano et al., 
2010). Further faecal samples were collected from each animal weekly, after 14 days 
moxidectin was administered to all of the yearlings on the farm. During the moxidectin trial 
the FEC results on days 0 and 42 did not significantly differ from those horses that had been 
treated with fenbendazole. Overall moxidectin egg suppression persisted for up  to 21 days, at 
35 days all but two of the 15 yearlings had some egg reappearance (Rossano et al., 2010). The 
findings of this study suggest fenbendazole resistance and reduced efficacy of moxidectin in 
this horse population (Rossano et al., 2010).   
In a more recent study Reinemeyer et al. (2015) evaluated the larvicidal efficacy of 
fenbendazole and moxidectin in a BZ resistant population in the USA. The results of this study 
indicated lower BZ larvicidal efficacy than historically reported, 71.2% against LL3 – L4 
compared to 85.2% for moxidectin. EL3 efficacy was 38.6% for fenbendazole versus 63.6% 
for moxidectin. The faecal egg count reduction tests were 44.6% and 99.9% for fenbendazole 
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and moxidectin respectively. While it may appear that there was still good moxidectin efficacy, 
the larvicidal effect was not significantly different between fenbendazole, moxidectin and the 
untreated controls (Reinemeyer et al., 2015). The authors conclude that the reason for the 
apparent reduction in larvicidal activity of both anthelmintics was most likely due to the time 
between treatment and necropsy. The findings of these studies taken collectively are a 
significant concern for the future treatment of encysted cyathostomin larvae.  
1.3.9.1. ML resistance 
The first reports of moxidectin and ivermectin resistant cyathostomins came from Brazil in 
2008 in a group of naturally infected horses (Molento et al., 2008). Faecal egg count reduction 
was 16% following moxidectin treatment and 56% following ivermectin treatment.  
In the UK there has been one case report of a failure of MLs to reduce strongyle egg output in 
donkeys (Trawford et al., 2005). However the authors of this study acknowledge that the 
moxidectin administered was “off-label” as it was an intra-muscular cattle formulation for 
injection. The pharmacokinetics of moxidectin in donkeys is unknown, horses and donkeys 
require different dosage rates. An extrapolation of horse data alone is not reliable when dosing 
donkeys (Molento et al., 2012). Therefore the findings of this study should be interpreted with 
extreme caution.  
Macrocyclic lactone resistance in cyathostomins identified through the faecal egg count 
reduction test have been reported in Brazil, Finland and Italy (Peregrine et al., 2014). These 
findings suggest ML resistance is spreading within the parasite population.  
1.4. Cross Species comparisons 
Anthelmintic resistance in nematode species of small ruminants is much better understood than 
for horses. Ruminant species harbour strongylid nematodes closely related to cyathostomins 
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with a high prevalence of BZ, THP and ML resistance worldwide (Kaplan and Nielsen 2010; 
Molento et al., 2012). From the situation of ML resistance in trichostrongyloids in sheep and 
the similarities to equine cyathostomins, it is likely than anthelmintic resistance to MLs will 
occur in equine cyathostomins (Sangster, 1999). The differences between cyathostomins and 
trichostrongylids need to be considered in that i) cyathostomins have a longer pre-patent period 
that varies with each species, ii) cyathostomins spend more time in inhibited development 
which provides greater refugia, iii) horse management, e.g. dung collection can reduce re-
infection that is not possible with sheep and iv) horse movement between properties allows 
greater risk of spreading resistant parasites (Sangster, 1999; Molento et al., 2012; Nielsen et 
al., 2014). 
The first reports of multi-drug resistance (MDR) in sheep were in the 1980s (Kaplan, 2004); 
since then the phenomenon has become widespread among sheep and goats and has been 
reported worldwide. In the strongylid nematodes of sheep, benzimidazoles were licensed for 
use in 1961; resistance was first reported in 1964. Ivermectin was licensed for use in sheep in 
1982, the first report of resistance to IVM in these nematodes was in 1985. Moxidectin was 
licensed for use in sheep in 1991 and resistance was reported in 1995 (Kaplan, 2004). In 2001 
Sargison et al. reported a case of MDR parasites at a sheep farm in Scotland with resistance to 
BZs, THPs and ivermectin. In 2005 Sargison et al. conducted a second study on the same farm 
to investigate the efficacy of moxidectin; resistance was confirmed and the decision was made 
to close the farm, highlighting the first case of MDR in sheep in the UK. The lessons learnt 
from sheep nematode control suggest that if sustainable parasite control mechanisms are not 
implemented for horses, then MDR parasites of horses will develop.  
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1.5. Combination Anthelmintics 
One of the  current approaches to preserving the efficacy on new groups of anthelmintics 
licensed for sheep is to combine two active ingredients that act on different sites of the parasite 
(Leathwick, 2012). The concept is to combine anthelmintics from different classes with 
different modes of action, to reduce the speed of anthelmintic resistance (Leathwick, 2012).  
This theory arose from the concept that if there is reduced efficacy to one anthelmintic class 
that is part of the combination the second anthelmintic class will remain lethal to the parasite 
(Leathwick, 2012). This approach has been successfully used with anti-malaria drugs, 
(Hastings, 2011).  
The use of combination anthelmintics has been modelled using a computer simulation and has 
been shown to preserve the duration of efficacy of new anthelmintic classes licensed for sheep 
in New Zealand (Leathwick, 2012). In a situation where there is adequate refugia and  high 
efficacy to MLs, the addition of a new active ingredient showed almost no increase in the 
frequency for the resistant gene (Leathwick, 2012). However where the efficacy of the 
combination falls below 70% combined, then the effect of the combination is lost (Leathwick 
et al., 2012). One problem with this approach is the potential for cross resistance to develop 
between classes (Leathwick, 2012).  
An interesting consequence of combination anthelmintics is the development of side resistance 
between the MLs and BZs (Mottier and Prichard, 2008).  It appears that the use of and 
resistance to MLs  in Haemonchus contortus increases the frequency of the β tubulin alleles 
containing the dominant codon for BZ resistance (Mottier and Prichard, 2008). This has raised 
concern over the use of combination therapy as these unpredicted mutations could increase the 
speed of MDR through cross resistance (Mottier and Prichard, 2008; Leathwick, 2012). 
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Lyons et al. (2016) reported that combinations of benzimidazoles, piperazine and pyrantel were 
not effective against strongyles of Thoroughbred foals in Kentucky. This is the first report of 
an attempt to use a combination anthelmintic in horses.  
1.6. Effect of anthelmintic treatment on the gastrointestinal tract 
Epidemiological studies into colic have identified anthelmintic treatment as a risk factor for 
colic (Proudman, 1991; Cohen et al., 1999; Hillyer et al., 2002).  For each of these studies colic 
episodes followed within one week of anthelmintic administration. However the reason behind 
colic following nematode treatment is unknown.  
Studies have also investigated the effects of larvicidal activity on the intestine. Steinbach et al. 
(2006) found that a five day larvicidal dose of fenbendazole led to mucosal inflammation and 
ulceration to the mucosa, this inflammation was not reported after treatment with moxidectin. 
It was suggested that the severe tissue damage caused by fenbendazole treatment could mimic 
larval cyathostomiosis (Steinbach et al., 2006). A more recent report by Nielsen et al. (2013b) 
evaluated the inflammatory response following anthelmintic treatment in an experimental herd 
of ponies in Kentucky. Ponies were dosed with moxidectin and blood samples taken to evaluate 
cytokine expression. The findings of this study highlighted no systemic inflammatory effect of 
anthelmintic treatment. In another study, also in Kentucky, inflammatory cytokines were 
characterised following moxidectin or fenbendazole treatment from blood samples. Moxidectin 
had no systemic effect on inflammatory cytokines with the exception of an increase on TNFα 
14 days following treatment. However there was a significant increase in TNFα, IL-1β and IL-
6 following a five day larvicidal dose of fenbendazole (Betancourt et al., 2015). These findings 
support the previous findings of Steinbach et al. (2006). Betancourt et al. (2015) propose that 
it is likely the moxidectin had an anti-inflammatory effect on the intestine. Anti-inflammatory 
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effects have previously been identified for macrocyclic lactones in a murine model (Yan et al., 
2011).   
1.7. Summary 
It is apparent that cyathostomins have a complicated biology that currently is not fully 
understood. There is an association between cyathostomins and colic however the mechanisms 
behind this are not fully understood either. It is apparent that some level of control over 
cyathostomins is required to maintain horse health. However the association between parasites 
and colic has left horse owners with an irrational fear of parasites, compelling them to treat 
horses regularly with anthelmintics. The lack of understanding of the cyathostomin lifecycle 
and fear of colic by horse managers has inevitably played a role in the progression of 
anthelmintic resistance. To ensure it is possible to treat mucosal encysted cyathostomin larvae 
into the future sustainable parasite control is essential to reduce the risk of intestinal disease 
occurring.  It is also important to understand the current efficacy of the most recent 
anthelmintics licensed for equine nematode treatment within the UK, to identify if resistance 
is developing within the macrocyclic lactones. Furthermore anthelmintic classes such as the 
benzimidazoles that have novel modes of action may still be useful, potentially in combination 
with other classes, against resistant populations. However the ovicidal efficacy of 
benzimidazoles on BZ resistant cyathostomins has not been characterised.  
 Curiously, as well as cyathostomins being implicated in colic, anthelmintic treatment has also 
been implicated in the onset of colic. It is possible that anthelmintic treatment may upset the 
complex relationship between nematodes and microbiota in the hindgut of the horse. To date 
the effect of anthelmintic treatment on the equine microbiome is not well reported. As post 
dosing colic is likely to be multifactorial in nature it is important to understand if anthelmintics 
play a role in disease onset. This information would allow veterinarians to inform horse 
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managers on sustainable and effective parasite control mechanisms without compromising gut 
health.  
1.8. Research Aims 
The aim of this research was split into two distinct parts, firstly: to identify current efficacy of 
the macrocyclic lactones against cyathostomins in UK pleasure horses, and to characterise the 
ovicidal efficacy of the benzimidazole group in the face of anthelmintic resistance.  
Secondly, to use a multi ‘omics approach to characterise the microbiological and biochemical 
response within the hindgut when horses are treated with anthelmintic. This includes 
identification of any functional changes in fermentation patterns following anthelmintic 
treatment.  
Objectives: 
 Evaluate the egg reappearance times of strongyles following treatment with 
macrocyclic lactones in a field situation. 
 Test the ovicidal activity of fenbendazole in horses harbouring BZ resistant 
cyathostomins. 
 Compare fermentation kinetics of feeds fermented in faeces from horses treated with 
anthelmintic compared to untreated controls.  
 Define the composition of microbiota in horses following anthelmintic administration 
 Identify potential metabolite biomarkers associated with anthelmintic administration. 
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Chapter 2 
2.0 Review of Methods   
In order to meet the objectives of this thesis, a range of different methods and techniques were 
used. These span from more fundamental parasitology to in vitro techniques for identifying 
feed substrate fermentation patterns and “next-generation” ‘omics technologies to evaluate 
microbial community profiling and metabolite abundances. Each of the applied methods is 
briefly reviewed within this following section.   
2.1. Parasitology 
One of the difficulties with evaluating parasite burdens and anthelmintic efficacy is that there 
are no universally accepted guidelines on methods. In 1992 Coles et al. published the first 
version of the World Association for the Advancement of Veterinary Parasitology (WAAVP) 
guidelines. These guidelines were updated in 2002 specifically for evaluating efficacy of 
equine anthelmintics using the critical test (Duncan et al., 2002). However critical tests are not 
commonly used due to the requirements of slaughter and necropsy. Thus the use of faecal egg 
tests remains prominent. In 2006 Coles et al. reviewed the 1992 WAAVP guidelines adding 
greater detail to molecular methods to detect BZ resistance but with limited practical 
application in the field. Outside of these broad-reaching guidelines, reviews and 
recommendations specifically for equine parasitology have been published by Kaplan and 
Nielsen (2010), Nielsen et al. (2010a), Stratford et al. (2011), Matthews et al. (2012) and 
Nielsen et al. (2013a). Thus within the literature there are varied methods and cut off values 
reported but a lack of standardisation which makes comparing studies difficult.   
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2.1.1. Faecal egg counts 
In chapter 1 it was identified that there are a range of variations employed for diagnostic tests 
within equine parasitology. The most commonly reported faecal egg counting technique is the 
McMaster method (Stratford et al., 2011), this is a faecal flotation method allowing 
quantification of nematode eggs using microscopy. There are a range of modifications to this 
method including centrifugation, increasing the number of counting grids on a slide and 
increasing the weight of the faecal sample to be tested. These modifications aid the clarity and 
therefore speed of the test and have allowed for lower egg detection limits (Nielsen, 2014). 
Modifications to the standard McMaster protocol also improve the reliability and repeatability 
of the test (Denwood et al., 2012). 
2.1.2. Faecal Egg Count Reduction Test (FECRT) 
Currently the only method widely used in the field to detect anthelmintic resistance is the 
Faecal Egg Count Reduction Test (FECRT) (Coles et al., 2006; Matthews, 2011; Stratford et 
al., 2011). This is considered to be the “gold standard” for evaluating anthelmintic efficacy 
(Nielsen et al., 2010a). 
The WAAVP set out guidelines for the FECRT applied to horses in 1992 (Coles et al., 1992). 
The original WAAVP guidelines were set out to standardise the testing of new anthelmintics, 
however it was recognised that a standardised protocol for equine FECRT was required for 
efficacy evaluation.  
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The FECRT is a simple in vivo test that can be used in all grazing animals and all anthelmintics 
that treat nematodes. The WAAVP approved protocol: 
1. Identify animals with positive FEC >150 epg 
2. Treat with correct dosage of anthelmintic 
3. Take a second FEC 10-14 days post dosing 
4. Use the following calculation: 
 
FECRT (%) =  
 
(Kaplan and Nielsen, 2010; Stratford et al., 2011) 
 
The WAAVP (1992) equine guidelines are based on detecting BZ resistance as this was the 
only concern when these guidelines were written. The WAAVP guidelines were originally 
designed for farm livestock kept and tested in large groups. The WAAVP 2006 review (Coles 
et al., 2006) on the detection of anthelmintic resistance in nematodes of veterinary importance 
updated the equine FECRT and recommends using a sample size of at least 6 horses where 
possible (Coles et al., 2006; Nielsen et al., 2013a). Coles et al. (2006) also suggest if new 
animals are introduced to a group it is acceptable to test just the one horse using a FECRT to 
gauge efficacy before introducing the new animal into a herd. The 2006 review suggested 
different FECRT cut offs for resistance are required for the different chemical groups, however 
these were not stated. Post-treatment FEC were recommended to  be conducted 3-7 days after 
THPs, 8-10 days after BZs and 14-17 days after MLs (Coles et al., 2006).  
(Baseline FEC- Post Treatment FEC) X100 
Baseline FEC 
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In 2010 Kaplan and Nielsen suggested cut off values for the different anthelmintic group when 
using the FECRT on groups of 5-10 horses on each farm, where possible. Where the group 
mean FECRT is below the cut off value for the anthelmintic being tested then this is indicative 
of resistance. The suggested percentage reduction cut offs are: 
Benzimidazoles:    90% 
Pyrantel:                90% 
Ivermectin:            95% 
Moxidectin:           95% 
The American Association of Equine Practitioners (AAEP) guidelines (Nielsen et al., 2013a) 
outline recommendations for faecal egg counting, the FECRT and egg reappearance times. This 
document is the only current set of practical guidelines on egg reappearance times. However 
the cut off values for reduced efficacy and resistance in these guidelines differ to other figures 
in the literature. The AAEP guidelines also clearly state that there are no specific equine 
FECRT guidelines and these are awaited from WAAVP.  
While the FECRT is used as the gold standard for detecting resistance, it does have limitations 
when used in the field. Time and cost need to be factored in, as well as poor data quality with 
low precision and reproducibility (Craven et al., 1999; Nielsen et al., 2010a). Furthermore it 
does not allow for inter-animal variation and pharmacodynamics within the host (Craven et al., 
1999). The FECRT will not detect resistance in a population if its prevalence is less than 25% 
of that population (Martin et al., 1989). 
2.1.3. Egg Hatch Assay (EHA) 
The WAAVP guidelines (1992) identified an in vitro assay, the Egg Hatch Assay (EHA) to 
measure anthelmintic efficacy. Eggs are collected from faecal samples and subjected to 
different concentrations of BZ anthelmintic in vitro. The discriminating dose will prevent 
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hatching of 99% of the eggs exposed to the anthelmintic and therefore those that do hatch are 
resistant (Coles et al., 1992; 2006). Originally validated for sheep, it has been successfully used 
for nematodes infecting horses (Coles et al., 1992; Matthews et al., 2012). 
The EHA is a more technically demanding, but more reliable than the FECRT (Craven et al., 
1999). The EHA provides no more early warning of anthelmintic resistance than the FECRT 
as studies have found 25% of the population need to be resistant before this assay will detect it 
(Taylor et al., 2002). The EHA is only suitable for use with BZs, other classes do not have 
ovicidal efficacy, however the EHA has been modified to work with tetrahydropyrimidines, 
specifically levamisole for ruminants (Taylor et al., 2002). As widespread BZ resistance is 
documented, the value of developing the egg hatch assay may be limited (Matthews et al., 
2012). Therefore most suitable diagnostic tool for monitoring ML efficacy remains the  FECRT 
(Coles et al., 2006).   
2.2. Measuring fermentation parameters in vitro 
In vitro techniques are useful research tools to non-invasively identify changes within the 
hindgut microbiome associated with diet and orally delivered medications. Currently Leng et 
al. (2017) are working on a multi-chamber model of the horse’s hindgut. Prior to this, hind gut 
models have been much simpler and focussed upon fermentation kinetics to measure 
digestibility of substrates in vitro. The original in vitro fermentation technique was described 
by Tilly and Terry (1963). This two stage process was designed to model microbial digestion 
in rumen inoculum followed by enzymatic digestion. As enzymatic digestion precedes 
fermentation in the horse the Tilly and Terry method is of limited use in equids.  
A second in vitro model for fermentation is the gas production technique. The manual 
transducer gas production technique developed by Theodorou et al. (1994) provides a simple 
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way of determining in vitro fermentation of feedstuffs providing detailed information of 
fermentation kinetics.  
2.2.1. In vitro gas production technique 
The in vitro gas production technique is based upon the measurement of gas, CH4 and CO2, 
produced by the fermentation of a feed substrate that is buffered in bicarbonate medium, 
inoculated with rumen/caecal fluid or faeces.  The original model was developed for ruminants 
however the technique has successfully been adapted for use with equids. Early equid studies 
relied upon horses cannulated into the caecum to provide caecal fluid. Lowman (1996) 
compared the fermentation kinetics of equine caecal fluid compared to faecal inoculum and 
concluded that faeces were a suitable source of inoculum for equine gas production studies.  
A potential concern for the use of faeces to create a faecal inoculum is the exposure of 
anaerobic bacteria to air directly following defecation.  The formation of equine faeces in faecal 
balls means the excreted bacteria remain anaerobic for some time and remain viable for several 
hours after voiding (Holter, 1991; Theodorou et al., 1993). If the faecal sample used to create 
a faecal inoculum is from the centre of a freshly voided dung pile the bacteria should remain 
viable.  
The in vitro gas production technique uses 125ml Wheaton bottles containing feed substrate, 
faecal inoculum, buffer and a reducing agent which are sealed with crimp top rubber seals. 
These bottles are then incubated at 39°C and as fermentation occurs gas is produced.  Gas starts 
to accumulate within the headspace in the bottles. The volume of gas and pressure inside the 
bottle is periodically measured and released from the bottle during incubation using a 
hypodermic needle and pressure transducer. The speed and the amount of gas produced are 
determined by the substrate being fermented. Thus there is a close relationship between the 
pattern of gas production and substrate degradation (Jessop and Herrero, 1997). The process of 
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gas production within culture bottles is not thoroughly understood. Direct gas production from 
fermenting feed substrate produces CH4 and CO2, other indirect gasses are also produced from 
the buffering of SCFAs within the closed environment i.e. not directly from the feed substrate 
but from fermenting VFAs. It is thought that the SCFAs produced by fermentation of the 
substrate react with carbonates in the buffer producing more CO2 than would be found in vivo 
(Rymer et al., 1997).  This is only problematic when comparing the in vitro gas production 
technique to degradation in vivo. When comparing differing feed substrates or animal treatment 
groups both in vitro, findings will be comparable as both groups will be subject to the same 
conditions (Moore-Colyer, Pers. Comm.). At the end of incubation the fluid medium can be 
sampled for pH and SCFA analysis and remaining substrate dried and weighted to determine 
end-point dry matter loss.  
During incubation bottles are maintained at 39°C, this figure was originally derived from 
ruminant studies as the rumen temperature is normally maintained between 39°C – 40.5°C 
(McDonald et al., 2007). Where the technique has been used with equids the incubation 
temperature has remained at 39°C even though the horses’ caecum is approximately 38.5°C 
(Lowman et al., 1999; Biddle et al., 2013). Furthermore Lowman et al. (1999) found lower gas 
production at 25, 30 and 45°C using equine faeces as inoculum. Therefore the optimum 
incubation temperature used for in vitro gas production appears to be 39°C.  
When considering the source of inoculum it is also important to consider the diet of the donor 
animals and the substrate to be fermented in vitro. As diet directly impacts upon the 
composition of the hindgut microbiota the diet to be fermented in vitro should be similar to that 
of the donor animal (Rymer et al., 2005).
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2.2.2. Mathematical models to describe gas production data 
Cumulative gas production is the most common way to present gas production profiles. There 
is a direct linear relationship between pressure and gas produced. However when the pressure 
in the headspace of the bottles increases above seven psi the relationship with gas production 
is less predictable (Theodorou et al., 1994).  To describe the relationship between gas volume 
and pressure the following equation V=XP+ I, where V is volume (ml), P is pressure (psi), X 
is slope and I is the intercept (bias correction factor), could be used to describe the relationship 
between volume and pressure for all bottles (Theodorou et al., 1994). The bias correction factor 
allows for slight manufacturing differences in the headspace of bottles or operator error when 
dispensing media during inoculation. As there is a linear relationship between gas produced 
and pressure in the bottle headspace the bias correction regression equation removes erroneous 
values from the data (Theodorou et al., 1994). Following this bias correction, cumulative gas 
profiles from each bottle should then be summed and a cumulative gas production curve formed 
(Theodorou et al., 1994).   
 Cumulative gas production curves only identify gas per gram of substrate and are only 
comparable to other substrates or conditions that were fermented within the same experiment. 
To allow comparison of fermentation parameters between different experiments and more 
detailed information on fermentation kinetics, mathematical modelling can be applied to 
cumulative gas profiles to produce rate parameters.  
There are differing gas models but all work on the principle that a substrate (S) is fermented to 
yield a volume of gas (Y) at a rate µ (µ - fractional rate of degradation per hour) at time (t) 
(Thornley and France, 2007). The model of France et al. (1993) was designed specifically for 
the manual pressure transducer technique of Theodorou et al. (1994). The France et al. (1993) 
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model models the sigmoidal response frequently encountered when fermenting feed substrates 
in vitro. The France et al. (1993) model assumes that when bottles are inoculated there is a lag 
time before fermentation begins. The fractional rate of substrate degradation is postulated to 
vary with time. Rate parameters are calculated within a maximum likelihood programme (Ross, 
1987) using the data from the inoculation period, gas produced and substrate loss over the 
experiment. The constants refer to the extent of substrate degradation linked to the lag time. 
The equation of the France et al. (1993) model is detailed below: 
Y=A {1 – exp [-b (t –L) – (√t -√L)]} 
Y= gas produced (ml) at time t 
A = asymptotic value for gas pool size 
b = rate constant (h-1) which is independent of time  
c = rate constant (h-0.5) whose influence decreases with time 
t = time 
LT = lag time (hours) 
 
The quadratic equation can also be presented as: Y = A – B Qt Z √t 
 
From this model, using the rate constants, the fractional rate of gas production (FRGP or µ) 
half way through incubation can be calculated: 
FRGP = b + (c/2√t50) 
The rate constants in the model b and c both influence the FRGP. As c changes with time it 
changes the shape of the curve. If the value for c becomes negative then the curve is sigmoidal 
and quadratic equation is used. When the value for c is positive then an exponential rate of gas 
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production has occurred (Figure 2.1.) and the following equation is applied to obtain the 
relevant parameters:     Y = A – B Qt 
 
Figure 2.1. Example of sigmoidal and quadratic curves and an example of a quadratic observed 
gas curve and the fitted France et al. (1993) model shown in red triangles.  
 
This modelling technique also allows the calculation of the extent of substrate degradation, 
which is not possible in other gas models. The extent of degradation considers the flow rate of 
digesta within its equation. This is specifically useful when considering feedstuffs for horses 
where the rate of passage through the gastrointestinal tract is much quicker than that of 
ruminants. Overall the France et al. (1993) model allows a greater insight into early stage 
fermentation as well as end point fermentation which is more comparable to the horses mean 
retention time compared to that of ruminants.   
2.3. Microbiome community profiling 
Over the past decade there has been a significant increase in the use of ’omics technologies 
within scientific research. The use of DNA sequencing allows the profiling of whole bacterial 
communities without the need to culture them. High-throughput sequencing has significantly 
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enhanced our understanding of microbial ecology (Langille et al., 2013). There are two 
differing approaches to DNA microbiome sequencing, full metagenomics or metataxonomics. 
Metagenomics is the study of all of the genomes within a given sample. This therefore provides 
a rich information set on the structure of the population and the functions of this population 
through gene expression (Kuczynski et al., 2012). Targeted amplicon studies, metataxonomics, 
analyse of all taxa within a sample by sequencing a specific gene (Kuczynski et al., 2012). 
Most commonly, for microbiota profiling, the bacterial 16S rRNA gene is targeted for 
metataxonomics (Langille et al., 2013).   
For targeted DNA sequencing the initial step is to amplify a desired region on the 16S gene. 
Within this thesis the V4 region was the specific target, this can be visualised in Figure 2.2 
below. Post amplification the amplicons are deep sequenced using next generation sequencing.  
 
 
Figure 2.2. Schematic of the 16S gene identifying variable regions (V1-V9), primers, 
amplicons and sequencing of those amplicons using the illumina platform. Adapted from 
Kuczynski et al. (2012). 
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Illumina MiSeq uses sequencing by synthesis to produce a large number of sequencing reads 
from a relatively small amount of DNA (Buermans and den Dunnen, 2014). This sequencing 
makes use of complementary flourescent-labelled neucleotides which are added to the 
anchored parallel strands. Each type of neucleotide base has different flourescent terminator 
dyes and these are imaged and cleaved when the nucleotide is added. All four types of 
terminator-bound neucleotides are present during this processing, allowing for natural 
competition and reducing bias. This occurs simultaniously to millions of DNA strands in 
different cells allowing the generation of a large number of sequencing reads to be acquired 
(Buermans and den Dunnen, 2014). Figure 2.3 depicts sequencing by synthesis.  
  
Figure 2.3. Schematic representation of sequencing by synthesis, part of the illumina 
sequencing technology. Adapted from www.cegat.de/en/services/next-generation-
sequencing/ [accessed 14/10/2017].  
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2.3.1. Bioinformatics 
Following sequencing, raw reads require bioinformatics to provide meaningful data. One of 
the most common bioinformatics pipelines for analysing MiSeq derived sequences is 
Quantitative Insights into Microbial Ecology (QIIME). QIIME is an open source pipeline that 
allows quality filtering. QIIME also facilitates the picking of operational taxonomic units 
(OTUs) which are clusters of sequence reads with 96% simularity or greater. This simularity 
is expected to correspond with a particular species. OTUs are picked from the sequence reads 
against large databases such as the Ribsomal Database Project (RDP). Following OTU 
picking taxonomic assignment is applied and phylonogetic reconstruction before analysis 
through graphic representation (Caprosa et al., 2010). Figure 2.4. demonstrates visual 
analysis of alpha and beta diversity outputs. The final stages of QIIME bioinformatics 
provides an OTU table that can be used for further analysis.  
 
Figure 2.4. Graphical output from QIIME (A) alpha rarefaction curve (B) beta diversity 
PCoA plot of two groups from a dataset plotted between principal coordinate one (PC1), PC2 
and PC3. Spatial grouping on this scores plot suggest differences in diversity of OTUs 
between these two groups. Adapted from www.github.com [accessed 14/10/17].  
 
A B 
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Once an OTU table has been generated, further statistical analysis can be carried out on the 
data to identify differences in microbial profiles within groups. However due to the distribution 
of OTU abundances within these types of data sets a non-parametric model that is also robust 
in the face of multiple comparisons is required. Linear Discriminant Analysis (LDA) effect 
Size (LEfSe) uses a Kruskall Wallis rank-sum test followed by a pairwise Willcoxon rank-sum 
test and finally linear descriminate analysis to estimate the effect size of each differently 
abundant feature, Figure 2.5. (Segata et al., 2011). This platform allows the identification of 
statistical significance, biological consistency and bacterial biomarkers of disease. The final 
output from LEfSe generates three plots, two different histograms identifying OTUs of 
significantly differing abundances and differing treatments/conditions and a cladogram of how 
differences are phylogenetically related. The primary histogram of differences in OTU 
abundances and cladogram can be seen in Figure 2.6. (Segata et al., 2011).  
  
 
Figure 2.5. Schematic representation of  LEfSe (a) Kruskall Wallis on data to identify OTUs 
of differing distributions, (b) Wilcoxon pairwise testing of those distributions identified in a. 
(c) The resulting vectors are used to build a LDA model from which the relative difference 
among classes is used to rank the features (Segata et al., 2011).  
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Figure 2.6. Cladogram obtained from LEfSe, this plot identifies the relationship between the 
biomarkers identified within the model (Segata et al., 2011).  
 
2.4. Metabolomics 
Metabolomics uses a systems biology approach by viewing ‘top down’ complex biological 
biochemistry integrated with computational systems and mathematical modelling, with the aim 
of characterising and quantifying small molecules within living systems (Nicholson and 
Lindon, 2008). Traditional study approaches were ‘bottom up’ selecting a specific target to 
form a hypothesis and then setting about testing that hypothesis, without consideration for the 
other interactions within that biological system. Systems biology takes a holistic approach with 
the idea that the complex networks within a biological system are greater than the individual 
parts that make up that system.    
Metabolomics allows the characterisation of metabolites within a biological sample e.g. a 
biofluid, to identify metabolites within that system. This may be applied to the study of disease, 
medical or dietary interventions or to study the effects of lifestyle, exercise or ageing (Markley 
et al., 2017). In the horse metabolomics is in its infancy, but to date the ‘normal’ metabolome 
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of the Thoroughbred race horse has been characterised using blood plasma, faeces and urine, 
providing a reference library for the healthy horse (Escalona et al., 2015).   Both faecal and 
urine samples can be collected non-invasively and are useful for metabolomics. Urine is the 
primary biofluid and provides information on the metabolic state of the whole organism and 
includes metabolites derived from the diet and from the gut microbiome. Similarly faeces offer 
the same advantages but also provide further information on excretory metabolites and those 
closely linked with the gut microbiome (Wu et al., 2010).   The gut bacteria have a huge 
contribution to the metabolites excreted in urine, Escalona et al. (2015) reported that from a 
metabolomics perspective, urine was the most informative biofluid in the horse.  
There are two analytical techniques commonly used for metabolomics, mass spectrometry 
(MS) and nuclear magnetic resonance (NMR) spectroscopy (Markley et al., 2017). Both of 
these techniques allow unbiased profiling of the majority of metabolites present within a 
biological system. Within this thesis NMR was the analytical technique applied. Proton nuclear 
magnetic resonance (1H NMR) uses the spin property possessed by all protons contained in the 
metabolites within a given sample (Levitt, 2005).  These spinning protons can be oriented into 
a higher or lower energy state. NMR applies an electromagnetic field to these protons and they 
are separated into two energy levels (Levitt, 2005). There are always an excess of nuclei in the 
lower energy state, this excess of low energy state spins provides the signal measured by 1H 
NMR spectroscopy. Using electromagnetic radiation low energy nuclei can be excited to 
resonate into a higher energy level. By removing (pulsing) the electromagnetic energy field the 
nuclei relax back to their normal energy state, emitting a small magnetic field. This signal is 
collected as waves which undergo Fourier transformation to convert the data from time to 
frequency, thus giving rise to peaks within a spectrum (Levitt, 2005). The chemical shift 
(position of the peak) in the spectrum is dependent on the electrons surrounding the nucleus. 
The chemical shift of spectral peaks are calibrated to an internal standard, commonly 3-
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trimethylsil-1-[2,2,3,3-2H4] propionate (TSP). NMR standards give a single strong resonance 
as all of their nuclei have identical protons that are strongly shielded (Levitt, 2005).  
The multiplicity of a peak is dependent on the spin–spin coupling affecting a proton (Levitt, 
2005). Coupling is caused by the interaction of neighbouring nuclei resulting in the NMR 
frequency being split into different multiplicities. The multiplicity of a peak can be in the form 
of a singlet, doublet, triplet, quartet, quintet or multiplet (Levitt, 2005).   Figure 2.7 provides a 
schematic representation of the use of 1H NMR in metabolomics. 
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Figure 2.7. Schematic representation of the use of NMR spectroscopy within the field of 
systems biology. Simple schematic representation of how the NMR applies magnetic fields to 
nuclei which, under pulse, causes waves that are detected by the spectrometer. Waves are 
converted by Fourier transformation into peaks within the NMR spectra. From these peaks 
metabolite abundances can be identified. Multivariate statistics and modelling of metabolite 
abundances allows detection of differences these can then be related back to the system. Figures 
adapted from Nicholson and Lindon (2008); www.systemsbiology.org [accessed 15/10/2017]; 
Institute of Chemistry (2017); www.ceitec.eu/ [accessed 15/10/17]. 
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2.4.2. Multivariate statistics for metabolomics analysis  
The datasets produced by 1H NMR provide information on thousands of possible metabolite 
variables. In order to identify differences in metabolic abundances multivariate statistics are 
applied (Trygg et al., 2007). Multivariate analysis allows simultaneous analysis of multiple 
measurements/variables within a sample of interest.  When applied to NMR spectroscopy data, 
multivariate statistics allows the detection of peaks within an NMR spectra that vary between 
groups of metabolic phenotypes. Peaks within spectra represent metabolites, thus multivariate 
models allow the identification of metabolites with significantly different abundances.  
Unsupervised multivariate models are used for primary data analysis, e.g. principal component 
analysis (PCA). This provides an overview summary of multivariate data e.g. NMR spectra, 
without detailed class membership of the samples within it (Holmes and Antti, 2002). 
Differences are identified between principal components rather than on a two dimensional X, 
Y axis. A principal component represents the plane of greatest variance between observations 
within the spread of the data. The plane that shows the greatest variation is referred to as the 
first principal component, PC1. The relation of each variable in PC1 to the plane with the 
second most variance (PC2) is also plotted, for ease of interpretation this can be plotted two 
dimensionally. If the PCA identifies differences in metabolic phenotype between groups then 
a loadings plot can be created to identify observations between these two principal components, 
Figure 2.8. The loadings plot identifies the differences in metabolite abundances between the 
principal components and the multiplicity and resonance can then be used to identify that 
specific metabolite.   
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Figure 2.8. Schematic representation of a PCA (A) first two components in a data set, (B) two-
dimensional scores plot showing the relationship between the observations and the first two 
principal components and (C) the loadings plot identifying the variables contributing to the 
position of the observation in the first principal component.  Adapted from Trygg et al. (2007). 
 
Following such preliminary data exploration, a supervised model is used to include information 
of the class membership of the samples/groups. Orthogonal Projections to Latent Structures 
Discriminant Analysis (OPLS-DA) uses a prediction and regression method between the 
descriptor (X data) and the response (Y data). In context X data may represent a control and Y 
data a treatment group. OPLS-DA models use an orthogonal filter to remove any systematic 
variation present in X that is not present in Y. The orthogonal filter rearranges the original 3D 
data in to 2D while using information from the control group to filter out systematic variation 
from the treatment group. This yields a multivariate model with improved interpretation and 
less complexity (Trygg and Wold, 2002). OPLS-DA models allow the visualisation of 
differences between metabolite abundances between two groups on a spectra plotted as 
covariance with class (Cloarec et al., 2005). The loadings plot has an R2 heat map, the stronger 
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the correlation coefficient between a metabolite and a treatment group is reflected by colour in 
the loadings plot. Figure 2.9. depicts an OPLS-DA model.   
 
 
Figure 2.9. Schematic representation of OPLS-DA (A) multidimensional dataset, (B) 
orthogonal filter applied to the dataset to remove variation not orthogonal to Y, (C) two-
dimensional plot showing separation between groups and (D) the OPLS-DA loadings plot 
showing differences between groups identified within the model. Adapted from Trygg et al. 
(2007).  
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Chapter 3.0   
Nationwide surveillance for evidence of reduced macrocyclic lactone efficacy in horses in 
the UK 
3.1. Introduction 
All anthelmintic drugs have a specific egg reappearance period post treatment which were 
established when the drug was first licensed. Shortened egg reappearance period (ERP), from 
that stated on the marketing authorisation, or compared to reports published when the drug was 
introduced, is an early indicator of anthelmintic resistance (Sangster, 1999). Monitoring egg 
reappearance period post treatment provides early indication of reduced drug efficacy prior to 
the onset of resistance (Sangster, 1999).   
In the UK the macrocyclic lactones ivermectin and moxidectin are the most recent 
anthelmintics to be licensed for nematode treatment in horses. These anthelmintics are also the 
drugs of choice used by horse managers in the UK for worm control (Allison et al., 2011). 
Ivermectin and moxidectin were licensed for use in the 1980s and 1990s respectively (Kaplan, 
2004). Ivermectin was reported to have an egg reappearance period of 8-10 weeks when it was 
first marketed (Borgsteede et al., 1993). Moxidectin egg reappearance was reported in excess 
of 13 weeks, and up to 24 weeks, post treatment when it was first introduced (Jacobs et al., 
1995; DiPietro et al., 1997). An ERP of 13 weeks is used on the moxidectin datasheet.  
Currently there are no universally adopted guidelines specifically for the evaluation of 
resistance or egg reappearance in horse strongyles (Relf et al., 2014). Published methods have 
been adapted from ruminant work from the WAAVP guidelines (Coles et al., 1992). The 
American Association of Equine Practitioners (AAEP) (Nielsen et al., 2013a) has set out 
guidelines for resistance and efficacy testing in horses. The suggestion for egg reappearance 
testing uses the faecal egg count reduction (FECR) test at intervals beyond 14 days using a 
90% efficacy cut-off for macrocyclic lactones. 
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To date, there have been no published reports of macrocyclic lactone resistance within 
cyathostomins in the UK. Only one UK study to date has suggested moxidectin resistance 
within cyathostomins from FECR data. This was in a population of donkeys being treated “off- 
label” with a formulation designed for cattle, for which the pharmacokinetics in equids are not 
well understood (Trawford et al., 2005). However, there have been reports in North and South 
America, central Europe and more recently the UK of shortened egg reappearance periods for 
both ivermectin and moxidectin within cyathostomins (Molento et al., 2008; Lyons et al., 2009, 
2011; Rossano et al., 2010; Relf et al., 2014). 
Resistance to the benzimidazole group of anthelmintics is reported as widespread within 
cyathostomins (Osterman Lind et al., 2007; Relf et al., 2014; Matthews, 2014). There are three 
new anthelmintic classes that have been licensed for animal use since the macrocyclic lactones 
but there appear to be no plans for these classes to be licensed for equine nematode treatment 
in the near future (Epe and Kaminsky, 2013). The reliance of prophylactic anthelmintic use as 
a colic prevention mechanism was originally introduced by Drudge and Lyons (1966). Interval 
dosing regimens are frequently used by many horse managers today (Nielsen, 2012). It is 
therefore important to understand the current efficacy of the macrocyclic lactones in equine 
strongyles in the UK.  
3.1.1. Objectives 
This retrospective study was performed with two objectives: 
(1) To determine egg reappearance periods after dosing horses with ivermectin or moxidectin 
under field conditions. 
(2) To identify trends in egg reappearance over a four year period.  
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The target population for both objectives was UK pleasure horses with persistently positive 
faecal egg counts in the face of anthelmintic treatment.   
3.2. Materials and Methods 
3.2.1. Ethical approval 
Ethical approval was granted by the University of Liverpool Ethics Committee, RETH000363.  
3.2.2. Parasite control programmes 
Parasite control records of horses tested for ivermectin and/or moxidectin efficacy by a 
commercial provider between 01/01/2008 – 29/08/2011 were reviewed (n=200). Parasite 
control programmes were designed around FEC data, animal age, breed, weight and pasture 
management. For each animal FECs were scheduled throughout the year to monitor nematode 
status and specific anthelmintic treatments for pre-patent cyathostomin spp. specifically those 
in hypobiosis and for Anoplocephala spp. were also scheduled. Where animals demonstrated 
persistently positive FEC results from monitoring FECs and when FECs were directly after the 
stated egg reappearance period of an anthelmintic, the commercial provider placed these 
animals under additional FEC monitoring. This involved additional FECs to check the length 
of the egg reappearance periods for anthelmintics to check the efficacy of these drugs. This 
process worked backwards from the end of the anthelmintics ERP, in weeks, to identify the 
time point of egg reappearance. All FEC results, drug dosing data and dates were recorded in 
the horses’ record. Sample collection and anthelmintic treatment were undertaken by the client, 
instructed by the commercial provider. The instructions given to clients for sample collection 
and dosing, FEC kits and anthelmintic were supplied by the commercial provider. When FECs 
were required clients were asked to randomly sub-sample from a freshly voided faecal pile and 
place into an airtight container which was then posted back to the laboratory. Prior to 
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anthelmintic dosing, clients were asked to estimate weight with a girth tape. From the weight 
measurement anthelmintic dosage was increased by 50 kg for small breeds and 100 kg for large 
breeds to prevent under dosing through inaccurate weight estimation and allow for some loss 
during administration.  Clients were given specific dates for FEC sampling and anthelmintic 
administration.  
3.2.3. Faecal egg counts 
All FECs during this period were processed at the University of Liverpool following the 
WAAVP guidelines for the modified McMaster technique (Coles et al., 1992) repeated in 
duplicate and taking the mean result, thus each egg represented 25 eggs per gram (epg).  No 
larval cultures were performed therefore all strongyle eggs were reported collectively.  
 
3.2.4. Database formation 
FEC results and treatment data were extracted from paper records of parasite control 
programmes and entered into a database for analysis. Faeces for FECs were taken between 4 
and 10 weeks post treatment for ivermectin and between 3 and 13 weeks for moxidectin. These 
time points had been selected by the commercial provider as a pragmatic efficacy testing tool 
(Nielsen et al., 2010a). FECs had been scheduled considering the animal’s age, the grazing 
conditions and management, presence of companion animals and the animals’ treatment 
history. 
FEC results were categorised by treatment i.e. ivermectin or moxidectin. Following 
recommendations for efficacy testing, horses with initial pre-treatment faecal egg counts less 
than 150 epg were excluded from the data set (Coles et al., 2006). An additional exclusion 
criterion was any horse that had received anthelmintic within 90 days of initial faecal egg count.   
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3.2.5. Study population demographics 
Of 200 records, 153 met the inclusion criteria, categorised as moxidectin (n=95), ivermectin 
(n=58). Records comprised of Thoroughbreds, including cross breeds (n=33), warmbloods, 
including cross breeds (n=40), draft horses (n=10), native ponies (n=22) and cob types (n=35), 
with some records no breed was recorded (n=13). There were 72 females and 81 males ranging 
from 1-31 years (mean 10 ± 7.2 years). Premises were distributed throughout Great Britain 
(Figure 3.1). Premises were predominantly DIY livery yards. Horses were deemed as high risk 
for parasitic infection due to persistently positive faecal egg counts. Some premises had records 
of the presence of benzimidazole resistant nematodes. DIY livery yards carry an increased risk 
of spreading resistant nematodes due to movement of horses between different DIY 
establishments. Collectively these factors were considered to leave these horses at high risk of 
parasitic infection.  
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Figure. 3.1. Locations of all premises tested, squares represent moxidectin and circles 
represent ivermectin. Adapted from www.sketchmap.co.uk.   
 
3.2.6. Calculation of egg reappearance period (ERP) 
 Egg reappearance period was described using three previously reported parameters : (1) the 
first time point a positive faecal egg count was recorded post treatment (Lyons et al., 2008; 
Molento et al., 2008), (2) the group arithmetic mean FEC >10% of Day 0 value (Borgsteede et 
al., 1993; Jacobs et al., 1995; Boersema et al., 1998; Mercier et al., 2001 ; von Samson-
Himmelstjerna et al., 2007; Larsen et al., 2011), and (3) <90% FECR within the stated egg 
reappearance period for the product (Larson et al., 2011; Nielsen et al., 2013a; Relf et al., 
2014).    
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FECR was calculated as: 
Pre-treatment FEC– Post treatment FEC X 90 
Pre-treatment FEC  
 
ERP metrics were evaluated at premises level (n=16 moxidectin, n=10 ivermectin). When only 
one test record per premises existed, data were reported at animal level (n= 61 moxidectin; n= 
31 ivermectin). All single animal premises results were analysed collectively.  
 
3.2.7. Longitudinal data analysis 
The FEC reduction data and percentage difference between pre-treatment and post treatment 
FECs for both ivermectin and moxidectin were analysed over the four year time period (2008-
2011). Mean FEC reduction and percentage difference data at 8 weeks post ivermectin 
treatment and 13 weeks post moxidectin treatment were analysed using the Mann-Kendall 
trend test in R (version 3.2.2).  
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3.3. Results 
3.3.1. Egg reappearance times 
Shortest observed ERP (time to first positive faecal egg count observed) for both ivermectin 
and moxidectin was 5 weeks.  Five of the 16 moxidectin premises displayed ERP (measured 
as >10% of day 0 FEC and FECR <90%) at 12-13 weeks (Table 3.1.). For moxidectin 
individual animal data collectively (Table 3.2.), the earliest ERP was 5 weeks, with a 67% 
FECR (n=1). At six weeks post dosing the mean FECR was 87% and there was 16% difference 
between pre-treatment and post-treatment FEC (n=3). Most tests (n=87) were conducted 
between 10 and 13 weeks post moxidectin, giving a mean FECR 80-85% and pre and post 
dosing FEC difference of 11-22%. Overall for moxidectin (Table 3.3.) 5% of animals had an 
ERP of 5-7 weeks, 95% of horses had an ERP of ≤13 weeks.   
 
3.3.2. Egg reappearance trends over the four year period 
At 8 weeks post ivermectin treatment the mean FEC reduction for each year over the four year 
period were 74.4%, 100%, 87% & 68.2%  and the FEC % differences were 22%, 0%, 8% and 
33% respectively (Table 3.4.). This was not statistically significant, P= 0.54 (r -0.0581). For 
moxidectin the mean FEC reduction at 13 weeks post treatment were 93.3%, 89.9% , 86.5% 
and 79.5% respectively (Figure 3.2.) this demonstrated a significant negative trend (r-.172) 
(P=0.022). For FEC % difference at 13 weeks results were 2%, 9%, 13% & 31 % respectively 
(Table 3.4.). 
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Table 3.1. Egg reappearance tests at premises level, classified by premises, drug and then by time point 
post dosing. Superscripts denote shortened egg reappearance a both FECR <90% and pre-treatment and 
post treatment FEC difference >10%. b indicates egg reappearance by one metric only. 
Premises 
Number 
of 
animals 
tested Drug 
Pre FEC 
(mean)  
Post 
FEC 
(mean) 
Time 
point 
(Weeks) 
post 
dosing 
Percentage 
difference 
between 
pre and 
post dose 
FECs (%) 
Mean 
FECR 
(%) 
1 3 Mox 375 50 13 13a 87a 
2 2 Mox 350 0 13 0 100 
3 3 Mox 408 267 13 65a 35a 
4 4 Mox 344 13 10 4 96 
5 2 Mox 238 0 13 0 100 
6 5 Mox 180 55 12 31a 69a 
7 3 Mox 400 42 13 10 90 
8 2 Mox 625 25 12 4 96 
9 2 Mox 375 0 12 0 100 
10 3 Mox 400 100 10 0 75 
11 2 Mox 525 88 13 17a 83a 
12 2 Mox 1563 0 10 0 100 
13 2 Mox 313 0 12 0 100 
14 2 Mox 850 263 13 31a 69a 
15 3 Mox 325 17 13 5 95 
16 7 Mox 364 14 13 4 96 
17 2 Ivm 713 125 5 18a 82a 
18 2 Ivm 388 38 9 10 90 
19 2 Ivm 200 13 7 6 94 
20 2 Ivm 413 38 8 9 91 
21 5 Ivm 300 250 10 83a 17a 
22 2 Ivm 188 463 8 247a -147a 
23 2 Ivm 313 0 6 0 100 
24 2 Ivm 263 0 7 0 100 
25 2 Ivm 475 175 10 37a 63a 
26 4 Ivm 606 131 8 22a 78a 
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Table 3.2. Egg reappearance data from single animal premises analysed collectively by drug 
and time point. Grouped by drug and week for analysis. Superscripts suggest early egg 
reappearance. 
Drug 
Time 
point 
(Weeks) 
post 
dosing 
Number 
of 
animals 
tested  
Pre 
dose 
FEC 
(mean)  
Post 
dose 
FEC 
(mean) 
Difference 
between 
pre and 
post dose 
FECs (%) 
Mean FECR 
(%) 
Ivm 4 2 550 0 0 100 
Ivm 6 2 763 100 13a 87a 
Ivm 7 3 775 75 10 90 
Ivm 8 13 521 121 23a 77a 
Ivm 9 3 533 342 64a 36a 
Ivm 10 8 516 159 31a 69a 
Mox 3 1 275 0 0 100 
Mox 5 1 150 50 33a 67a 
Mox 6 3 1613 250 16a 85a 
Mox 7 1 325 50 15a 85a 
Mox 8 1 1850 0 0 100 
Mox 9 1 150 0 0 100 
Mox 10 15 433 58 13a 87a 
Mox 11 4 444 50 11a 89a 
Mox 12 11 250 0 0 100 
Mox 13 23 490 107 22a 78a 
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Table 3.3. Egg reappearance data for all horses tested collectively within the data set, classified 
by drug and then by time point post dosing. Superscript letters denote shortened egg 
reappearance. a highlights shortened egg reappearance calculated by FECR <90% and >10% 
difference between pre-treatment and post treatment FEC from a small sample. b indicates 
shortened egg reappearance agreed by both metrics from a larger sample. C indicates early egg 
reappearance by one metric only.  
 
Drug 
Time 
point 
(Weeks) 
post 
dosing 
Number 
of 
animals 
tested  
Pre 
dose 
FEC 
(mean)  
Post 
dose 
FEC 
(mean) 
Difference 
between 
pre and 
post dose 
FECs (%) 
Mean FECR 
(%) 
Ivm 4 2 550 0 0 100 
Ivm 5 2 713 125 18a 82a 
Ivm 6 7 490 100 8 80c 
Ivm 7 6 441 100 23c 93 
Ivm 8 19 488 138 28b 72b 
Ivm 9 4 544 275 51a 49a 
Ivm 10 18 433 172 40b 60b 
Mox 3 1 275 0 0 100 
Mox 5 1 150 50 33a 67a 
Mox 6 3 1613 250 16a 85a 
Mox 7 1 325 50 15a 85a 
Mox 8 1 1850 0 0 100 
Mox 9 1 150 0 0 100 
Mox 10 24 447 41 9 91 
Mox 11 4 444 50 11a 89a 
Mox 12 11 250 0 0 100 
Mox 13 48 479 88 18b 82b 
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Figure 3.2. Faecal egg count reduction (%) yearly trend for moxidectin from 2008-2011, trend 
significantly decreasing (P=0.022) r-0.172 over time. The green line represents the moxidectin 
trend over time, the black line is the 90% FECR threshold. 
 
 
 
Table 3.4.  Egg reappearance data for ivermectin at 8 weeks and moxidectin at 13 weeks over 
the four year period. Superscript letters denote shortened egg reappearance. a highlights 
shortened egg reappearance calculated by FECR <90% and >10% difference between pre-
treatment and post treatment FEC. b indicates shortened egg reappearance from one metric 
only. 
Drug Year 
Time 
point 
(weeks) 
post 
dosing 
Number 
of 
animals 
tested  
Difference 
between 
pre and 
post dose 
FECs (%) 
Mean FECR 
(%) 
Ivm 2008 8 6 22a 74a 
Ivm 2009 8 6 0 100 
Ivm 2010 8 9 8 87b 
Ivm 2011 8 36 33a 68a 
Mox 2008 13 5 2 93 
Mox 2009 13 13 9 88b 
Mox 2010 13 50 13a 87a 
Mox 2011 13 27 21a 80a 
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3.4. Discussion 
This study suggests shortened ERP following treatment with ivermectin and moxidectin 
compared to original published values. Sangster (1999) suggested that a reduction in the ERP 
of an anthelmintic is an early indicator of reduced efficacy, which longer term will lead to 
resistance. Shortened egg reappearance in Kentucky was reported by Lyons et al. (2011) in 
strongyle populations in Thoroughbred yearlings that were displaying an ERP half the length 
of that published in the marketing authorisation for both ivermectin and moxidectin. Traversa 
et al. (2009a) reported shortened egg reappearance times for macrocyclic lactones in Italy.  
Results of this present study, the work of Relf et al. (2014) and Tzelos et al. (2017) all suggest 
that there is a reduction in the egg reappearance time after macrocyclic lactone treatment in 
strongyle populations of some horses in the UK. All three studies report egg reappearance for 
both drugs starting at 35 days post dosing. This present study’s findings for ivermectin are 
consistent with the work of  Von Samson-Himmelstjerna  et al. (2007) and Relf et al. (2014), 
both reporting early egg reappearance from ivermectin treatment at 5 and 6 weeks respectively.  
Recent UK studies suggest that resistance is not present in strongyles to macrocyclic lactones 
when tested with the FECR test at 14 days post dosing (Lester et al., 2013; Stratford et al., 
2013; Tzelos et al., 2017) however findings from the present study and those of Relf et al. 
(2014)  and Tzelos et al. (2017) suggest reduced efficacy. 
When moxidectin was introduced for equine nematode treatment the ERP was reported as 13 
weeks which is used on the product datasheet. ERP was reported up to 24 weeks when 
moxidectin was first introduced (Jacobs et al., 1995; DiPietro et al., 1997; NOAH 
Compendium, 2013). Ivermectin ERP has been reported up to 10 weeks (Borgsteede et al., 
1993) however DiPietro et al. (1997) reported ERP at only 6 weeks, suggesting some 
variability in the ERP of this drug.   
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The results of the present study suggest that the ERP for ivermectin was from 7 weeks post-
treatment, less than the originally reported 8-10 weeks (Borgsteede et al., 1993) with some 
cases of egg reappearance at 5 weeks. Moxidectin ERP within high risk UK pleasure horses in 
the present study was 11-13 weeks compared to in excess of 13 weeks (DiPietro et al., 1997) 
and up to 24 weeks (Jacobs et al., 1995) when first marketed.  Boersema et al. (1998) reported 
egg reappearance at 9 weeks after moxidectin administration in some individual animals, our 
present study highlighted egg reappearance for moxidectin was as low as 5 weeks in individual 
animals. 
When looking at the Mann Kendall trend for reduced egg reappearance over the four year 
period, there was a significant reduction in the moxidectin ERP over time. Some caution should 
be taken in the interpretation of these findings as the number of tests per year varied. However 
in the case of moxidectin, as the number of tests increased the ERP decreased. This would 
suggest that the ERP was reducing over the time period, or was already reduced and was being 
detected as more efficacy tests were carried out. The ivermectin data over time also had few 
tests in 2008 compared to 2011, however as the number of horses tested increased the 
identification of shortened ERP increased again suggesting a reduction over time.  
Ivermectin has been used extensively for treating equine nematodes for the past 20 years, yet 
resistance has been slow to develop when compared to the benzimidazoles. Kaplan (2004) 
suggested that the reason for ivermectin retaining high efficacy against cyathostomins is its 
lack of efficacy against the encysted mucosal stages of larvae, which are in refugia. Lyons et 
al. (2009) reported from critical efficacy tests that ivermectin was efficacious against L5 
cyathostomins but failed to remove L4 larvae at six days post-treatment.  One yearling that was 
necropsied  25 days post treatment harboured 19,150 adult parasites suggesting that the lack of 
L4 efficacy allowed these larvae to mature (Lyons et al., 2009).  
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The results of our present study indicate that ivermectin treatment was associated with earlier 
egg reappearance for strongyles than moxidectin; the reasons for this are likely to be 
multifactorial. One reason could be low efficacy against L4 larvae as reported by Lyons et al. 
(2009). Early egg reappearance could also be linked to overuse of ivermectin over the past 
three decades, increasing selection pressure from repeated use. Epidemiological studies 
indicate that ivermectin and moxidectin are the drugs most frequently used by horse owners in 
the UK (Biggin et al., 1999; Allison et al., 2011; Relf et al., 2011; Ireland et al., 2013)   
The parasite control programmes of our study population had an emphasis on the use of 
macrocyclic lactone anthelmintics especially on premises where BZ resistance had previously 
been reported. These treatment trends are consistent with reported UK pleasure horse parasite 
control practices (Allison et al., 2011).   
The animals in this study comprised a range of ages, 1-31 years mean 10±7.2 years. The 
pharmacokinetics of anthelmintics can differ in younger animals compared to older animals 
(Gonzalez Canga et al., 2009).  As the age range in this study was so great the effect of age on 
pharmacokinetics may have influenced our findings in this study. 
The AAEP guidelines (Nielsen et al., 2013a) for FECR test results state these can only be 
evaluated at premises level. However Coles et al. (2006) previously reported that the test could 
be used at animal level in horses, where necessary, to indicate anthelmintic efficacy.   In this 
present study the animal level results were very similar to those at premises level and more 
reflective of a field situation where horses are often kept alone or in pairs. In these situations 
efficacy testing could not normally be conducted using the AAEP guidelines. There is a lack 
of standardisation for calculating egg reappearance, this limits the ability to compare many of 
the published reports. In the present study three different, previously validated methods were 
adopted (Borgsteede et al., 1993; Jacobs et al., 1995; Boersema et al., 1998; Mercier et al., 
2001; von Samson-Himmelstjerna et al., 2007; Lyons et al., 2008; Molento et al., 2008; Larsen 
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et al., 2011; Relf et al., 2014).  Interestingly in these results 99% of the FECR calculations and 
the pre-treatment and post treatment FEC percentage differences, both at animal and premises 
level, were in agreement with each other for detecting the ERP.  It should be remembered that 
all the faecal egg count efficacy tests make the assumption that if few eggs are excreted, that 
this is due to high anthelmintic efficacy; it could be due to many other factors influencing faecal 
egg output for example pre-patent nematodes and faecal egg distribution within faeces 
(Vidyashankar et al., 2007).  
The author recognises the limitations to this study. Data were analysed retrospectively, original 
sampling and dosing was carried out by horse owners, thus sampling and dosing may not have 
been accurate which could influence these findings. Data represent field cases throughout Great 
Britain, FECs were not planned experimentally and ERP may have occurred earlier than we 
report due to the timing of the scheduled FECs. As this study was not planned as an experiment 
this limits the ability to draw robust conclusions on some of these findings. There could be 
alternative reasons for early egg reappearance outside of reduced anthelmintic efficacy, e.g. 
incorrect weight estimation and dosing which would also influence these findings. There was 
also a possibility that the animals in this study had persistently positive FECs due to poor 
anthelmintic efficacy, rather than true early egg reappearance, however, true 14 day FECR data 
was not available.  
At premises level sample numbers were small; where only one record per premises was 
available, results were analysed collectively, and therefore conclusions should be drawn with 
some caution. However it is common for horses to be kept in small groups and for practical 
identification of anthelmintic efficacy this dataset suggests that it is possible to gain an 
indication of egg reappearance times on premises with very few animals.  
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When looking at the changes in ERP over time the number of tests in 2008 and 2009 were few 
for both ivermectin and moxidectin and this is a limitation. However the data from a greater 
numbers of tests in 2010 and 2011 suggest a reduction in the ERP over time. 
Data from this present study suggests that both the adapted % FECR method and the >10% 
difference between pre- and post-treatment FEC method are acceptable tools for evaluating the 
egg reappearance period. Furthermore, these two metrics used together may provide a more 
robust metric for defining reduced efficacy. 
This sample population may not be representative of the whole UK horse population; horses 
were selected that had signs of early egg reappearance thus biasing the sample towards horses 
harbouring strongyles demonstrating possible reduced efficacy. However all of these horses 
were following a targeted worm control strategy based upon faecal egg counting and pasture 
management before anthelmintic intervention. Notwithstanding the limitations described 
above, these data do provide an insight into ivermectin and moxidectin efficacy in a field 
situation. 
 
3.5. Conclusion 
These results provide evidence for reduced strongyle ERPs following macrocyclic lactone 
treatment in pleasure horses in a field situation over a four year period. This work further 
supports the recent development of reduced efficacy of macrocyclic lactones in the UK.  
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Chapter 4.0 
Ovicidal efficacy of fenbendazole after treatment of horses naturally infected with 
cyathostomins  
 
 4.1. Introduction 
Benzimidazoles (BZ) are the only class of anthelmintics with ovicidal efficacy (Lacey, 1990).  
Recent reports of BZ resistance in cyathostomins in the UK have highlighted its increasing 
prevalence (Lester et al., 2013; Stratford et al., 2013). However reports by Garcia et al, (2013) 
in Texas USA and Milillo et al, (2009) in Italy highlighted that BZ susceptibility was present 
at horse premises within their respective studies. The marketing authorisation for fenbendazole 
states that this product is only suitable for use in animals with BZ-sensitive cyathostomins 
(NOAH Compendium, 2013), however efficacy testing is not common practice by horse 
managers in the field (Biggin et al., 1999; Allison et al., 2011; Relf et al., 2011). 
Previous equine nematode work has focused upon adulticidal and larvicidal efficacy (Traversa 
et al., 2009b; Matthews, 2011, Stratford et al., 2011).  Although rarely reported, ovicidal 
activity of BZs as measured by the egg hatch assay (EHA) (Le Jambre, 1976), was highlighted 
as a useful marker of anthelmintic resistance for research purposes. To date, most of the work 
investigating BZ ovicidal activity has been conducted on ruminant nematodes, particularly 
Haemonchus contortus. To the best of the author’s knowledge there are no published studies 
on BZ ovicidal efficacy on equine cyathostomins in the face of resistance.  
In ruminant nematodes Leathwick et al. (2012) and Bartram et al. (2012) proposed a 
mechanism to slow down anthelmintic resistance by the use of combination anthelmintics. The 
rationale behind this being one product containing two different drugs with differing modes of 
action to attack nematodes. The combined drug would have good efficacy against nematodes 
and resistance to this combination approach would be slower to develop. For this to be 
successful both anthelmintics in the combination require good efficacy against nematodes from 
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the outset (Leathwick et al., 2012; Bartram et al., 2012). With mounting evidence for reduced 
efficacy of macrocyclic lactones, (Lester et al., 2013; Stratford et al., 2013; Relf et al., 2014; 
Daniels and Proudman, 2016; Tzelos et al., 2017), it is important to understand whether 
ovicidal efficacy, a unique element to the BZ class of anthelmintics, still performs in the face 
of resistance. 
 
4.1.1. Objective 
The objective of this study was to investigate the ovicidal efficacy of fenbendazole in horses 
under field conditions when given at 7.5 mg/kg BW as a single dose, or on five consecutive 
days.
4.2. Materials and Methods 
4.2.1. Pilot Study 
A pilot study (n=6) was carried out to inform sample size estimates, time points for sampling 
and method for strongyle egg collection.  Horses with faecal egg counts ≥ 150 eggs per gram 
(epg) were dosed with either a single dose (n=3) or five day dose of fenbendazole (n=3) 
according to the manufacturer’s instructions. Results indicated that after dosing with a single 
dose of fenbendazole at 7.5mg/kg per os, hatch rates returned to baseline level within five days. 
After dosing with fenbendazole at 7.5mg/kg for five consecutive days within feed, hatch rates 
returned to baseline levels within 10 days of the last dose.  The WAAVP Egg Hatch Assay 
protocol (Coles et al., 1992) was adapted and successfully used to collect and incubate eggs 
for hatch analysis. Pilot data gave a hatch rate standard deviation of 0.1414, a value that was 
used in subsequent sample size calculations.  
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4.2.2. Sample size estimates 
Estimates were conducted in SiZ (Cytel v 1.0), using a Wilcoxon-Mann-Whitney model. 
Assuming a standard deviation of 5 % in egg hatch rate, a 5-fold difference in mean % egg 
hatch with 95% confidence and 80% power, could be detected with a sample size of 40 horses 
(20 in each group). A 2-fold difference could be detected under the same assumptions with a 
sample size of 100 horses (50 in each group). The model was very sensitive to standard 
deviation indicating the need for a pilot study to establish parameter values for modelling 
sample size. This led to the adoption of a sample size of 40 horses (20 in each group) which 
gave 80% power and 95% confidence to detect a 7-fold difference in egg hatch rate for this 
study. 
4.2.3. Ethical consent 
This study received ethical approval from the University of Liverpool Ethics Committee, 
RETH000363.  
4.2.4 Sample Population 
From 109 animals at four premises in South-West England and one in South Wales, 40 horses 
met the inclusion criteria of: faecal egg count (FEC) ≥150 eggs per gram faeces (epg) (Coles 
et al., 2006), no anthelmintics administered within the previous 13 weeks and in good health 
(Table 4.1). All farms harboured BZ resistant cyathostomins identified post hoc by faecal egg 
count reduction test. Horses were sampled between August and October 2012. The study 
population consisted of 20 females and 20 males, aged 0.5-20 years, mean 6 ± 4.7 years. Breeds 
comprised: 20 warmbloods, four Thoroughbreds, two warmblood cross Thoroughbreds, seven 
native ponies, five cobs and one Irish draft horse. Pre-treatment FEC for the population ranged 
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from 150 epg to 1300 epg with an arithmetic mean of 550 epg ± 328 epg and a median of 475 
epg. A further 70 horses were screened but did not meet the inclusion criteria.  
At all five premises horses were out at pasture during the day, three premises horses were 
maintained only at pasture and the other two premises the horses were stabled at night. Grazing 
was mixed with other horses on the premises, which were screened but did not meet our 
inclusion criteria. All horses were in fields where dung was not removed from the pasture.  
Premises one, two and three had not used BZ anthelmintics for 10 years, premises four and five 
used BZ infrequently (Table 4.1). Horse exposure to BZ prior to arrival on these premises was 
unknown. None of the premises quarantined new animals on arrival. Time on the current 
premises varied, <1 month to >5 years. Premises were deemed high risk for intestinal parasite 
transmission due to a high proportion of young animals and frequent movement of horses on 
or off the premises (Nielsen et al., 2010a; Relf et al., 2011).  
Body weight was estimated by weigh tape and rounded up to the nearest 50 kg for light/small 
breeds and 100 kg for heavy/large breeds to counter inaccuracy (Ellis and Hollands, 1998).   
4.2.5 Treatment group allocation 
At the time of treatment BZ susceptibility was unknown. Treatment was not randomized; 
approximately 50% of treatments at each premises were single doses and the remaining 50% 
received a five day dose (Table 4.1). Allocation of delivery route depended upon management, 
e.g. feasibility of offering medicated feed once daily.  
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4.2.6. FEC sample collection and analysis 
Prior to treatment a single, fresh, spontaneously voided, faecal sample was collected from each 
animal for FEC analysis. Samples were refrigerated at 4°C prior to analysis. A modified 
McMaster method (Coles et al., 1992) was used, where each egg represented 25 epg.  
4.2.7. Method 
For each sample 3g of faeces were weighed out and added to 42 ml of tap water. The samples 
were agitated with a spatula and then sieved though a 0.250 mm aperture to remove debris. The 
liquid collected was then divided between two 17 ml test tubes and centrifuged for 10 minutes 
at 1800 x g. After centrifugation the supernatant was discarded, the pellet was vortexed and 
then re-suspended in saturated sodium chloride solution. Samples were homogenised and 1ml 
pipetted from the meniscus into a two-chamber McMaster slide. Nematode eggs were then 
counted under a microscope using the x10 objective. Strongyle eggs were recorded for each 
replicate of the sample, multiplied by 50 and then the mean epg per animal calculated, thus 
each egg observed represented 25 epg.    
4.2.8. Faecal egg count reduction test 
A second FEC was conducted 14 days post-treatment, as described above, to calculate FEC 
reduction (FECR). The mean pre-treatment and post treatment results, per premises, were used 
to calculate FECR. FECR was calculated as: 
Pre-treatment FEC– Post treatment FEC X 90 
Pre-treatment FEC  
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A cut-off value of 90% faecal egg count reduction was used to determine anthelmintic 
resistance as recommended by Coles et al. (1992) and Stratford et al. (2011) for BZ.  From 
FECR results, strongyle populations per premises were categorized post hoc as “BZ 
susceptible” or “BZ resistant”. FECR results indicated that on no premises could the strongyle 
population (in all tested horses) be classified as BZ susceptible. Two groups were considered 
in the analysis of the results from this study: a single dose group (n=21) and a five day dose 
group (n=18). 
4.2.9. Anthelmintic treatment and sample collection for egg hatch tests 
Before treatment a fresh, spontaneously voided, faecal sample was collected from all animals. 
Samples were placed in air tight, screw top plastic beakers and filled to the top with water to 
keep the contents under anaerobic conditions. In the laboratory samples were stored at room 
temperature (Coles et al., 1992).  All 21 horses in the single dose group were administered a 
dose of 18.75% w/w fenbendazole at 7.5 mg/kg on day 0 orally using the oral dosing device 
supplied, ensuring that the entire dose was swallowed. Further faecal samples were collected, 
and stored, for five consecutive days from the day after dosing with fenbendazole. All 18 of 
the horses receiving five consecutive days’ treatment were administered fenbendazole (10% 
w/v) at 7.5 mg/kg BW daily for five consecutive days (day -4 to 0), orally in feed following 
the manufacturer’s recommendations. Feed intake was monitored to ensure the full dose was 
ingested. Further faecal samples were collected, as previously described, and stored from one 
day after the last dose of fenbendazole and then on days 3, 5, 7 and 9 post-treatment for the 
five consecutive day dosing group.  All samples were stored as described by Coles et al. (1992) 
and were used for egg hatch testing. 
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4.2.10. Egg hatch test 
The egg hatch assay described by Matthews et al. (2012), was modified to an egg hatch test 
(EHT) that did not expose eggs to anthelmintics, simply tested the ability of excreted strongyle 
eggs to hatch in vitro.  
Strongyle eggs were extracted by sieving each faecal sample mixed with tap water through a 
stack of sieves from 2 mm, 0.75 mm, 0.35 mm, 0.075 mm and 0.038 mm apertures which 
separated faecal matter from nematode eggs. The lining of the 38 micron sieve was then 
backwashed with tap water into a collecting jug and the contents divided equally between two 
soft polyalymer 15 ml centrifuge tubes.   
Following centrifugation at 1800 x g for 2 minutes, forceps were used to pinch the polyalymer 
tubes above the pellet thus separating the pellet from the supernatant. The supernatant was 
discarded and the pellet re-suspended in 15 ml saturated sodium chloride solution. Re-
suspended pellets were then centrifuged again for a further 2 minutes at 1800 x g.  
After centrifugation, using forceps to pinch the tubes below the meniscus, content above this 
point was poured onto a 0.038 mm aperture sieve and eggs were washed with tap water to 
remove the salt solution. The eggs and a small amount of water were then backwashed from 
the sieve and transferred into beakers.  
Twenty-four well cell culture plates, with lines scored on the underside to aid counting, were 
used for the incubation of the eggs. For each sample, duplicates of 3 ml of water containing 
approximately 100 eggs per ml were transferred by pipette into the plate wells and the plate 
was incubated for 48 hours at 26°C. This volume of egg suspension was used to ensure that a 
minimum of 100 eggs per well were incubated at each time point. 
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After incubation the plates were removed from the incubator and examined using an inverted 
microscope. For each well the number of hatched larvae and eggs were recorded. While it was 
possible to distinguish between viable and non-viable eggs all eggs were recorded as un-
hatched for the purposes of this study.   Data were entered into a Microsoft® Excel spreadsheet 
(Microsoft Excel 2007) and the percentage egg hatch was automatically calculated. The mean 
percentage hatch was calculated from the two replicates for each animal at each time point. 
The mean number of eggs and larvae per animal per time point were also calculated.  From 
faecal cultures no large strongyles were identified, therefore all strongyles were classified as 
cyathostomins.   
4.2.11. Statistical analysis 
Differences pre and post treatment within each group were analysed using the Friedman non-
parametric ANOVA with post hoc testing and Bonferroni correction applied. All tests were 
carried out in SPSS (IBM v 20).  
 
 4.3. Results 
One mare on premises two was sold just as the trial started therefore the results represent 39 
animals instead of 40. All premises demonstrated BZ-resistant parasites (Table 4.1.). On three 
premises 11 animals had individual FECR values of 91.6-100% after a five consecutive day 
dose of fenbendazole. At day 14 post-treatment five of the horses from the 39 (8%) had a FEC 
greater than before treatment and a further two had the same FEC as before treatment indicating 
a 0% FEC reduction. Mean FEC at 14 days post-treatment for all 39 horses was 250 ± 270 epg 
with 34 of the 39 horses recording a positive result (≥25 epg).
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Table 4.1. Population data including parasite control strategies employed and premises FECR 
* Only 39 out of the 109 horses had FEC ≥150 epg 
Premises Type 
Total Animals on 
Premises Number Sampled (%) 
Number 
of 
animals 
given a 
single 
dose of 
FBZ Median Age years (range) Treatment History FECs in use 
FECR 
% Mean 
of 
treated 
animals 
 
 
 
FECR 
% 
Median 
of 
treated 
animals 
1 Stud 10 6 (60) 3 6.5 (0.5-15) 
Blanket chemical – 
No BZ No -27 
 
 
32 
2 Dealer 21 8 (38) 4 7 (5-20) 
Blanket chemical – 
No BZ Random 61 
 
 
86 
3 Stud 4 4 (100) 2 8 (4-15) 
Blanket chemical – 
No BZ No 54 
 
 
64 
4 Stud 26 4 (15) 2 1 (0.5-7) 
Blanket chemical - 
BZ No 35 
 
 
27 
5 Stud 48 17 (35) 10 5 (1-14) 
Targeted from FEC - 
BZ Yes 38 
 
 
83 
All  109 39*(36)       
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Median egg hatch rate after treatment is illustrated for both treatment groups in Figure 4.1.  In 
the single dose group there was a significant difference between the pre- and post-treatment 
egg hatch rates (P= 0.0001). There was a significant reduction in the number of eggs and larvae 
post treatment (P=0.001), at day five total eggs and larvae remained significantly lower than at 
day zero (P=0.003) (Fig. 4.2A). 
Five consecutive daily doses of fenbendazole led to significant differences between pre- and 
post-treatment egg hatch rate (P=0.001). Significant differences between sampling points are 
indicated in Fig. 4.1B. There was a significant reduction in eggs and larvae immediately post 
dosing (P=0.0001) and levels of eggs and larvae remained significantly lower than pre-
treatment at day nine (P=0.004) (Fig. 4.2B). 
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Figure 4.1. X Box and whisker plot illustrating the distribution of egg hatch rates, following 
(A) single dose fenbendazole in animals harbouring resistant cyathostomins; and following (B) 
treatment for 5 consecutive days in horses with BZ resistant cyathostomins.  Population values 
for egg hatch rate that are significantly different from the previous sampling point are labelled 
“#”. For both the single dose and five day dose groups’ egg hatch was significantly reduced for 
three days after treatment, before returning to baseline levels.   
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Figure. 4.2. Box and whisker plot illustrating distribution of eggs and larvae pre and post 
treatment with a (A) single dose of fenbendazole and (B) five consecutive daily doses of 
fenbendazole. Significant differences compared to the previous sampling point are labelled 
“#”.  Numbers of eggs and larvae at day five and nine days post-treatment remain significantly 
lower than at day zero following single dose and five consecutive days dosing respectively. 
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4.4. Discussion  
Data from this present study show a significant reduction in egg hatch rate for three days 
following a single dose or five consecutive day dose of fenbendazole in horses with resistant 
cyathostomins. While all premises were classified as resistant based on FECR tests, there was 
nonetheless a significant reduction in the number of eggs and larvae present in samples post 
treatment.  
There is limited published data on the ovicidal effect of BZ on susceptible cyathostomins, 
making it difficult to compare findings from this present study to previous work. Miller and 
Morrison (1992) reported fenbendazole treatment resulted in little or no development of 
strongyle eggs in cattle faeces from 12 to 72 hours after treatment.  In comparison, in the 
present study at 72 hours post treatment egg hatch significantly increased, returning to baseline 
hatch rate. This could be due to species variation or due to the influence of the resistant 
proportion of cyathostomins within this population. It should be assumed that most BZ-
susceptible cyathostomins were removed by the fenbendazole treatment, thus skewing the 
population to the resistant proportion of cyathostomins which continued to hatch post 
treatment. It is important to consider that horses commonly harbour multiple species of 
cyathostomins. Previous work has identified that the efficacy of benzimidazoles and 
susceptibility to anthelmintic resistance can differ between cyathostomin species (Traversa et 
al., 2009b). 
Hotson et al. (1970) reported a 70% FECR in small ruminants demonstrating BZ resistance, 
however the BZ treatment showed little effect on the adult parasite burden in a post slaughter 
worm count. Compared to untreated controls the female worms had fewer eggs present. The 
authors suggested that fenbendazole treatment temporarily suppressed egg laying but allowed 
the parasites to survive (Hotson et al., 1970). This suggests anthelmintics have the ability to 
temporarily damage adult parasites and parasite eggs in resistant nematodes. To the author’s 
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knowledge there have been no such reports from equine cyathostomins of the viability of the 
eggs shed post-treatment with BZ (Chandler et al., 2000; Chandler and Love, 2002; Rossano 
et al., 2010). When considering the numbers of eggs and larvae post treatment from this present 
study it is important to remember that there is no direct linear correlation between the numbers 
of nematode eggs excreted and the number of intestinal worms present within horses (Nielsen 
et al.,2010c). However results from this present study do indicate the presence of egg-laying 
cyathostomins within these horses post treatment. 
In the present study the population of horses comprised animals with a range of ages. The 
pharmacokinetics of anthelmintics can differ in younger animals in comparison to older 
animals (Gonzalez Canga et al., 2009).  Older animals often have lower FEC results due to 
immunological defence from previous cyathostomin exposure (Klei and Chapman, 1999), yet 
some animals never develop a sufficient immune response. It has previously been suggested 
that resistance is more prevalent in immunologically immature animals (Klei and Chapman, 
1999; Chapman et al., 2003; Blanek et al., 2006) of which there were many within this study 
population. Premises where Garcia et al., (2013) reported 100% FECR to BZ was made up of 
a population of 11 horses with a mean age of 18 years that therefore would have developed 
some immunity to cyathostomin infections. The age range and mean age of the animals that 
did not meet the inclusion criteria for the present study were similar to that of rest of the study 
population. As these animals also resided on the same five premises, this would suggest that 
age alone did not influence FEC.  Therefore the grazing environment, also known to influence 
parasite burden (Osterman Lind et al., 1999), may have played a significant role.   
Both the single dose and five day doses of fenbendazole were administered according to the 
manufacturer’s instructions. There is evidence in other species, dogs and small ruminants, that 
fenbendazole administration with food significantly increases bioavailability compared to an 
oral bolus (McKellar et al., 2008). McKellar et al. (2002) suggested that in horses 
 82 
 
administering fenbendazole by oral bolus directly followed by food appeared to reduce 
bioavailability, however these conclusions were drawn from a very small sample. Differences 
in the administration routes should be considered when directly comparing these groups.   
Use of any anthelmintic product should be based on local, regional and farm-level, 
epidemiological information about susceptibility of nematodes (NOAH Compendium, 2013).  
In the present study the mean FEC at 14 days post-treatment was 250 ± 270 epg with 34 of the 
39 horses recording a positive result (≥25 epg). Lester et al. (2013) reported FECR for BZ at 
day 14 where the FEC was higher than at day 0 (pre-treatment). This was also a finding here: 
at day 14 post-treatment, of 39 horses with BZ-resistant strongyles five (8%) had a FEC greater 
than before treatment and a further two had the same FEC as before treatment indicating a 0% 
reduction.   
Resistance in equine cyathostomins appears highly prevalent within the UK horse population 
(Relf et al., 2011), indicating the need to understand how anthelmintics perform in the face of 
resistance. Treatment histories for premises in this study (Table 4.1) highlighted reliance on 
anthelmintics without diagnostic testing. Similar parasite control strategies were reported 
within commercial, high risk premises by Relf et al. (2011). Previous work has highlighted that 
BZs are less commonly used by today’s horse managers and have been in decline over the past 
10 years (Biggin et al., 1999; Allison et al., 2011).Yet even with reduced exposure to BZs, 
resistance in cyathostomins appears to be highly prevalent within the UK horse population 
(Biggin et al., 1999; Allison et al., 2011; Relf et al., 2011; Wood et al., 2013). Greater 
education is required in the sector encouraging diagnostic testing and targeting of appropriate 
anthelminthic treatments (Nielsen et al., 2010a). 
The FECRT used in this study to determine anthelmintic efficacy, was originally developed for 
small ruminants. The FECRT it is seen as the gold standard field test for equine nematodes 
(Coles et al., 2006; Matthews, 2011). The sensitivity of this test in the horse has previously 
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been criticised (Stratford et al., 2011; Matthews et al., 2012; Geurden et al., 2013). It has been 
suggested in small ruminants that 25% of the parasite population requires the resistant mutation 
before resistance is detected using this method (Martin et al., 1989), Stratford et al. (2011) 
suggested this can be extrapolated to equine nematodes. Within the literature there is a lot of 
variation in the interpretation of the requirement of the pre-treatment FEC for evaluating 
anthelmintic efficacy using FECRT. This present study followed the recommendation of Coles 
et al. (1992) WAAVP guidelines and Coles et al. (2006) of ≥150 epg. Other work suggests the 
minimum inclusion for efficacy testing to be ≥50 epg (Milillo et al., 2009; Traversa et al., 
2009a; Stratford et al., 2014) or ≥100 epg (Canever et al., 2013). This differs again somewhat 
to current cut off recommendations of 200-500 epg for anthelmintic treatment of animals within 
the field (Uhlinger, 1993; Matthews, 2008). In the present study the WAAVP (1992) guidelines 
were chosen as they are the current, globally recognised gold standard for efficacy testing. This 
does however make it difficult when comparing results to other published work. Within this 
study both the median hatch rate and the arithmetic mean were selected as metrics to evaluate 
the data. Faecal egg count data rarely follows a normal distribution therefore the median is the 
most appropriate measure of central tendency (Denwood et al., 2010; Nielsen et al., 2010a).  
The author acknowledges a number of limitations to this study which limit the extrapolation of 
findings. The sample size estimates indicated the need for a study of 20 horses per treatment 
group in order to detect a 7-fold difference in egg hatch rate with 95% confidence.  The study 
comprised only 39 horses, allocated to two treatment groups, and was therefore underpowered 
to detect differences of this magnitude or smaller.  
The study population may not be representative of the UK horse population as a whole, but 
represents a category of high risk horses within this population where sustainable anthelmintic 
treatment should be targeted. A study design issue here was the low prevalence of premises 
with cyathostomin populations that were demonstrably BZ-susceptible making comparisons 
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difficult. Notwithstanding these limitations, this study adds valuable information to our 
understanding of the ovicidal effect of fenbendazole in UK horses under field conditions.    
 
4.5. Conclusion 
These results suggest that the ovicidal effect of fenbendazole appears to be present but short 
lived in benzimidazole-resistant cyathostomins when dosed as a single oral dose, or for five 
consecutive days administered in feed. Numbers of eggs and larvae present immediately post 
treatment were significantly lower than before treatment. Hatch viability in post treatment eggs 
appeared to return to pre-treatment values within three days of a single dose or five consecutive 
day’s treatment at 7.5 mg/kg BW.  
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Chapter 5.0  
The effect of moxidectin administration on in vitro equine hindgut fermentation kinetics 
of hay and oats.  
5.1. Introduction 
Microbiota within the horse’s hindgut play a complex role in digestion and metabolism 
(Proudman et al., 2015). Within the caecum and large colon resides a microbial population 
uniquely adapted to ferment dietary plant fibre (Shirazi-Beechey, 2008). Under normal 
conditions the hindgut ecosystem remains in balance producing short chain fatty acids 
(SCFAs), carbon dioxide and hydrogen (Shirazi-Beechey, 2008; Santos et al., 2011). There is 
very little lactate present under normal conditions and the hindgut pH remains ≥7 (Shirazi-
Beechey, 2008; Daly et al., 2012).  
Rapid changes in the hindgut microbiome, often brought about by management changes, have 
been associated with the onset of colic (Al Jassim and Andrews, 2009). Epidemiological studies 
have identified dietary changes, involving both forage and concentrates, to be the greatest 
management-associated risk factors for colic (Cohen, 1999; Hillyer et al., 2002).  
Another key risk factor for colic is intestinal parasite burden. Both Uhlinger (1990) and Cohen 
et al. (1999) report that structured parasite control programmes, which included anthelmintic 
dosing, had a protective effect against colic. However anthelmintic treatment has also been 
identified as a risk factor for the onset of colic (Cohen et al., 1999; Hillyer et al., 2002). Both 
Cohen et al. (1999) and Hillyer et al. (2002) identified an increased risk of colic within seven 
days of anthelmintic treatment. Specifically the administration of the macrocyclic lactone 
anthelmintics ivermectin and moxidectin were associated with colic onset (Hillyer et al., 2002).  
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Little is known about the effect of anthelmintic treatment on the horse’s hindgut microbiome. 
To date studies in humans, goats and sheep using 16S rRNA sequencing have provided 
conflicting findings on the effect of anthelmintic on the gut microbiota (Cooper et al., 2013; 
Bartley et al., 2015; Li et al., 2016). A reduction in cellulolytic bacteria and an increase in 
Lactobacilli and Streptococci have previously been reported by Jacotot et al. (2004). Using 
bacterial counts after anthelmintic treatment these authors observed greater changes following 
moxidectin when compared to ivermectin or fenbendazole.  
Fermentation patterns can serve as an indicator of microbial activity and digestibility of 
substrates. SCFA output and pH are readily measurable in vitro using the method described by 
Theodorou et al., (1994).  Analysis of fermentation kinetics using this method has not been 
used previously to study the effect of anthelmintics on the hindgut microbiome. 
5.1.1. Objective 
The objective of this study was to describe the in vitro fermentation kinetics of hay and oats 
using samples from horses treated with moxidectin compared to untreated controls. 
5.2. Method and Materials 
5.2.1. Study population 
From a group of 17 polo ponies managed exclusively on pasture, six were randomly selected 
using the sample function in R (i386 3.1.2). The horses ranged from 6-16 years (mean 11 ±3 
years), comprised four mares and two geldings. Breeds represented were Argentinian polo 
pony cross Thoroughbred (n=5) and Argentinian polo pony cross quarter horse (n=1). Horses 
were not exercised and being kept in fields, no concentrate feeds were given and their diet was 
supplemented with meadow haylage ad libitum.  
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The healthcare plan for these horses for the previous three years included an interval dose worm 
control programme comprised of moxidectin three times per year. Two of the horses were 
imported from Argentina in spring 2015 with unknown anthelmintic history. In September 
2015, once on pasture turnout, screening FECs were conducted on all horses using a 
modification of the McMaster method (detection sensitivity to 25 eggs per gram) as described 
in chapter 4.  All horses underwent further FECs at the end of January and the end of February 
2016, all FEC tests reported no eggs seen. Based upon these FEC results, animal age, pasture 
management information, lack of access to pasture during the polo season and past anthelmintic 
history the parasite status of this group of horses was categorised as low (Nielsen et al., 2013a).  
5.2.2. Ethical approval 
This study was given favourable ethical opinion by the University of Surrey Animal Welfare 
and Ethical Review Board NASPA-2015-008-SVM. 
5.2.3. Treatment group allocation 
From the six horses previously selected, treatment and control animals were randomly assigned 
using the sample function in R (i386 3.1.2). Three animals were dosed with moxidectin and 
three remained untreated controls. 
5.2.4. Anthelmintic treatment 
Moxidectin is the most recent anthelmintic licensed for equine nematode treatment, and the 
most commonly used by horse managers (Allison et al., 2011), therefore it was selected for use 
in this study. Prior to dosing, each horse in the treatment group had its weight estimated using 
a commercial weigh tape. Due to known inaccuracies of this method (Ellis and Hollands, 1998), 
treatment weights were rounded up ≥50 kg. Moxidectin (18.92mg/g oral paste) was delivered 
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orally using the dosing device provided at as per the manufacturer’s instructions at a dose of 
0.4 mg/kg body weight.  
5.2.5. Sampling method 
Sample collection took place in March 2016. Using previously published pharmacokinetics 
and faecal excretion times for moxidectin (Gokbulet et al., 2001; Perez et al., 2001) sampling 
time points were selected as: prior to treatment (time zero), 16 hours after anthelmintic 
treatment, 40 hours after anthelmintic treatment and 160 hours after anthelmintic treatment. 
Samples were collected in the morning on each of the sampling days. On day 0 prior to 
anthelmintic treatment a fresh, spontaneously voided, faecal sample was collected from each 
animal. For each horse a thermos flask was pre warmed by filling with boiling water, sealed 
and transported to the farm in an insulated polystyrene container containing two hot water 
bottles.  As each animal defecated the water in the thermos flask was discarded and the flask 
filled with faeces to the top, sealed and placed back into the insulated container. Samples were 
then transported back to the laboratory, within two hours of collection. This sampling process 
was repeated at each of the faecal sampling time points.   
On the afternoon of day zero at approximately 4pm the treatment group were dosed with 
moxidectin per os, as described above.  
5.2.6. Experimental methods 
5.2.6.1. Sample storage 
On returning to the laboratory the thermos flasks were placed into a pre-warmed incubator at 
39⁰C.
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5.2.6.2. In vitro model feed preparation 
 Prior to sample collection two horse feeds, meadow hay and rolled oats were oven dried 
separately at 60⁰C for 24 hours and left to cool. Samples were then milled to 2 mm using a 
Fritsch Pulversette 19 universal cutting mill. One gram of feed was weighed out and placed 
into pre-labelled 125ml serum bottles. Each diet treatment, hay and oats, was run in triplicate 
for each horse. There were also two blank bottles, containing no substrate, per diet per horse, 
thus for each horse at each time point there were 10 bottles (Figure 5.1.). In total 240 bottles 
were used in this experiment.  
 
 
 
 
 
 
 
 
 
Figure 5.1. Schematic representation of donor horses and the number of bottles with differing 
substrates that was set up at each of the four sampling time points. 
5.2.6.3. Preparation of culture medium 
Modified Van Soest culture medium as described by Theodorou et al. (1994) was prepared in 
a 6 litre flask at room temperature, by dissolving 0.2 g of trypticase peptone, 0.2 ml micro-
Mox treated group Control group 
Hay Hay 
Oats Oats 
No substrate No substrate 
No substrate No substrate 
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mineral solution, 400 ml buffer, 400 ml macro-mineral solution and 2 ml resazurin solution in 
1 litre of distilled water.  The flask contained a magnetic stirrer on a magnetic plate were used 
to ensure the each ingredient was fully dissolved, prior to the addition of the following 
ingredients (in the order presented above). CO2 was continually passed through the solution 
until the medium turned pink, indicating the medium was anaerobic. The composition of the 
buffer, micro-mineral and macro-mineral solutions are detailed in Table 5.1. These solutions 
were stored in the refrigerator at 4⁰ C until required.  
Table 5.1. Chemical compositions of the solutions used in the culture medium.  
Solution Chemical Compound Formula g/1.4 litres distilled 
water 
Buffer Ammonium hydrogen carbonate NH4HCO3 5.6 
 Sodium hydrogen carbonate NaHCO3 49 
 
Macro-mineral 
 
Di-sodium hydrogen 
orthophosphate dodeca-hydrate 
 
Na2HPO4-12H2O 
 
13.23 
 Potassium di-hydrogen 
orthophosphate 
Magnesium sulphate 7-hydrate 
KH2PO4 
 
MgSO47H2O 
8.68 
 
0.84 
 
Micro-mineral 
 
Calcium chloride 2-hydrate 
Manganese chloride 6-hydrate 
Cobalt chloride 6-hydrate 
Ferric chloride 6-hydrate 
 
CaCl22H2O 
MnCl26H2O 
CoCl26H2O 
FeCl36H2O 
 
13.2g/100 ml  
10g/100 ml 
1g/100 ml  
8g/100 ml 
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5.2.6.4. Preparation of faecal inoculum  
From individual thermos flasks 75g of faeces were taken from the centre of the sample and 
placed into a food blender with 375 ml of Van Soest medium. The blender was turned on for 
40 seconds during which time the mixture was flushed with CO2.  The mixture was passed 
through a muslin bag in a funnel into a beaker to collect the liquid. This procedure was repeated 
for each horse at each sampling time point.  
5.2.6.5. Preparation of culture bottles 
Each culture bottle was flushed with CO2 for approximately 4 seconds before adding 70 ml of 
culture medium from an automatic dispenser, 4 ml of reducing agent (2.5g cysteine HCl, 16 ml 
1M NaOH, 2.5g sodium sulphate, 380 ml distilled water) was added to each bottle via a bottle 
top dispenser and 10 ml of faecal inoculum was added to each bottle using a disposable 10 ml 
syringe. Rubber stoppers were pushed firmly into the neck of each bottle and sealed with 
aluminium crimp seals. Bottles were then placed into a pre-heated incubator set at 39⁰C 
(Lowman et al., 1999).  The sample preparation was followed for the blank bottles, these 
contained no feed substrate.  
Bottles were adjusted to ambient pressure (zero reading on the pressure transducer display) 
using the transducer and a hypodermic needle. The start time, at ambient pressure, was recorded 
to inform gas reading times.  
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5.2.6.6. Gas accumulation measurements 
Readings were taken using the manual pressure transducer technique of Theodorou et al. 
(1994). A three-way valve was attached to a pressure transducer containing an LED digital 
read-out meter. A syringe and hypodermic needle was set to one arm of the valve with the other 
set to allow gas from the bottle to flow through to the transducer. The needle was inserted 
through the rubber seal and the pressure reading recorded, Figure 5.2.  
 
Figure 5.2.  In vitro gas production set up for gas readings. 
 
The syringe plunger was then withdrawn until the LED read zero, whereupon the needle was 
removed from the bottle and the volume of gas withdrawn was recorded. The gas was discarded 
and the process repeated for each bottle. Culture bottles were only removed from the incubator 
for a short period of time for gas readings, during this time they were placed in a water bath to 
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ensure they remained at 39°C. The transducer pressure was recorded in pounds per square inch 
(psi). Readings were taken at approximately 4 hourly intervals up to 113 hours post inoculation. 
Once the bottles stopped producing gas the experiment was stopped. 
 
5.2.6.7. After fermentation ceased 
After completion of the last gas reading the rubber stoppers and crimps were removed from the 
bottles. The contents of each bottle was filtered using pre-weighed Whatman No.1 filter paper 
in a funnel, bottles were back washed with 20 ml of distilled water to collect remaining 
substrate. The pH of the faecal inoculum was recorded using a calibrated pH probe (Orion Star 
A211). Microfuge tubes, in duplicate, of the inoculum from the culture bottles were collected 
and frozen at -80°C for metabolite analysis at a later date. 
5.2.6.8. Dry matter loss 
Once the inoculum had passed through the pre weighed filter paper the papers were oven dried 
at 60⁰C. The filter papers were weighed and the weight of the residue, subtracted from the filter 
paper weight. This was recorded and used to calculate substrate dry matter loss using the 
equation below.   
DM loss (%) = DM into bottle-DM residue in bottle   X 100 
DM into bottle 
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5.2.7. Data analysis 
5.2.7.1. Cumulative gas production 
Data were inputted into a Microsoft® Excel spreadsheet (Microsoft Excel 2010) to process the 
pressure and volume readings for each bottle. For each bottle gas volume readings were 
corrected against pressure readings, bias correction, using linear regression (Theodorou et al., 
1994). Corrected volumes were then adjusted according to the readings from the blank bottles 
(those containing no food substrate) to remove background fermentation from the faecal 
inoculum itself. Values were then summed to provide a cumulative gas volume of each bottle.  
The maximum likelihood program (MLP; Ross, 1987) was used to fit curves to the cumulative 
gas profiles using the France et al. (1993) model detailed below.  
Where: 
Y= cumulative gas pool in ml 
t= time in hours 
A= asymptote value for gas pool size (ml) 
B= A e bT+c√t 
Z= e –c 
Q=e –b 
LT = lag time in hours 
b = rate constant (h-1) 
c= rate constant (h-0.5) 
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Equation 1  
Y= A-BQtZ√LT 
 
Equation 2 
 Y= A-BQt 
 
When the initial rate of gas production was quadratic, i.e. the rate constant c was negative, 
equation 1 was used. If an exponential rate of gas production was noted i.e. when c=0, equation 
2 was used.  
The fitted France et al. (1993) parameters of LT, A, B, Q and Z, the time to reach 50% of gas 
produced (t50), time to 95% gas produced (t95), fractional rate of gas production (FRGP) half 
way through fermentation were analysed for hay and oats separately, comparing the treatment 
and control groups.  
For each inoculation time point (0, 16, 40 and 160) comparable gas reading times within a 2 
hour window were compiled in the database for repeated measures analysis. These time points 
were: 0, 10, 20, 30, 44, 60 and 70 hours post inoculation of the bottles. 
5.2.7.2. Statistical analysis 
Data demonstrated a normal distribution. For analysis of cumulative gas production for both 
treatment and control groups over time a repeated measures ANOVA was used. The feed 
treatments hay and oats were considered separately. The same approach was taken for the 
analysis of dry matter loss of substrate (%) and faecal inoculum pH and parameters derived 
from the France et al. (1993) model. Post hoc testing was conducted using Fishers least 
significant difference (LSD) test. All statistical analysis was conducted in GenStat 18th ed. 
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5.3. Results 
5.3.1. Pre-treatment gas production 
At sampling point zero, for both diets the treatment and control groups demonstrated no 
significant differences in cumulative gas production pre-treatment with moxidectin (Figure 
5.3.). 
 
Figure 5.3. Modelled gas production prior to moxidectin treatment fermenting (a) hay and (b) 
oats in vitro, error bars represent 95% confidence limits.  
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At pre-treatment there were no significant differences in any of the fermentation kinetic 
parameters calculated in the France et al. (1993) model. There were no differences in dry matter 
loss or inoculum pH for either treatment group for both substrates. The fermentation model 
produced very similar results for hourly gas production for each treatment group for both of 
the feeds (Figure 5.4.). The France et al. (1993) model was a good fit to the cumulative gas 
produced, Table 5.2.   
However the pre-treatment bottles only produced gas for 48 hours post inoculation, this was a 
minimum of 22 hours less than the other time points suggesting less than optimum in vitro 
fermentation. As these fermentations ran for a much shorter time than bottles inoculated at 16 
hour, 40 hours and 160 hours post moxidectin the data were analysed separately using a T-Test 
and not included in the repeated measures ANOVA for cumulative gas production, dry matter 
loss and inoculum pH.  
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Figure 5.4. Mean gas produced per hour (ml) prior to moxidectin treatment for both hay and 
oat substrates for both the treatment and control groups. Hay fermentation for both treatment 
groups was less variable, demonstrated by the 95% confidence interval error bars, than oat 
fermentation. For hay and oats substrates neither treatment group was different from the other 
for gas produced per hour prior to moxidectin administration.  
 
5.3.2. Post Treatment  
Cumulative fermentation kinetics identified a significant reduction in gas produced 16 hours 
after moxidectin administration (P=0.001) for both hay and oat feed treatments. There was no 
significant difference in cumulative gas production at any other time points for either of the 
feed substrates, Figure 5.5.  
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Figure 5.5. Panel plot for mean modelled gas production curves for hay (plots a, b, c) and oats 
(plots d, e, and f). Plots a and d are mean gas production from bottles inoculated with faeces 
collected 16 hours post moxidectin treatment, plots b and e bottles inoculated from faeces 
collected 40 hours after treatment and plots c and f bottles inoculated from faeces collected 160 
hours post moxidectin treatment. Error bars demonstrate 95% confidence intervals. Only plots 
A and D demonstrate significant differences between treatment and control groups (P=0.001).  
 
The hourly rate of gas production post moxidectin treatment is illustrated in Figure 5.6. These 
graphs demonstrate that in fermentations inoculated with faeces collected 16 hours after 
moxidectin administration gas produced per hour is reduced compared to untreated controls. 
Fermentations inoculated with faeces collected at 40 and 160 hours after moxidectin 
administration there was no difference in gas production (Figure 5.6. B & C).  
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Figure 5.6. Panel plot of gas produced per hour for both feed substrates and both treatment 
groups at 16 (A), 40 (B) and 160 (C) hours after moxidectin administration. Error bars 
demonstrate 95% confidence intervals. Plot A treatment and control group differ in hourly gas 
production rate for both feed substrates up to 60 hours. Plot C the treatment groups differ in 
gas produced for the hay substrate up to 40 hours.  
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5.3.3. Dry matter loss 
The percentage dry matter loss of substrate was calculated for each fermentation experiment 
after moxidectin administration for both treatment groups. There was a significant difference 
in dry matter loss of hay and interaction with time between treatment groups (P=0.014). Post 
hoc testing indicated this was in fermentations inoculated from faeces collected 40 hours after 
moxidectin administration, Figure 5.7. There was no difference between the treatment groups 
and time points for the oats substrate (P<0.05).  
 
Figure 5.7. Dry matter loss (%) of hay substrate over the three sampling time points after 
moxidectin administration, between the two treatment groups. There was a significant 
interaction between time and treatment (P=0.014). Error bars represent 95% confidence 
intervals, significance is marked with a *.  
 
5.3.4. Inoculum pH 
Post moxidectin administration the pH of the faecal inoculum varied in both treatment groups 
over the time points, both treatment groups followed the same pattern of variance. Due to inter-
horse variability the time points for the moxidectin treatment group were compared to each 
other post treatment and the same approach taken for the control group. There was a significant 
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increase in pH of faecal inoculum that fermented hay one week after moxidectin administration 
in the treated group (P=0.002). There was no significant difference in the pH of the faecal 
inoculum that fermented hay in the control group, Figure 5.8. For the oats substrate the pH of 
the moxidectin treated group was significantly lower the day after moxidectin administration 
(P=0.005) (Figure 5.9. A). The pH of the faecal inoculum for the control group was not 
significantly different over the time points.   
 
Figure 5.8. pH of faecal inoculum after hay fermentation post moxidectin administration (A) 
the treated group and (B) the untreated controls. The moxidectin group pH significantly 
differed between time points (P=0.002) however the control group pH did not differ between 
time points (P>0.05). Error bars represent 95% confidence intervals, significance points are 
indicated by *.  
* 
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Figure 5.9. pH of faecal inoculum after oat fermentation post moxidectin administration for 
(A) the treated group (P=0.005) and (B) the untreated controls. The control group was not 
significantly different between the sampling points. Error bars represent 95% confidence 
intervals, significance points are indicated by *. 
5.3.5. Model fit 
To ensure that the France et al. (1993) model was a good fit to the cumulative gas production 
data, R2 values were calculated during the modelling calculations. These values indicated the 
model was a good fit to the cumulative data over the consecutive fermentation experiments. 
The R2 values are presented in table 5.2. 
 
 
 
* 
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Table 5.2. R2 values for cumulative gas production and the France et al. (1993) modelled data, 
indicating the model was a good fit to the data. 
Treatment 
Pre 
Treatment 
16 Hours 
Post 
Treatment 
40 Hours 
Post 
Treatment 
160 Hours 
Post 
Treatment 
Oats Mox 0.993 0.998 0.996 0.996 
Oats 
Control 0.991 0.997 0.996 0.989 
Hay Mox 0.993 1 1 1 
Hay 
Control 0.998 1 1 1 
 
5.3.6. Hay fermentation kinetics 
From the France et al. (1993)  model at 16 hours after moxidectin administration there was a 
significant interaction in the fractional rate of gas production between the two treatment groups 
for hay substrate half way through incubation, this was also observed at 160 hours following 
moxidectin administration  (P=0.001) Figure 5.10.   
 
Figure 5.10.  Fractional rate of gas production (FRGP) halfway through fermentation of hay 
for faecal inoculum exposed to moxidectin and untreated controls at 16, 40 160 hours post 
moxidectin administration. Interactions are identified by * identified by LSD. The error bars 
represent 95% confidence intervals.  
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5.3.7. Oat fermentation parameters  
The models using a diet of oats demonstrated a significant interaction between the treatment 
and control groups for the extent of substrate degradation (P=0.008) 16 hours after moxidectin 
administration, Figure 5.11. There were no differences in any of the parameters at 40 and 160 
hours after moxidectin administration for the oats substrate. 
 
Figure 5.11. Degradation rate of oats following moxidectin administration, time interaction at 
16 hours (P=0.008), error bars represent 95% confidence interval. 
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5.4. Discussion 
Prior to dosing with moxidectin there was no difference between the fermentation profiles, dry 
matter loss (%) of substrate or pH of the faecal inoculum for either of the treatment groups. 
However the morning following moxidectin administration fermentation of hay and oats in our 
in vitro model were significantly reduced in fermentations inoculated with faeces from treated 
animals. When looking at the repeated measurements of cumulative gas production there was 
no significant difference between the treatment and control groups from two days after 
moxidectin administration. However over the week after treatment and there were some 
differences between the treatment groups when looking at the fractional rate of gas production, 
rate and amount of substrate degradation.  
Dry matter loss of oat substrate did not differ between the groups and time points after 
moxidectin administration but did significantly alter for hay substrate. The two treatment 
groups followed the same pattern initially for dry matter loss of hay substrate but two days after 
moxidectin administration the control group used significantly more substrate than the treated 
group. By one week after moxidectin administration the treatment groups were not significantly 
different in hay substrate loss and the moxidectin treated group were using more substrate than 
they had in both of the previous post treatment time points.   
 The pH of the faecal inoculum was measured at the end of fermentation for both substrates. 
Due to inter-horse microbiome variability (Willing et al., 2009; Blackmore et al., 2013) pH 
changes within groups were analysed over the sampling time points. For both hay and oats 
substrates the control group pH did not significantly differ over the sampling points. The pH 
values for the moxidectin treated group followed the same pattern over time as the control 
group. However with hay fermentation pH significantly increased a week after treatment 
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compared to the first two days after treatment. With the oats substrate the pH of the faecal 
inoculum was significantly lower the morning after moxidectin administration.  Jacotot et al. 
(2004) found moxidectin treatment significantly lowered the pH and altered the bacterial 
composition of the caecum, increasing Streptococci spp. and Lactobacilli spp. and significantly 
reduced cellulolytic bacteria for five hours after anthelmintic administration. In the present 
study the pH of the inoculum from fermenting oats was lower than that of hay around the time 
of moxidectin administration. This would be expected as starch fermentation would lead to a 
lower pH than forage (Julliand et al., 2001; Medina et al., 2002), thus the substrate would 
influence the inoculum pH. It should be noted here that while the pH of the faecal inoculum 
was significantly lower around the time of moxidectin administration it remained within the 
normal range for the horse hindgut (Daly et al., 2012). Biddle et al. (2013) reported that the 
pH of faecal inoculum in culture bottles decreased to a pH ≤ 6 within 12 hours of fermentation 
when exposed to starch and lactate, but by 50 hours had increased to pH ≥7 in some animals. 
These findings are a further illustration of the variable nature of hindgut pH and inter-horse 
variability.  In the present study pH readings were taken at the end of fermentation, the readings 
gained may not reflect the pH of the faecal inoculum part-way through fermentation where the 
fermentation profiles between groups differed.  
In this present study the bacterial composition of faecal inoculums was not analysed, however 
fermentation serves as a measure of hindgut microbial activity. Santos et al. (2011) stated that 
fermentation patterns can serve as an indicator of microbial activity and therefore a 
representation of the horse’s hindgut ecosystem. Therefore the reduction in gas production and 
alteration of other fermentation parameters in the present study suggests moxidectin 
administration was associated with alteration in the bacterial activity within the faecal 
inoculum. Interestingly while the main difference in the fermentation kinetics was detected at 
16 hours after moxidectin administration, there were other changes in gas production over the 
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week following administration of moxidectin, predominantly within the hay substrate. 
Fermentation kinetics were reported by Biddle et al. (2013) as a measure of hindgut microbial 
activity alongside inoculum pH measurements over time and 16S rRNA sequencing to identify 
microbial composition change within the hindgut. In our present study pH was only measured 
at the endpoint of fermentation and microbial composition was not measured. Both pH and 
microbial composition warrant investigation in vivo from the findings of this in vitro study.  
The combined results of this present study suggest that following moxidectin administration 
there was a fluctuation in the pH of the faecal inoculum within the in vitro system. This may 
be linked to the differences in fermentation observed in fermentations inoculated with faeces 
collected 16 hours after moxidectin treatment.  
The findings for the hay substrate fit with the findings of Jacotot et al. (2004) who identified 
that cellulolytic bacterial counts decreased significantly 24 hours after moxidectin 
administration. One week after moxidectin administration the pH of the faecal inoculum for 
the hay substrate significantly increased. However there was still a difference in the fractional 
rate of gas production and a longer lag time for in the treated horses, suggesting the ecosystem 
had not fully returned to normal.  
The results of the oat fermentations may also fit with the findings of Jacotot et al. (2004), 
initially fermentation was reduced around the time of moxidectin administration however pH 
fluctuations may have made the inoculum environment more suited to starch fermentation. 
Jacotot et al. (2004) reported as caecal pH dropped and the cellulolytic bacteria decreased there 
was an increase in Lactobacilli and Streptococci. In this situation it may be expected that starch 
fermentation would improve as the bacteria proliferating in the ecosystem are much more 
suited to starch as a substrate. The morning after moxidectin administration there was a 
significant reduction in gas production for the oats substrate, however beyond this time point 
 109 
 
there were no differences in the fermentation kinetics for the treatment and control groups, thus 
suggesting the adaption of the hindgut microbiota to a more acidic environment within the 
treatment group. The oat substrate fermentation was much quicker to return to normal than the 
hay substrate, suggesting changes in fermentation activity were optimised to starch rather than 
structural carbohydrates.  
Prior to and during the experiment the donor horses received no concentrate feed, therefore the 
bacterial ecosystem in the faecal inoculums would not have been used to starch as a substrate. 
This may explain some of the inter horse variability for starch fermentation. Changes in diet 
from grass to concentrates has shown increases in the relative abundance of the Bacillus-
Lactobacillus-Streptococcus lactate producing bacteria and a 4-fold decrease of cellulolytic 
Fibrobacter spp., this change has been associated with lowered colonic pH (Shirazi-Beechey, 
2008). Ideally the donor horses should be fed similar diets to that being fermented in the in 
vitro system (Rymer et al., 2005).  The forage in the culture bottles differed slightly to that of 
the donor horses’ diet, however Muller et al. (2008) found no difference in fermentation 
kinetics between hay and haylage in horses so this should not have influenced the findings in 
this present study.  
 Changes in bacterial faecal inoculum composition were reported by Biddle et al. (2013) using 
a similar culture based technique when exposing inoculum from donor animals on a forage 
based diet to starch substrate in vitro. Using 16S rRNA sequencing Biddle et al. (2013) saw an 
increase in Firmicutes spp., specifically an increase in Streptococcus spp., during the first 24 
hours after inoculation. This would also fit with the findings of the present study as these 
microbiota composition changes would be associated with reduced forage fermentation.  
The in vitro gas production system was originally designed to analyse fermentation kinetics in 
ruminants (Theodorou et al., 1994) and has been successfully adapted to study equine 
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fermentation. Reports by Lowman et al. (1996) and Machboeuf et al. (1997) identified that 
equine faeces were a good substitute for caecal fluid for in vitro gas production models. 
Lowman et al. (1999) reported that the in vitro gas production technique was a good 
representation of in vivo fermentation in the horse. Since then this method has been adapted for 
a range of equine studies including pure nutrition, changes associated with the starch content 
of the diet and tracking microbial changes when simulating starch overload (Biddle et al., 2013; 
Murray et al., 2014).  
In this sealed-system, in vitro model, the products of fermentation e.g. volatile fatty acids are 
retained within the faecal inoculum, in vivo these would be absorbed. Theodorou et al. (1994) 
identified that while volatiles remained in the in vitro environment this did not alter the pH or 
significantly impact fermentation kinetics. The media used in these experiments was also 
originally optimized for ruminants and this should also be considered when interpreting results 
as this might not allow the culturing of some bacteria normally present within the horse 
hindgut. One further limitation is that this system is totally anaerobic, Julliand et al. (2001) 
found that as cereal concentration in the diet was increased the number of aero-anaerobes 
significantly increased compared to horses fed only forage. It would be unlikely these 
organisms would thrive in the in vitro gas production environment due to the lack of oxygen.  
 A similar in vitro method to model bacterial changes associated with starch overload was 
successfully used by Biddle et al. (2013). Thus the model used in the present study gives a fair 
representation of the horse’s hind gut environment. In a more advanced in vitro model Leng et 
al. (2017) have developed a three chamber hind gut, in which each vessel demonstrated 80% 
similarity in bacterial composition and produced short chain fatty acids as a product of 
fermentation.  This also suggests it is possible to simulate some of the complexity of hindgut 
microbial fermentation in vitro. In ruminants Danielsson et al. (2014) used the in vitro gas 
production method, sequencing bacterial DNA from rumen fluid prior to bottle inoculation and 
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harvested bottles during fermentation for further sequencing.  The study found that bacterial 
composition in the in vitro gas production system was a good representation of the rumen. 
Taken together these previous studies suggest in vitro models give a fair representation of the 
horses’ hindgut microbiome.   
Within our present study both hay and oats were chosen as a substrates for the in vitro system, 
hay representing a typical forage ration and oats because many horses are managed on 
concentrate diets containing starch from cereal grains. Hindgut microbiota are optimized for 
forage fermentation and the effect of high levels of starch reaching the hindgut is already 
known to be associated with microbial changes (Daly et al., 2012). Cereal inclusion in the diet 
has previously been identified as a risk factor for colic. Furthermore anthelmintic 
administration has also been identified as a colic risk factor (Cohen et al., 1999; Hillyer et al., 
2002). The findings of our present study show that anthelmintic administration briefly altered 
the activity of microbiota. Previous studies have identified that dietary changes alter both 
activity and composition of microbiota, increasing the risk of colic. As anthelmintic 
administration appears to alter the activity of microbiota further work is required to identify if 
this also leads to changes in microbiota composition.  
During sampling at pre-treatment it took longer to collect samples than the following sampling 
time points. While the pre-warmed flasks were kept in a polystyrene container during the 
sampling process the pre-treatment samples may have dropped below optimum temperature 
therefore affecting the bacterial viability. The fermentation profile at this time point did show 
that there was no difference in the fermentation kinetics between the groups prior to moxidectin 
administration. By having an untreated control group throughout the experiment meant the 
limitations in the data prior to moxidectin administration did not significantly impact on the 
viability of this study. Furthermore the dry matter loss (%) was the same at 160 hours post 
treatment as it was at pre-treatment suggesting some reliability in this data. However 
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interpreting the gas production data from this pre-treatment time point and any other analysis 
from the fermentations from this time point should be taken with caution.  
This present experiment did use a low number of donor animals, this is comparable to other 
studies using this culture based technique. One particular restriction to increasing the sample 
size in this experiment was the amount of time taken to collect samples, inoculate and collect 
readings from the culture bottles. 
5.5. Conclusions 
Notwithstanding limitations, the data from this present study suggest that moxidectin 
administration in vivo reduced cumulative gas production associated with the fermentation of 
both hay and oat substrates in an in vitro model 16 hours following moxidectin administration. 
While cumulative gas production did not differ between the treatment and control groups at 40 
and 160 hours after moxidectin administration, there were some differences in fermentation 
kinetics and substrate losses. These findings suggest that moxidectin may alter hindgut 
microbial metabolism around the time of treatment. Further work is required to better 
characterise changes in microbial function and to determine whether they are associated with 
changes in microbial community profile.   
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Chapter 6.0  
The effect of moxidectin administration on equine faecal microbiota composition using 
16S rRNA sequencing 
6.1. Introduction 
There is limited understanding of the relationship and communication between nematodes and 
the hindgut microbiome within the horse (Peachey et al., 2017a). Currently there is limited 
knowledge on the effect of nematodes and anthelmintic treatment on the equine hindgut 
microbiome. Equine hindgut microbiota are extremely sensitive to change (Daly et al., 2012; 
Dougal et al., 2013), in chapter five moxidectin significantly altered fermentation patterns for 
both hay and oats around the time of administration. Alterations in microbiota and metabolome 
of pigs infected with T. suis have previously been reported when compared to uninfected 
controls (Li et al., 2012).  
The interaction between parasites and gut microbiome is potentially perturbed by anthelmintic 
treatment. This phenomenon has been explored by Bartley et al. (2015) who reported changes 
within the microbiota of sheep infected with nematodes when compared to uninfected controls 
with some composition changes around anthelmintic administration. Cooper at al. (2013) 
identified in humans infected with T. trichiura that parasite burden and anthelmintic treatment 
did not alter the microbiota composition when compared to parasite free untreated controls.  
Goats infected with Haemonchus contortus were reported to have a significantly altered 
ruminal microbiota composition compared to uninfected controls (Li et al., 2016).  
This interaction has been explored in horses by Jacotot et al. (2004) who reported a reduction 
in cellulolytic bacteria and reduction in caecal pH followed by an increase in Lactobacilli and 
Streptococci after treatment with moxidectin. These findings warrant further investigation into 
bacterial composition of equine gut microbiota following anthelmintic administration.  
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6.1.1. Objectives 
There were two objectives of this study: 
1) To characterise the composition and diversity of faecal microbiota prior to and post 
anthelmintic treatment in animals with very low intestinal parasites burdens. 
2) To monitor faecal pH prior to and following moxidectin treatment.  
6.2. Materials and methods 
6.2.1. Study population 
A group of 17 polo ponies managed exclusively on pasture at a farm in Gloucestershire were 
recruited on to this study. The population comprised both mares (n=12) and geldings (n=5) 
with a mean age of 12 ±3.5 years, and a range of breeds (Thoroughbreds n=4, Thoroughbred 
cross Argentinian polo pony n=8, Argentinian polo pony n=4, Argentinian polo pony cross 
Quarter horse n=1.   Horses were not exercised and no concentrate feeds were given, their diets 
were supplemented with meadow haylage ad libitum. The healthcare plan, including parasite 
control and treatment history for these horses, was the same as described in chapter five.  
6.2.2. Ethical approval 
This study was given favourable ethical opinion by the University of Surrey Animal Welfare 
and Ethical Review Board NASPA-2015-008-SVM. 
6.2.3. Treatment group allocation 
Treatment and control animals were randomly assigned using the sample function in R (i386 
3.1.2). Nine animals were dosed with moxidectin and eight remained untreated controls. 
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6.2.4. Anthelmintic treatment 
Moxidectin was selected as the anthelmintic for this study as it is most recent anthelmintic 
licensed for equine nematode treatment, and the most commonly used by horse managers 
(Allison et al., 2011).   
6.2.5. Sampling method 
Sample collection took place in March 2016. On day 0 prior to anthelmintic treatment a fresh, 
spontaneously voided, faecal sample was collected from each animal. Faecal pH was recorded 
using a hand held pH monitor (Hanna pHep, HI98128) as described by Muller et al. (2008) in 
the fresh faecal pile.  A small sample of faeces was collected into labelled 50 ml screw top vials 
and placed into an insulated container containing ice for transport to the laboratory. On arrival 
at the laboratory samples were frozen at -80◦C. This process was repeated at each sampling 
time point, 16 hours, 40 hours and 160 hours post moxidectin treatment.  On the afternoon of 
day 0 at approximately 4pm the treatment group were dosed with moxidectin, as previously 
described in chapter 5.  
6.2.6. Next generation sequencing 
6.2.6.1. Bacterial DNA Extraction 
Bacterial DNA was extracted from faecal samples in preparation for 16S rRNA sequencing. 
Extraction was undertaken using PSP® Spin Stool DNA Kit (Stratec Molecular, Germany). 
All reagents and buffers were supplied within the kit and were prepared in line with the 
manufacturer’s instructions. For each sample 200 mg of faeces were weighed into a 2 ml 
microfuge tube and mixed with 1.2 ml of lysis buffer and then vortexed for one minute. 
Microfuge tubes were incubated on a pre-heated thermomixer at 95◦C for 10 minutes whilst 
being shaken.  Each microfuge tube had five Zirconia II beads added and samples were bead 
beaten for two minutes on a vortex.  Samples were then centrifuged at 11,100 x g for one 
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minute. The supernatant was transferred to the inviAdsorb-tube and vortexed for 15 seconds. 
Samples were incubated at room temperature for one minute before centrifugation for three 
minutes at full speed (14,000 x g). The supernatant was transferred to a new microfuge tube 
and centrifuged again for three minutes at full speed.  From the supernatant 400 µl was 
transferred into a new microfuge tube and 25 µl of proteinase k was added, the solution was 
mixed briefly by vortex.  The sample was then incubated in a pre-heated thermomixer at 70◦C 
for 10 minutes at 900 rpm.  
After incubation 200 µl of binding buffer A was added and mixed briefly by vortex. The 
mixture was then transferred to RTA spin filter tubes and incubated at room temperature for 
one minute.  Spin filters were then centrifuged at 11,000 x g for two minutes. The RTA filter 
was then transferred to a new receiver tube and the previous tube and filtrate discarded. Once 
fitted to a new receiver tube 500 µl of wash buffer one was added to the spin filter. Samples 
were then centrifuged at 11000 x g for one minute. Again the filter was transferred to a new 
receiver tube and the previous tube and filtrate were discarded. Then 700 µl of wash buffer II 
was added to the filter and centrifuged at 11,000 x g for one minute. The filtrate was again 
discarded and the receiver tube re-used, to ensure all ethanol from the wash buffers was 
removed the samples were centrifuged at 14,000 x g (full speed) for four minutes. After 
centrifugation the filtrate and receiver tubes were discarded and the filters placed on new 
microfuge tubes. Then 200 µl of pre warmed molecular biology grade water, at 70◦C, was added 
to the filters to elute the DNA. Samples were incubated for one minute at room temperature 
and then centrifuged for one minute at 11,000 x g. The spin filter was removed and the eluted 
DNA contained in the microfuge tube. To ensure that DNA was present 1 µl of elution fluid 
was placed on a calibrated Nano-drop spectrometer to estimate DNA concentration in ng/ µl. 
Mean DNA concentration per sample was  89.6 ± 49.9 ng/ µl. Samples were then frozen at        
-20◦C prior to sequencing.  
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6.2.6.2. 16S rRNA Sequencing 
Pre-sequencing PCR to amplify the V4 region of the 16S rRNA gene (using primers F515 
(GTGYCAGCMGCCGCGGTA) and R927 (CAGCCCGYCAATTCMTTTRAGT)), clean up 
and sequencing was performed at the Animal and Plant Health Agency (APHA) using the 
Illumina MiSeq platform.  
6.2.7. Data analysis  
6.2.7.1. pH data 
Faecal pH data was recorded in a Microsoft® Excel spreadsheet (Microsoft Excel 2010). pH 
was analysed using a repeated measures ANOVA in GenStat 18th ed. 
  6.2.7.2. Bioinformatics of sequencing data 
Filtering and processing of raw reads generated during sequencing was carried out using 
QIIME v. 1.6.0. Reads were initially aligned using Pandaseq and cut off at 380-420 reads, these 
were then combined into combined_fasta files.  Using the USEARCH programme in QIIME 
v.1.8.0 operational taxonomic units (OTUs) were clustered at a level of 96% similarity using 
pick_otus.py.  OTUs were then classified using the Ribosomal Database Project (RDP) 
classifier 2.0 (Wang et al., 2007).  Once OTUs were assigned pick_rep_set.py was used to pick 
sets of representative sequences, one per OTU. This was then followed by assigning taxonomy 
using assign_taxonomy.py and then aligned using the PyNast programme align_seqs.py. The 
output of the aligned sequences was used to create an OTU table using make_otu_table.py.  
The ‘fasttree’ QIIME script was then used to build a phylogenetic tree using programme 
make_phylogeny.py.  
Once the phylogenetic tree and OTU table were created alpha and beta rarefraction analysis 
was carried out using the QIIME scripts alpha_diversity.py, jacknifed_beta_diversity.py, 
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beta_diversity_through_plots.py and multiple_rarefaction. Two alpha rarefaction indices were 
calculated, Obs and Chao1. Chao1 rarefaction looks at species richness and evenness within 
the sample whereas Obs looks only at the richness within the sample. Following this taxa 
summary plots were created using summarize_taxa_through_plots.py for phyla, class, order 
and family levels of classification.  
The Linear Discriminate Analysis (LDA) effect size (LEfSe) platform was then used to identify 
significantly different abundant OTUs between the treatment groups and time points. This non-
parametric model is robust in the face of multiple comparisons (Segata et al., 2011).    
 
6.3. Results 
None of the horses showed any signs of colic after moxidectin administration. One of the horses 
in the treatment group excreted cyathostomins the day following treatment.  
6.3.1. pH data 
From the faecal pH data there were no significant differences between the treatment and control 
groups identified (P>0.05). Mean pH values are displayed in table 6.1. 
 
Table 6.1. Mean faecal pH values for the Moxidectin treated and control groups over the four 
sampling time point. 
Group 
Pre-
Treatment 
16 Hours Post 
Treatment 
40 Hours Post 
Treatment 
160 Hours Post 
Treatment 
Moxidectin 6.8 ±0.13 6.9 ± 0.29 6.7 ± 0.33 6.7 ± 0.10 
Control 6.7 ± 0.20 7.0 ± 0.28 6.8 ± 0.16 6.8 ± 0.13 
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6.3.2. Sequencing data 
Total sequences within the data set was 4,034,103, the minimum number of sequences per 
sample was 1,388, the maximum was 101,512. The mean number of sequences per sample was 
62,063. After filtering and removal of chimeras 5746 OTUs were identified from the sequenced 
samples.   
 
6.3.2.1. Alpha Diversity 
Alpha diversity was calculated for each horse at each sampling point. Both Obs and Chao1 
alpha rarefaction indices were plotted against the number of sequences for individual animals, 
and treatment groups. When looking at the rarefaction curves for both observed species 
richness and evenness moxidectin administration did not influence species richness or evenness 
within samples over the four sampling time points, Figure 6.1.    
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Figure 6.1. Panel plot of alpha diversity measures. (A) Species richness using Chao1 alpha diversity at subject level for both treatment and control groups over the 
four time points for individual animals.  (B) Species richness and evenness using Chao1 alpha diversity for treatment groups over the four time points. (C) Observed 
species rarefraction curve for all horses, both treatment groups, at all four time points. (D) Rarefraction curve of observed species per treatment group at each 
sampling time point. In the legends 0, 16, 40 and 160 reflect the time points, M and C refer to treatment groups and the number defines the animal. Error bars 
represent 95% confidence interval. 
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6.3.2.2. Beta Diversity  
Beta diversity defines diversity between groups, in comparison to alpha diversity which is 
within groups. Principle coordinate analysis of beta diversity, classified by treatment group, 
indicated no clustering between groups (Figure 6.2.). Beta-diversity between treatment groups 
across all time points was also explored (Figure 6.3.) and no clear clustering was identified. 
Jack-knifed beta diversity identifies robustness of Unweighted Paired Group Method with 
Arithmetic Mean (UPGMA) clusters. Jack-knifed beta-diversity PCoA plots again suggest no 
significant differences between treatment groups and time points, Figure 6.4. Inter-horse 
variability was also plotted using beta diversity, there was some clear animal level clustering 
over the time points for both treatment groups, Figure 6.5.  
 
 
Figure 6.2. Beta diversity PCoA plot separated by treatment group only, including all of the 
sampling time points.  
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Figure 6.3. PCoA plot of beta diversity between the treatment and control groups over the four 
sampling points. There are no distinct clustering between the treatment groups or time points. 
C0-3 identifies control group at time points 0, 16, 40 and 160, M0-3 identifies the moxidectin 
group at sampling points 0, 16, 40 and 160.  
 
 
 
Figure 6.4. PCoA plot of jack-knifed beta diversity between treatment groups over the four 
time points. There appears to be no visually spaced clusters between treatment groups and time 
points. C0-3 identifies control group at time points 0, 16, 40 and 160, M0-3 identifies the 
moxidectin group at sampling points 0, 16, 40 and 160. 
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Figure 6.5. Beta diversity at horse level for each sample for the moxidectin treated horses (A) 
and the untreated controls (B). Within both treatment groups there is some clustering by horse.  
Within the key the number on the right refers to the animal, numbers in parenthesis reflect the 
number of samples from that animal.  
 
 
 
 
A 
B 
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6.3.3. Taxa summary  
Taxa plots at phyla, order and family level can be seen in Figure 6.6. At phyla level there are 
no significant changes around the time of moxidectin administration. Moving down two 
taxonomic levels to order level there are no changes only some minor fluctuation within the 
Firmicutes phyla. The Veillonellaceae here represent approximately 1-2% of the microbiota 
and did not fluctuate around the time of treatment. These data suggest moxidectin 
administration did not alter the composition of the faecal microbiota. 
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Figure 6.6. OTU abundances (%) for the two treatment groups over the four sampling points, 
A is phyla level, B is order and C is family.  
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6.3.4. Discriminant analysis 
There were no significantly differing OTU abundances identified between the two treatment 
groups over the four time points. As there was a significant change in fermentation identified 
in the in vitro fermentation experiment (Chapter 5), an OTU table specifically looking at 16 
hours after treatment was analysed in LEfSe. At this time point the treatment group had three 
OTUs with differing abundances compared to the control group. Two of these OTUs were 
archaea one representing methane producing organisms and the second methane suppressing 
organisms. The third OTU a Firmicutes, Coprobacillaceae that ferment glucose to acetate and 
lactate.  The control group also had a single OTU of increased abundance but this referred to 
an OTU only labelled at kingdom level, Figure 6.7.  
 
  
Figure 6.7. LEfSe discriminate analysis of the treatment and control group 16 hours after 
moxidectin administration.  
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6.3.5. In vitro fermentation samples 
Sequence data from the samples used in the in vitro gas production experiment, chapter 5, were 
also analysed separately. Alpha diversity plots, Figure 6.7., showed no differences in diversity 
within the treatment groups. Beta diversity plots, Figure 6.8., also showed no differences 
between treatment groups, but there was some animal-level clustering for both treatment 
groups.  
The OTU abundances of the two groups used in the in vitro fermentation experiment are 
presented at phyla, order and family level in Figure 6.9. At phyla and order level there is no 
evidence of marked differences in bacterial population structure compared to the samples 
described above in the complete study population. At family level there were some small 
fluctuations in Bacteroidetes Porphyromonadaceae and Bacteriodales BS11 which both 
decreased slightly at 16 hours after moxidectin administration. Ruminococcaceae and 
Veillonellaceae slightly increased 16 hours after moxidectin administration, the former in the 
treated group the latter in the controls. None of these fluctuations were significant. For linear 
effect size discriminate analysis (LEfSe) there were no significantly differing OTUs in the 
samples between treated and control animals from the in vitro gas production experiment. 
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Figure 6.7. Panel plot of alpha diversity indices for samples used in the in vitro gas production experiment. (A) Chao1 rarefraction index of alpha 
diversity for individual animals used in the in vitro gas production over the sampling time points. (B) Chao1 rarefraction index of alpha diversity 
for the treatment groups over the four sampling time points. (C) Alpha rarefaction index observed species individual animals used in the in vitro 
gas production experiment over the four time points. (D) Alpha rarefaction index observed species for the in vitro gas production treatment groups 
over the four time points. Error bars represent 95% confidence intervals.
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Figure 6.8. Beta diversity indices for samples used in the in vitro gas production experiment. 
(A) Jack-knifed beta diversity of the treatment and control groups over the in vitro gas 
production experiment. (B) Jack-knifed beta diversity of the treatment and control groups over 
each of the four sampling points. (C) Beta diversity of the treatment and control groups over 
the four sampling time points. (D) Beta diversity of faecal samples used for in vitro gas 
production at horse level, mox treated (7, 9, 17) and controls (10, 11, 16).  
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Figure 6.9. Panel plot of (A) phyla (B) order and (C) family level OTU abundances from the 
treatment groups used in the in vitro gas production experiment over the four time points.  No 
changes in OTU abundances occurred around moxidectin administration.   
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6.4. Discussion 
In the present study faecal pH did not differ between the treatment groups or over the sampling 
time points. There were no changes in the bacterial composition of faecal microbiota following 
anthelmintic treatment between the treatment groups when compared over all four sampling 
points. The findings of our in vitro fermentation experiment suggest that some form of 
alteration in the horses’ hind gut ecosystem occurred around the time of moxidectin 
administration. The findings in this present study suggest that the changes were not in bacterial 
population composition. When focusing solely on the results from 16 hours after moxidectin 
administration there were four significantly differing OTUs identified using LEfSe. For one 
OTU within the control group labelled bacteria, details of the taxonomy below kingdom are 
unknown. Within the treated group three OTUs were identified, two archaea and 
Coprobacillaceae. Archaea are prokaryotes and within the gut are responsible for methane 
activity. In the present study 16 hours after moxidectin administration there was an increase in 
abundance of these methane producing bacteria within the Methanobacteriaceae family in the 
moxidectin treated horses. However there was also an increase in abundance of Archaea in the 
Thermoplasmata family which is responsible for methane suppression in the treated group. 
Coprobacillaceae are within the Firmicutes phyla, they ferment structural carbohydrates and 
produce acetate and lactate. While these OTU abundances were identified as significantly 
different between the treatment groups 16 hours after moxidectin administration, the overall 
effect was at such a small magnitude which was not detected when comparing groups over all 
of the sampling time points. 
 Both Chao1 and Obs rarefaction indices for alpha diversity were compared up to 50 000 
sequences per sample, at which points reads were reaching a plateau. Beta diversity and jack- 
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knifed beta diversity highlighted no differences between the treatment groups over the 
sampling time points.  
Previous studies have suggested that faecal pH is a reasonable indicator of the pH in the caecum 
and proximal colon (Berg et al., 2005). However Willing et al. (2009) found faecal pH did not 
alter around the time of a significant increase in starch within the diet. Willing et al. (2009) did 
find changes in bacterial composition the faecal microbiota using 16S rRNA sequencing.  
These past results suggest that faecal pH does not always replicate what is happening the hind 
gut ecosystem.   
In the present study we detected minimal change in the faecal microbiota composition 
following moxidectin administration. The lack of change in the faecal microbiota in our study 
is consistent with no identified differences in faecal pH. The taxa summary for the horses used 
in the fermentation experiment, chapter 5, suggests minor fluctuations in fibre degrading 
bacteria. Whilst there were no differences in abundances of OTUs of fibre degrading bacteria 
these minor downward fluctuations may have played a role in the reduced fermentation seen 
in chapter 5. It is entirely possible that any changes within the gut microbiome around the time 
of anthelmintic administration are purely functional. This hypothesis would fit with the 
findings of the in vitro gas production experiment in chapter 5. By using the 16S rRNA 
approach this only allows profiling of bacterial composition, this method does not allow 
evaluation of functional changes. It is possible that moxidectin alters the metabolism of 
microbiota instead of altering composition. Full metagenomic sequencing would be required 
to evaluate gene expression to test this hypothesis.  
The findings of our present study are similar to those of Cooper et al. (2013) who found that 
in humans ivermectin treatment did not significantly alter the composition of faecal microbiota 
when given to children infected with T. trichiura >2000 epg nor did it effect their control group 
who received the same treatment with no detectable parasite burden from FEC. In other animal 
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studies those that have reported changes around the time of an anthelmintic administration were 
treating animals with significant nematode burdens (Bartley et al., 2015). In this present study 
the horses had very low parasite burdens, therefore it is possible that at the time of anthelmintic 
treatment there was a limited potential for parasite death to affect the microbiota of the treated 
horses. In a recent pilot study in the USA Kunz et al. (2017) treated 6 Quarter horses with 
moxidectin and praziquantel combined and used 16S rRNA sequencing to characterize the 
effect on faecal microbiota. The study found no significant changes in bacterial diversity 
around the time of moxidectin administration. These researchers used different sampling points 
to the present study and lacked a control group. The findings of Kunz et al. (2017) are 
consistent with the present study i.e. moxidectin treatment does not cause a shift in the bacterial 
composition of the horses’ faecal microbiota. Another recent study reported changes in the 
faecal microbiota of Thoroughbreds infected with cyathostomins when compared to horses 
with low cyathostomins burdens (Peachey et al., 2017b).  
The horse’s gut microbiome appears to be more sensitive to changes than that of humans and 
ruminants (Daly et al., 2012). When comparing these differing species the horse normally has 
little lactate present in the hindgut (Shirazi-Beechy, 2008). Previous studies have found that in 
the horse the lactate utilizing Veillonellaceae make up approximately 1% of the microbiome 
(Daly et al., 2012; Proudman et al., 2015), whereas in the human colon they can represent 10% 
of the microbiome (Duncan et al., 2007; Daly et al., 2012; Segata et al., 2012). Daly et al. 
(2012) proposed that where there is an increase in lactic acid in the hindgut, horses are unable 
to convert this rapidly to SCFAs which may play a role in the alterations in the hindgut 
ecosystem, which can lead to colic. Anthelmintic administration has previously been identified 
as a risk factor for colic (Kaenne et al., 1997; Cohen et al., 1999; Hillyer et al., 2002). However 
the reasons for this are not fully understood (Hillyer et al., 2002). In the present study 
anthelmintic administration did not significantly alter faecal microbiota composition or the 
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faecal pH.  Veillonellaceae appeared in both treatment and control group at approximately 1-
2% across the sampling time points.  
Equine microbiota studies have previously reported inter-horse variability (Blackmore et al., 
2013; Dougal et al., 2013), this was also a finding within the present study. The beta diversity 
PCoA panel plot, Figure 6.5, shows clustering by animal in both the treatment and control 
groups. Stability in faecal microbiota of ponies was reported by Blackmore et al. (2013) using 
two 72 hours sampling periods 11 weeks apart. Blackmore et al. (2013) suggested that using 
horses as replicates in treatment and control microbiome studies may be problematic due to the 
levels of inter-horse variability within treatment groups.  
Faecal microbiota are commonly used in studies to represent the hindgut microbiota, reasons 
for this being the convenient non-invasive approach (Costa et al., 2012; Shepherd et al., 2012; 
Blackmore et al., 2013; Proudman et al., 2015). Faecal microbiota do not accurately represent 
the proximal part of the hindgut, however Julliand and Grimm (2017) report that the faecal 
microbiota was a sensitive indicator of dietary change. This is supported by Dougal et al. 
(2013) who reported that the bacterial composition in the caecum was different from faeces 
and the right dorsal colon. Whilst the use of faeces is convenient for studying hindgut 
microbiota, it should be remembered that the faecal microbiome might not accurately reflect 
the caecal microbiome. Therefore findings within the faecal microbiome that reflect expected 
caecal changes need to be interpreted with some caution.  
Previous studies have identified a reduction in caecal pH and a change in bacterial composition 
identified in cannulated horses following moxidectin administration (Jacotot et al., 2004). In 
the present study there were no significant changes in pH. This may reflect the use of faeces 
over caecal fluid when comparing to previous studies. It could be that changes associated with 
anthelmintic administration are of such a small magnitude they could not be detected using a 
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top down ‘omics approach, or that changes are functional and therefore unable to be detected 
by microbiota profiling.  
 
6.5. Conclusions 
The primary objective of this study was to determine whether moxidectin administration 
altered the hindgut bacterial composition.  Our findings suggest that when administered to 
horses with a low cyathostomin burden, moxidectin did not significantly alter bacterial 
diversity or composition of the faecal microbiota, nor did it alter the faecal pH. None of the 
horses showed signs of colic post administration. Our study is consistent with recent findings 
in the USA where moxidectin and praziquantel combined did not alter the faecal microbiome 
following treatment.
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Chapter 7.0. 
The effect of moxidectin administration on the equine metabolome using 1H NMR spectroscopy 
7.1. Introduction 
Interactions between gut microbiota and mammalian metabolism can be analysed indirectly through the 
use of metabolic profiling of host biological samples for host-microbe co-metabolites (Wu et al., 2010). 
Metabolomics uses a top-down systems biology approach to simultaneously measure all low molecular 
weight metabolites present in a biofluid (Waldram et al., 2008; Escalona et al., 2015). This robust and 
well validated approach allows the untargeted characterisation of metabolic phenotypes and of 
multidimensional biochemical responses of complex biological systems to differing stimuli (Nicholson 
et al., 1999; Rezzi et al., 2007).  
Our understanding of the role of gut microbiota is limited, metabolomics allows insight into the 
complex metabolic interactions that occur between the host and its microbiome (Escalona et al., 2015). 
As our understanding of the equine gut microbiome increases this raises further questions on the 
metabolic interactions within the gut microbiome and the effect of diet and drug treatments. In humans, 
metabolomics has allowed a much greater understanding of the host-microbiome metabolic axis which 
involves the gut, brain, liver and muscle (Nicholson et al., 2012). Within the past 10 years as the use of 
‘omics technologies have taken off with development of differing areas of use. One of these areas is 
pharmacometabolomics which allows greater understanding of the impact of drug treatments and the 
pathways involved in the metabolome (Kaddurah-Daouk et al., 2008).  
Within equine research previous studies have profiled metabolites from biofluids using 1H NMR 
spectroscopy, to provide normal values for healthy individuals (Escalona et al., 2015). Further studies 
have used this approach to explore metabolic conditions such as laminitis and metabolic syndrome 
(Hodervance et al., 2007; Keller et al., 2011).   
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Previous studies have indicated that gut microbiota play a role in drug metabolism (Rowland, 1986). Li 
and Jai (2013) identified drugs that are metabolised by the human microbiome and documented 
observed microbial transformations. One of the drugs featured in their study was the anthelmintic 
levamisole. To date no studies have reported the effect of anthelmintic treatment in the horse using 
metabolomics.  
7.1.1. Objectives 
There were two objectives of this study: 
1) To profile bacterial metabolites in urine prior to and after anthelmintic treatment. 
2) To profile faecal bacterial metabolites in faeces and hay fermentation inoculums following 
moxidectin administration.  
7.2. Materials and methods 
7.2.1. Ethical approval 
This study was given favourable ethical opinion by the University of Surrey Animal Welfare and Ethical 
Review Board NASPA-2015-008-SVM. 
7.2.2. Study population, treatment groups and sampling 
The study population and treatment group allocation were the same as described in chapter 6. Briefly, 
17 polo ponies which were predominantly Thoroughbreds with a mean age 12 ±3.5 years, managed 
exclusively at pasture, with very low parasite burdens that were randomly allocated into treatment and 
control groups. The sampling time points remained the same as described in chapters 5 and 6, sampling 
prior to treatment, then 16 hours, 40 hours and 160 hours following moxidectin treatment. At each 
sampling time point free catch urine samples were collected using a collection beaker on a stick and 
transferred into 50 ml screw top vials. These were transported to the laboratory on ice and aliquoted 
into 5 ml cryo-vials on arrival. Samples were then frozen at -80°C prior to analysis. Urine samples were 
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the primary biofluid chosen for this study as urine has previously been identified as the best biofluid 
for metabolomic studies in the horse, followed by faeces, (Escalona et al., 2015). Faecal samples from 
the horses used in the in vitro gas production experiment and the fermentation samples saved from the 
hay fermentations from chapter 5 were also used in this study. The hay fermentations were selected for 
metabolite analysis over the oat fermentations as hay was more representative of the horses’ forage 
based diets and therefore more comparable to the faecal samples.  
7.2.3. Sample preparation 
Phosphate buffer solution was made in a one litre flask by combining the ingredients listed in Table 
7.1. A magnetic stirrer was used to ensure the solution was fully dissolved prior to sample preparation.    
Table 7.1. Ingredients used in the phosphate buffer solution. 
Chemical Compound Formula Amount (g) 
Disodium phosphate Na2HPO4 28.86 
Monosodium phosphate NaH2PO4 5.25 
Sodium 3(Trimethylsilyl) 
propionate-d4) (TSP) (1 mM) 
C6H14O2Si  0.172 
Sodium azide NaN3 0.193 
Heavy water  D2O 500 ml 
Water  H2O 500 ml 
 
7.2.3.1. Urine samples and fermentations 
Samples were defrosted and then vortexed, 400 µl was then aliquoted into microfuge tubes and 200 µl 
of phosphate buffer was added. Samples were then vortexed again before centrifugation for 10 minutes 
at 10 000 x g. Following centrifugation 550 µl of supernatant was transferred by pipette into 5 mm 
internal diameter NMR tubes. The same method was used for preparing the fermentation samples.  
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7.2.3.2. Faecal samples 
Faecal samples were defrosted, 0.3g of faeces weighed out into a microfuge tube and 1.2 ml of 
phosphate buffer was added. To ensure lysis, two 1.7 mm Zirconia beads were added to the microfuge 
tubes which were then placed in a bead breaker for 10 minutes followed by centrifugation for 10 minutes 
at 16 000 x g. Supernatants were transferred into new microfuge tubes and the centrifugation process 
was repeated again two further times. After the final centrifugation 500 µl of supernatant was pipetted 
into 5 mm internal diameter NMR tubes.  
7.2.4.. 1H NMR Spectroscopy 
1H NMR spectroscopy was conducted at Imperial College London in the division of Computational and 
Systems Medicine within the Department of Surgery and Cancer. Spectroscopic analysis of all samples 
was carried out on a 700 MHz Bruker NMR spectrometer equipped with a cryo-probe. For each of the 
urine, faecal and fermentation samples standard one-dimensional 1H NMR spectra were acquired with 
water peak suppression using a standard pulse sequence. For each sample 8 dummy scans were followed 
by 256 scans and collected in 64K data point. A spectra width of 20 ppm was used for all sample types. 
Chemical shifts in spectra were referenced against the TSP singlet at δ 0.0. 
7.2.5. Data analysis  
Spectra were phased and baseline corrected in Topspin 3.0 before alignment and normalisation (total 
quotient method) was carried out in Mathworks Matlab R2014a. Samples were analysed using 
multivariate statistics to compare the profiles of the urine, faeces and fermentations between the 
treatment groups. Initially unsupervised principal component analysis (PCA) models were constructed. 
Where there was spatial clustering between groups, supervised models were constructed using 
orthogonal projections to latent-structures-discriminate analysis (OPLS-DA). OPLS-DA models were 
used to identify group-specific metabolic changes. Within OPLS-DA models goodness of fit is 
 140 
 
measured by R2Y and prediction ability is measured by Q2Y (Trygg et al., 2007). Only OPLS-DA 
models with Q2Y values >0.4 and metabolite abundances differences R2 >0.5 are reported. It is possible 
with these complex models that over-fitting occurs, where too many latent variables are added reducing 
the predictive ability and creating bias within the model (Gowan et al., 2010). To ensure models were 
not over-fitting OPLS-DA models underwent permutation testing, to 1000 permutations, to ascertain 
the significance by comparing the permutated model to the original OPLS-DA model. Only models 
with good prediction ability and no over-fitting (p <0.01) were kept.  
Reference metabolite resonances from Escalona et al. (2015) and the human metabolome database 
(HMDB) were used to identify metabolites from the groups that significantly differed in the OPLS-DA 
models.  
Metabolite concentrations were then calculated between treatment groups and time points. Using 
Matlab a peak integral was obtained for the NMR peak of interest. This integral value could then be 
used along with integral of the internal standard TSP, and the number of protons giving rise to the 
measured resonance. These values were used to calculate the actual concentration of interest using the 
equation below. A Students t-test was used to identify significant differences between concentrations 
and metabolite values, using a Bonferroni correction for multiple comparisons (p <0.02).  
Concentration = peak area of metabolite  X protons represented by TSP peak      X Concentration of 
of metabolite           peak area of TSP      protons represented by metabolite peak          TSP 
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7.3. Results 
7.3.1. Urine samples 
There were no significant shifts in bacterial metabolite abundance following treatment between 
treatment groups over any of the different samplings points, Figure 7.1.A.  In the in vitro fermentation 
experiment chapter 5, at 16 hours following moxidectin administration there were significant changes 
in fermentation patterns, however in this experiment no differences in urinary metabolite abundances 
between treatment groups were identified at this time point in this experiment, Figure 7.1.B. Horse 
variability was plotted within groups, Figure 7.2. There was no effect of horse variability in urine 
samples over time. 
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Figure 7.1. Scores plot (A) of urine samples from both treated and control horses over the four sampling 
points. No significant clustering was observed between groups and time points, PC 1 21% of variation, 
PC 2 12% of variation. Plot (B) of treatment and control group urinary metabolites 16 hours after 
moxidectin administration. There was no significant clustering between groups, PC 1 37% of variation, 
PC 2 17% of variation. 
 
A 
 
B 
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Figure 7.2. Horse variability of urinary metabolites over the four sampling points (A) control group 
and (B) treatment group. Numbers refer to the donor horse. Similar clusters are present for both 
treatment groups over the time points with little inter-horse variability.  
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7.3.2. Faecal samples 
 
7.3.2.1. Analysis between treatment groups 
 
Faecal water samples from the horses used in the in vitro fermentation experiment were analysed over 
the four sampling time points, Figure 7.3. There was no clustering identifying metabolic differences 
between treatment groups or time points. There was some clustering by horse over the repeated time 
points, this is identified by horse number in Figure 7.3 below.  
 
 
Figure 7.3. Scores plot of faecal water NMR for the horses used in the in vitro fermentation experiment 
over the four time points. Markers within the plot identify treatment group and sampling point, numbers 
next to markers represent the donor animal. Some clustering by animal can be seen over the sampling 
points, PC1 56% of variation, PC 2 12% of variation.  
 
Within the in vitro fermentation experiment, chapter 5, 16 hours post moxidectin administration was 
the time point where significant changes in fermentation were identified between treatment groups. 
Faecal samples from this time point was then analysed for difference in metabolome; no significant 
difference between the treatment groups was identified.  
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7.3.2.2. Analysis within treatment groups  
Within both treatment groups, separately, faecal metabolite output was also analysed over the time 
points. Within the control group there were no differences in metabolite abundances over any of the 
four sampling points.  Within the moxidectin treated group some clusters identifying metabolic profiles 
can be seen between post administration time points, Figure 7.4. Clustering was identified between 
samples taken at 16 hours and 40 hours post moxidectin administration. This data was modelled using 
OPLS-DA but the model was rejected due to poor prediction ability. Due to insufficient sample numbers 
it was not possible to create an OPLS-DA model between 16 and 160 hours post moxidectin 
administration.  
 
 
 
Figure 7.4. Scores plot of faecal metabolite output of moxidectin treated horses used in the in vitro 
fermentation experiment at time points following moxidectin administration. Clusters highlighted are 
between Mox 16 (X), and Mox 40 (*), PC 1 64% of variation, PC 2 11% of variation. The OPLS-DA 
model was rejected due to poor prediction ability.  
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7.3.3. Fermentation samples 
 
7.3.3.1. Analysis of faecal samples compared to fermentations 
 
Differences between the metabolic profile of faecal samples and the fermentations were observed, 
Figure 7.5. Inter-sample variation in metabolite profile was greater in the hay fermentation samples 
than in the faeces, Figure 7.5. The OPLS-DA model was of moderate fit (Q2Y = 0.44) and the following 
metabolites differed in abundance between the two sample types; alpha-methyl aspartate (R2 0.6), 
butyrate and adipate (R2 0.55) within the model (Figure 7.6). Calculated differences in metabolite 
concentrations can be found in table 7.2.  
 
 
 
Figure 7.5. Scores plot of faecal samples and hay fermentation inoculums split into treatment groups 
and sampling time points. There is a significant cluster between sample type, faeces and hay 
fermentations, PC 1 63% of variation, PC 2 11% of variation.  
 
Hay fermentations Faeces 
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Figure 7.6. OPLS-DA loadings plot of metabolite abundances for faeces versus fermentations, Alpha-
methyl aspartate R2 0.6, Butyrate and Adipate R2 0.55, other metabolites R2 < 0.5. Q2Y of 0.44, at 1000 
permutations the model fit R2 value of 1.  
 
 
 
7.3.3.2. Analysis of hay fermentations between treatment groups 
Faecal fermentations from the in vitro fermentation of hay were analysed between treatment groups 
over the four sampling points. Differences in metabolic profiles were observed 16 hours following 
moxidectin administration between the treatment and control groups (OPLS-DA model Q2Y = 0.48). 
Metabolites responsible for this difference were ethanol, 5-hydroxyindole-3-acetate and alanine (Figure 
7.7.). There were no significant differences between the treatment groups at any of the other time points 
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Figure 7.7. (A) Scores plot of hay fermentations 16 hours post moxidectin for both treatment and 
control groups, PC 1 47% of variation, PC 2 23% of variation. (B) OPLS-DA loadings plot with a Q2Y 
of 0.48 and R2 of 0.94. Metabolites with differing abundances (R2 > 5) were ethanol, alanine and 5-
hydroxyindole-3-acetate (5-HT).  Formate had an R2 0.45. Other common metabolites are labelled for 
reference only.  
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7.3.3.3. Analysis of hay fermentation within treatment groups 
 
Within the untreated control group, no differences in metabolite profile were detected between any of 
the sampling time points. Within the moxidectin treated group there was a difference in metabolic 
profile between 16 hours and 160 hours after moxidectin administration within the treated horses, 
Figure 7.8. The OPLS-DA model had a Q2 Y of 0.77. Metabolites with differing abundances with an 
R2 > 0.8 were formate, ethanol and maltose in the 16 hours post moxidectin administration 
fermentations. At 160 hours after moxidectin administration, metabolites present here were SCFAs 
butyrate, acetate and propionate. There were no differences in metabolic profiles between 0 and 16 
hours, 16 and 40 hours or 40 and 160 hours after moxidectin administration in the hay fermentations.  
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Figure 7.8. (A) Scores plot of metabolites for hay fermentations inoculated with faeces from the 
moxidectin treatment group at 16 hours post administration vs 160 hours post administration. Loadings 
plot (B) identifying metabolites with differing abundances (Q2 Y = 0.77, R2 = 1). 
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Table 7.2. Summary of OPLS-DA models, metabolites, resonances, concentrations and functions. Resonance key s; singlet, d; doublet, t; triplet, 
q; quartet.  Metabolites referenced to Human Metabolome Database (HMDB).  
OPLS-DA 
Model 
Q2Y & 
Permutation 
P values 
Metabolite 1H 
Resonance 
(δ) 
Correlation 
coefficient 
(R2) 
Concentration 
 (mean & SD)  
Concentration 
Significance 
Function & 
reference to Human Metabolome Database 
Faeces v 
Fermentations 
0.44 
 
P=0.008 
Butyrate 0.9 (t) -0.55 Faeces  
0.08 ± 0.03 
Ferms 
0.19 ± 0.10 
 
P= 0.001 
 
Microbial dietary metabolite HMDB00039 
  Adipate 1.56 (m) -0.55 0.77 ± 0.35 0.92 ± 0.31 P= 0.13 Dietary & drug metabolite HMDB00448 
  Alphamethyl
-aspartate 
1.48 (s) -0.6  1.63 ± 0.8 2.11 ± 0.73 P= 0.042 Amino acid derivative, agonist at the 
NMDA receptor -mimics the action of 
glutamate. HMDB0002393 
Fermentations 
16hrs mox v 
control 
0.48 
 
P=0.01 
Alanine 1.46 (d) -0.8 Mox 
4.57 ± 0.82 
Control 
5.14 ± 0.15 
 
P=0.4 
Endogenous metabolite. Involved 
in urea cycle, Glucose-alanine 
cycle & Glycine & serine metabolism 
HMDB00161 
  Ethanol 3.65 (q) -0.7 4.24 ± 0.86 5.19 ± 0.33 P=0.2 Metabolite, glucose and D-lactate 
metabolism HMDB0000108 
  5-HT 3.59 (s) -0.7 3.01 ±0.76 3.49 ± 0.44 P=0.4 Microbial & plant metabolite. Involved in 
Trypophan metabolism HMDB00197 
Fermentations 
mox 16hrs v 
160hrs 
0.77 
 
P=0.01 
Formate 8.46 (s) -0.95 16h 
16.38 ± 14.08 
160h 
5.42 ± 8.64 
 
P=0.31 
Microbial metabolite. Acetate & Folate 
metabolism. 
Responsible for metabolic acidosis 
HMDB0000142 
  Ethanol 1.2 (t) -0.95 3.05 ±0.59 1.87 ± 1.45 P=0.2 Metabolite, glucose and D-lactate 
metabolism HMDB0000108 
  Maltose 3.41 (t) -0.85 1.14 ± 0.22 0.7 ± 0.54 P=0.25 Endogenous metabolite. Starch & sucrose 
metabolism HMDB00163 
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7.4. Discussion 
No difference was detected in bacterial metabolite profiles within treatment groups or between 
treatment groups for urinary metabolites prior to or following moxidectin administration. There 
was no change in faecal bacterial metabolites within treatment groups or between treatment 
groups over the sampling time points. However we did observe a significant difference in 
metabolite profile in the fermentations initiated with faeces from moxidectin-treated horses. 
The observed difference was seen in abundance between alanine, ethanol and 5-HT from 
samples collected the morning after moxidectin treatment when compared to the control group. 
There was also a difference in metabolic profile within the moxidectin treatment group when 
comparing fermentations inoculated with faeces from 16 hours after moxidectin treatment to 
fermentation inoculated with faeces collected one week after moxidectin treatment. The 
metabolites responsible for this difference were formate, ethanol and maltose. There was also 
a difference in metabolic profile between faecal samples and fermentations. The metabolite 
responsible for this difference was butyrate but it is unlikely to be of biological significance as 
butyrate was also differentially produced between control faeces and control fermentations.  
The differences between ruminants and mono-gastric mammals and differences in 
pharmacokinetics between species should be considered when reviewing previous veterinary 
studies. In a ruminant study by Lifshitz et al., (2005), neither ivermectin nor moxidectin were 
metabolized or degraded in ruminal or abomasal contents. However benzimidazoles, 
specifically albendazole, have been identified as being activated within the rumen by intestinal 
microbiota (Lanusse et al., 1992; Virkel et al., 1999). From these previous studies it would 
appear that while benzimidazoles and levamisole may be metabolised by the gut microbiota, 
this does not appear to be the case for macrocyclic lactone anthelmintics.  
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The faecal samples analysed in the present study were the same as those used to create the 
faecal inoculum for in vitro fermentation; we demonstrate a difference in metabolic profile 
between these two sample types. The fermentations are likely to have had increased levels of 
metabolites as in vitro gas production is a closed system, whereas the faeces would have lost 
many of the metabolites detected in the fermentation through absorption in the horses’ 
gastrointestinal tract prior to excretion. This is clearly seen in the difference in butyrate 
concentrations (Figure 7.6.). Theodorou et al. (1994) suggested that the accumulation of 
volatile fatty acids did not significantly alter pH or fermentation kinetics during in vitro gas 
production. However metabolite abundances would be likely to differ when sampling from this 
closed system at the end of fermentation.  
Within the faecal samples the higher abundance of alpha-methyl aspartate between sampling 
points may be associated with moxidectin. The mode of action of moxidectin is on glutamate-
gated chloride channels and alpha-methyl aspartate mimics the action of glutamate (Cobb and 
Boeckh 2009: Abongwa et al., 2017). One possible reason for an increase in the abundance of 
alpha-methyl aspartate could be a product of the metabolized drug which acts upon glutamate-
gated chloride channels that has been excreted. However there is limited detailed published 
data on excreted metabolites of moxidectin to support this hypothesis.   
The greater abundance of adipate in the fermentations may be associated with the effect of 
treatment on fermentation kinetics. Clapperton (1977) observed that adipate altered methane 
production in rumen fermentation. The changes in gas production in chapter 5 could be due to 
the influence of treatment linked to an increase in adipate abundance during in vitro 
fermentation. This would support the findings in chapter 6 where changes in abundance of 
methanogenic organisms in the faecal microbiota were observed 16 hours after moxidectin 
administration.    
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Alanine is a non-essential amino acid and a product of lactate fermentation from anaerobic 
respiration (Brennan et al., 2002; Hansen and Owen, 2013). Normally lactate is transported to 
the liver and converted to glucose via the glucose alanine cycle (Hansen and Owen, 2013). 
Within the closed in vitro system any lactate produced may be fermented by microbiota and 
the products of this would remain within the system which may explain an increase in alanine 
within the fermentations. Within the fermentations inoculated with faeces from the horses that 
had been treated with moxidectin 16 hours previously there was an increase in abundance of 
5-hydroxyindole-3-acetate (5-HT). 5-HT is the main metabolite of the neurotransmitter 
serotonin, which is a powerful vasoconstrictor and plays an important role in gastrointestinal 
motility. 5-HT is metabolized by gut microbiota and is specifically associated with E.coli and 
clostridium spp. playing a role in the brain-gut axis (Nicholson et al., 2012).  
When comparing fermentation metabolic profiles of the moxidectin treated horses 16 hours 
post treatment to samples 160 hours post treatment there was a difference in formate, ethanol 
and maltose. Formate is a microbial metabolite that is involved in acetate and folate metabolism 
(Escalona et al., 2015). It also plays a role in metabolic acidosis (Escalona et al., 2015). Both 
formate and lactate are organic acids and in humans have been associated with parasite burdens 
(Holmes et al., 2011). In the present study the horses had low strongyle egg counts but this 
cannot account for pre-patent infection. There was evidence of cyathostomins excreted in 
faeces the day following moxidectin administration in one of the horses used in the in vitro 
fermentation experiment, demonstrating strongyle presence. However it is unknown if this 
individual animal influenced the difference in formate abundance between groups. This may 
explain the increase in formate at this time point. The presence of formate the day following 
moxidectin administration also suggests a drop in pH within the in vitro system. This finding 
supports the reduced pH identified in chapter 5 within these fermentations 16 hours after 
treatment. Formate and ethanol are both products of glucose fermentation, specifically products 
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of the fermentation of D-lactate (Ward, 2015).  Cross fermentation, where bacteria use more 
than one energy pathway to ferment glucose results in the production of formate and ethanol 
(Ward, 2015). This is a common route for facultative anaerobes and is the method by which 
Clostridia spp. produce butyrate. It is therefore possible that the increase in these metabolites 
was due to the anaerobic in vitro fermentation environment rather than the effect of moxidectin 
on the metabolome. However the timing of the observed difference in formate, the day 
following treatment, is suggestive of a causal relationship.  
D –lactate, produced by species of Lactobacilli (Al Jassim et al., 2005), and is associated with 
carbohydrate-overload in laminitis. Both formate and ethanol are products of D-lactate 
fermentation, therefore it is possible that following moxidectin administration there was an 
increase in D-lactate in the fermentations which was then fermented to VFAs, formate and 
ethanol which were observed here.  This hypothesis is supported by the findings of Jacotot et 
al. (2004) who saw an increase in Lactobacilli spp. in bacterial counts following moxidectin 
administration. However while there was a pH reduction in the fermentation inoculated with 
faeces collected 16 hours following moxidectin administration, lactate abundance did not differ 
when compared to any of the other sampling points within the treatment group. The findings 
of de Fombelle et al., (2003) suggest that lactate production is not always detected as it is 
converted by lactate utilizing microbiota to propionate. Nor were any significant changes in 
bacterial composition identified, e.g. Lactobacilli spp. when profiling the microbiota in chapter 
6. In the fermentations when comparing the treatment and control groups 16 hours after 
moxidectin administration there was a difference in the abundance of alanine, a product of 
lactate fermentation, in the moxidectin treated group. This was not seen when comparing within 
treatment groups, the moxidectin treated horses 16 hours following administration to 160 hours 
post moxidectin administration, where the abundance of formate and ethanol differed.  
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Interestingly 5-HT has been associated with the onset of laminitis (Bailey and Elliott, 1998a), 
however a significant amount of 5-HT would be required in the blood stream to act as a 
vasoconstrictor and increase the risk of the onset of laminitis (Bailey and Elliott, 1998b). 
Previous studies have noted that some horses have had bouts of laminitis after anthelmintic 
treatment (Perymans et al., 1991; Hood, 1999; Heymering, 2010). Anthelmintic treatment was 
also identified by Wylie et al. (2013) as a risk factor for laminitis within four weeks of 
administration. No signs of colic or laminitis were identified in the horses used in the present 
study, however metabolites associated with laminitis were detected in the in vitro 
fermentations. The findings of this present study warrant further investigation of the link 
between moxidectin administration and a significant increase in metabolites that are also 
associated with intestinal disease. This could be achieved readily with the in vitro gut model 
described by Leng et al. (2017).  
  
Inter-horse variability has previously been identified as a problem for microbiota profiling. 
Escalona et al. (2015) found that when profiling the Thoroughbred racehorse metabolome that 
there was little inter-horse variability within urine samples; the present study confirms this 
observation in a polo pony population. Inter-horse variability was more likely in faecal samples 
than other biofluids (Escalona et al., 2015).  In the present study there was some inter-horse 
variability within the faecal samples, which is consistent with previous reports.  
Urine was the primary biofluid selected for this experiment, faecal and fermentation sample 
sizes were small as they only reflected the in vitro fermentation element. Some of the faecal 
samples failed to generate data, thus limiting analysis of 1H NMR for faecal water.  
1H NMR is not a truly quantitative method of determining metabolite concentrations. It is 
possible that the sample sizes for faeces and fermentations within this experiment were too 
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small to determine significant differences in metabolite concentrations that reflect the 
difference in abundances detected within the OPLS-DA models. 
 
The differences in metabolite abundances in the hay fermentations 16 hours post moxidectin 
administration suggest some alterations in bacterial metabolism in these fermentations. As 
there were no differences in metabolite abundances within the control group over any of the 
sampling time points it is reasonable to infer that the changes seen here were associated in 
some way with moxidectin administration.  
 
7.5. Conclusions 
The findings of this study suggest that moxidectin administration did not alter the faecal or 
urinary metabolome of treated horses at the time of treatment or over 160 hours after treatment. 
In vitro hay fermentations, inoculated with faeces collected from animals 16 hours post 
treatment did show significant differences compared to models inoculated with faeces of 
untreated animals. These in vitro findings suggest that moxidectin treatment may have a 
significant functional effect on the equine faecal microbiome.  
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Chapter 8.0  
General Discussion 
 
The first two aims of this thesis were to characterise aspects of efficacy of two of the three 
anthelmintic classes licensed for equine nematode treatment. Specifically, egg reappearance 
times for the macrocyclic lactone anthelmintics and to identify if ovicidal activity of BZs may 
still be useful in the face of resistance. Previous reports by Lester et al. (2013), Stratford et al. 
(2013) and Relf et al. (2014) suggested that anthelmintic resistance was not present in 
cyathostomins to the macrocyclic lactone group in both Thoroughbreds and leisure horses. 
However these studies did report a reduction in the expected egg reappearance period. More 
recently Tzelos et al. (2017) also reported a reduction in the egg reappearance times following 
macrocyclic lactone treatment. All of these findings support the findings of the study reported 
here. There appears to be a shortened egg reappearance time for the macrocyclic lactones when 
treating horse strongyles in the UK.  
The reports by Lester et al. (2013), Stratford et al. (2013) Relf et al. (2014) and Tzelos et al. 
(2017) are all comparable as they all use the same study design. However many other studies 
that have previously evaluated anthelmintic efficacy are difficult to compare due to the lack of 
standardisation for its measurement. One of the fundamental problems with efficacy testing in 
equine parasitology is that all of the guidance to date has been adapted from ruminant models. 
This can be problematic when applying to premises with very few animals, which is often how 
horses are kept.  Both Coles et al. (2006) and Nielsen et al. (2013a) have identified in the 
WAAVP and AAEP guidelines that efficacy testing should be on a minimum of six horses. 
The requirements for efficacy testing reflect the statistical power of the calculation used. This 
should not be problematic for farms of horses with high stocking densities similar to livestock 
farming. However this is much more difficult on premises with very few horses. For the 
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purposes of identifying shortened egg reappearance times the findings in chapter 3 for groups 
of horses over six were comparable to groups made up of less than six. While this model would 
lack statistical power for detecting resistance it does provide a useful tool for assessing the egg 
reappearance time in horses on premises with less than six animals.  
Updated WAAVP guidelines are awaited, to date there is no provision in the WAAVP 
guidelines for egg reappearance testing. The AAEP guidelines (Nielsen et al., 2013a) identify 
expected egg reappearance times and suggest the use of a modification of the FECRT. In 
chapter 3 of this thesis multiple metrics were used for the same data to calculate a more robust 
measure of egg reappearance times. Further work would be required in an experimental setting 
to validate the use of multiple measures of calculating egg reappearance times, however the 
approach described in chapter 3 does provide a more robust approach than some of the 
previously reported methods (Little et al., 2003; Lyons et al., 2008; Molento et al., 2008).  
The use of combination anthelmintics in sheep has been modelled and trialled to preserve 
efficacy and slow down the speed of resistance (Bartram et al., 2012; Leathwick et al., 2012). 
The experiment in chapter 4 was designed to identify whether the novel ovicidal activity of the 
benzimidazoles was retained in populations of BZ resistant cyathostomins. If the ovicidal 
efficacy remained, there would be the potential to use BZ as part of a combination anthelmintic 
to target cyathostomins. One of the limitations to the interpretation of the findings in chapter 4 
is the lack of data on ovicidal efficacy and how long this is retained after administering 
fenbendazole. However when compared to previously reported cattle findings (Miller and 
Morrison, 1992) the data from chapter 4 suggests there is a reduced ovicidal effect in BZ 
resistant cyathostomin populations.  In a recent report Lyons et al. (2016) identified 
combination of BZ, THP and piperazine we unsuccessful for strongyle control. Taken together 
the findings of chapter 4 and Lyons et al. (2016) suggest that it is unlikely that the ovicidal 
element of BZ can be incorporated into combination anthelmintics for horses.  
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The findings of our investigation into egg reappearance times for the ML group of 
anthelmintics is concerning with regards to their efficacy. This group of anthelmintic has 
played an important part of parasite control in horses for three decades.  Recent findings of 
Peachey et al. (2017c) have identified that P-glycoproteins play a role in macrocyclic lactone 
resistance in cyathostomins. The findings from Peachey et al. (2017c) also suggest that P-GP 
inhibitors maybe a useful tool to increase drug sensitivity when combined with ivermectin 
administration.  
The increase in the availability and decreased cost of next generation ‘omics technologies has 
facilitated our understanding of the horses’ hindgut microbiota. Older studies reliant on culture 
work and bacterial counts identified that changes e.g. to diet can lead to changes in the 
composition of microbiota which can result in intestinal disease. Similarly changes in the 
composition of hindgut microbiota can reflect alterations in fermentation, as strict fibrolytic 
species only function in conditions greater than pH 6. Changes in bacterial composition are 
often linked to pH shifts, specifically a reduced pH leads to proliferation of gram positive 
Bacillus-Lactobacillus-Streptococcus group of bacteria. A previous report on the effect of 
anthelmintic administration on equine hindgut microbiota identified changes in pH and 
composition from bacterial counts following treatment (Jacotot et al., 2004).  
The finding from chapters 5, 6, and 7, collectively suggest that moxidectin administration 
briefly altered bacterial metabolism reflected in fermentation changes and metabolite 
abundances from the in vitro model.  However there were no changes in faecal microbiota 
community profile associated with moxidectin administration.  
One of the problems with the metataxonomics approach is that by profiling the 16S rRNA gene, 
function of bacterial communities is not measured. A systems biology approach would be to 
apply full metagenomics and map gene expression. This approach would allow identification 
 161 
 
of altered bacterial function following moxidectin administration as suggested by the 
fermentation kinetics and the metabolite abundances presented in this thesis.  
The next generation ‘omics approach is still in its infancy. Interesting findings reported by 
Taxis et al. (2015) suggest that while individuals may have differing metataxonomic profiles, 
when gene expression was mapped the functional output was the same. Thus a focus on changes 
in community profile might not always reflect changes in the microbiome.  
8.1. Parasites and microbiota 
The complex relationship between microbiota and macrobiota may be key in our understanding 
of parasitic infection. Previous equine studies (Klei and Chapman, 1999) have identified Th-2-
type response to cyathostomin burdens in horses. This response has been identified in other 
animal models (Helmby, 2009). It would appear helminth infections lead to a Th-2-type 
immune response that helminths are able to survive (Helmby, 2009). In mice Grencis (2001) 
reports that host genotypes which expressed a Th-1-type response to helminth burdens had 
increased susceptibility to parasitic infection. Thus a combination of immune response and 
novel immune evasion strategies allow parasite survival (Grencis, 2001).  This response has 
been identified for both adult and immature strongylids (Cantacessi et al., 2012). Where the 
parasite infestation is chronic a TH1-type response is observed but with significant changes to 
the immune response to the helminths allowing their survival (Cantacessi et al., 2012).  
In rodents, induced parasite burdens lead to changes in the composition of microbiota and 
alterations in carbohydrate metabolism. However anti-parasite treatment reversed these 
changes to reflect composition and metabolism prior to infection (Reynolds et al., 2015). 
Similar findings have also been reported in strongylid parasites of small ruminants (Li et al., 
2016). In our study we identified that low parasite burdens did not influence the composition 
of microbiota. Recent findings of Peachey et al. (2017b) identified changes in the composition 
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of microbiota in horses harbouring high cyathostomin burdens. Collectively these findings 
suggest that high cyathostomin burdens may influence the composition of gut microbiota. This 
may be linked to the more complex immune responses that have been identified previously, as 
the microbiome plays a role within the immune system.  
Microbiota and macrobiota have co-evolved to co-inhabit the horse’s hindgut. The compulsion 
of horse-owners to eradicate nematodes to reduce the risk of intestinal disease does not take 
into account the potential benefits of a low parasite burden. The hygiene hypothesis suggests 
that being exposed to potential pathogens may have health benefits. In western countries where 
hygiene is good, there are greater incidences of allergic diseases that are not seen in developing 
countries that have less well developed hygiene practises (Wills-Karp et al., 2001; Okada et 
al., 2010). In the horse a previous epidemiological study identifying risk factors for equine 
grass sickness identified horses with a low strongyle burden were at greater risk of the disease 
(McCarthey et al., 2004). Strongyle parasite infection appears to confer some resistance to 
equine grass sickness. 
From all of the evidence to date it would appear the high burdens of cyathostomins are 
potentially pathogenic in the horse. However, scientists and vets are currently unable to answer 
the question: “what constitutes a high parasite burden.” Previous studies indicate that high 
burdens defined by FEC are “best guess” figures (Uhlinger, 2007). Until a quantitative, equine 
cyathostomin ELISA test is commercially available to identify pre-patent infection, the FEC 
remains the gold standard for estimating cyathostomin burdens in horses (Mitchell et al., 2016).  
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8.2. The future of equine parasite control?          
Developments within diagnostic parasitology have been slow to emerge. However a recent 
study has identified that faecal egg counting via a mechanised system and smartphone 
application provided increased precision and comparable accuracy to the McMaster technique 
which is most commonly used in practice (Scare et al., 2017). This technology would allow 
field use of diagnostics but interpretation of these tests by owners is a barrier to implementing 
this technology. Furthermore this is an update of a historic approach to parasite diagnosis which 
lacks sensitivity and relies on patent infection to predict parasite burden.  
To date the study presented in chapter 7 is the first to use an NMR-based metabolomics 
approach to investigate equine parasite control. In our study we were specifically looking for 
changes in microbial metabolism following anthelmintic treatment. This approach has recently 
been applied in humans in a study which identified differences in metabolite abundances of 
patients with parasite burdens when compared to uninfected controls (Kostidis et al., 2017).  
The recent findings of Peachey et al. (2017b) support the theory that macrobiota do influence 
the composition of microbiota within the microbiome. The works of Reynolds et al. (2015) 
reported that parasitised mice showed increases in Firmicutes specifically Lactobacilli spp. As 
parasite burdens increased Lactobacilliaceae also increased, suggesting a mutualistic 
relationship. The functional fermentation changes identified in chapter 5 may also be identified 
in untreated parasitised animals if parasites do alter microbiome composition, this has potential 
to alter forage fermentation if there are changes in Lactobacilli spp. abundances. This requires 
further investigation.  
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Much attention is currently being paid to the intestinal microbiome and effects of different 
conditions or treatments on it. However the next step is to consider the “nemabiome”.  In 2015 
Avremenko et al. used a next generation sequencing approach to amplify rDNA ITS-2 using 
NC1 and NC2 primers complementary to 5.8S and 28S coding sequences of nematodes of 
cattle. This was the first study to introduce the concept of the nemabiome to describe the 
parasitic community present within a host (Avremenko et al., 2015).   This approach is complex 
due to large families of genes with similar genetic structures, large population sizes with high 
levels of sequence polymorphisms and the difficulty of accessing parasitic stages that occur 
within the host (Wit and Gilleard, 2017). However genome reference libraries are now 
available for referencing the nemabiome. The nemabiome has recently been used to identify 
the onset of anthelmintic resistance to macrocyclic lactones within cattle nematodes 
(Avremenko et al., 2017).  Thus ‘omics technologies provide a new and valuable tool to allow 
a much greater understanding of parasite biology, host parasite interaction and markers for 
anthelmintic resistance.  
The interaction with parasites and the microbiome leaves many further questions to be 
answered. In this thesis we demonstrated that while moxidectin did not alter the community 
profile of faecal microbiota it did influence the metabolism of faecal microbiota for a short 
period reflected by metabolite abundances and fermentation kinetics in vitro.  Both Nielsen et 
al. (2013b) and Betancourt et al. (2015) suggest that the macrocyclic lactones appear to 
promote an anti-inflammatory effect within the intestine, an effect previously identified in mice 
(Yan et al., 2011). Macrocyclic lactones have also been identified as risk factors for the onset 
of colic (Hillyer et al., 2002) and the onset of equine grass sickness (McCarthey et al., 2004). 
These findings, taken together, suggest a complex relationship between macrobiota, 
microbiota, host, and drug treatment that may be possible to explore further in the future using 
these next-generation ‘omics technologies.  
 165 
 
8.3. Parasitism, anthelmintic treatment and intestinal disease  
Studies to date provide a wealth of evidence that cyathostomin burdens, especially large 
burdens are associated with colic in horses (Duncan and Love, 1991; Love, 1992; Kaenne et 
al., 1997; Love et al., 1999; Cohen et al; 1999; Hillyer et al., 2002; Matthews, 2008).  The 
mechanism of the link between anthelmintic treatment and colic that has previously been 
identified (Proudman 1991; Cohen et al., 1999; Hillyer et al., 2002) remains poorly 
characterised.  The mechanism leading to colic following anthelmintic treatment is likely to be 
multifactorial. The previous mechanisms proposed including changes in gut motility and 
parasite death may all play a role (Bueno et al., 1979; Love, 1992; Proudman, 1999).   
8.4. Future study  
The findings of the in vitro fermentation kinetics and metabolomics studies require further 
investigation with a larger sample size to confirm whether anthelmintic administration has a 
significant effect on microbial metabolism. Ideally this should be implemented using full 
metagenomics rather than metataxonomics. Furthermore the findings of Peachey et al. (2017b) 
and Kostidis et al. (2017) suggest that cyathostomin burdens do modify the hindgut 
microbiome and that changes in the metabolome associated with parasitism can be identified 
using NMR. Thus the next stage in this research should be to identify the effects of anthelmintic 
treatment on cyathostomin burdens of different magnitude through faecal and urinary 
metabolomics and fermentation kinetics. This will help to determine the associations between, 
parasitism, anthelmintic treatment and intestinal disease.  
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9.0 Conclusions 
The role of cyathostomins in equine colic is likely to be multifactorial, however the evidence 
to date suggests that it is important to prevent large cyathostomin burdens in horses to reduce 
the risk of intestinal disease.   
The egg reappearance time, therefore efficacy, of the macrocyclic lactones in horses is 
decreasing. This is concerning as moxidectin is one of the two anthelmintics which is effective 
against the most pathogenic stage of cyathostomins. Benzimidazole resistance has been 
reported as widespread for some time, the conclusion of chapter 4 is that a novel element of 
this anthelmintic, its ovicidal effect, is short lived in the face of BZ resistant strongyles. 
The conclusion of chapters 6 and 7 is that anthelmintic treatment did not alter the composition 
of faecal microbiota, nor did it alter the urinary metabolome.  However in vitro gas production 
was used to identify significant changes in feed fermentation kinetics, cumulative gas pool and 
the rate of fermentation, directly following moxidectin administration (chapter 5). From the 
fermentations, metabolomics identified differences in abundance of metabolites previously 
identified as associated with colic and laminitis. Whilst no clinical symptoms were seen in any 
of the horses in these trials this data suggests functional changes in the metabolome and 
fermentation activity directly following moxidectin administration. Previous reports have 
speculated that changes associated with parasite death and changes in gut motility may play a 
role in colic following anthelmintic treatment. Studies reported in this thesis suggest that 
changes in the metabolome may also play a role.  
The findings from these studies provide progress in unravelling the complex relationship 
between parasite, host and microbiota in intestinal disease in horses. Further development of 
‘omics technologies will allow further exploration of this complex relationship.  
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